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GENERAL INTRODUCTION
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease which is characterized by 
inflammation and frequently structural damage in the sacroiliac joints and/or spine. Patients 
typically present during young adulthood (typically before the age of 45) with chronic 
back pain (at least three months’ duration) – often of inflammatory character – and spinal 
stiffness. AxSpA is frequently split into two subtypes: (1) non-radiographic axSpA, in which 
patients have clinical signs and symptoms of axSpA but without sacroiliitis on radiographs; 
and (2) radiographic axSpA (i.e. Ankylosing Spondylitis (AS)), in which patients have the 
abovementioned clinical presentation in combination with definite sacroiliitis on radiographs.1 
Patients with axSpA may have several so called spondyloarthritis (SpA) features, although 
this varies strongly across patients. These SpA features include elevated acute phase reactants 
(C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), Human Leukocyte Antigen 
B27 (HLA-B27), sacroiliitis on imaging (radiography and magnetic resonance imaging (MRI) 
of the sacroiliac joints), inflammatory back pain (IBP), good response to non-steroidal anti-
inflammatory drugs (NSAIDs), positive family history of SpA, peripheral arthritis, dactylitis, 
enthesitis, acute anterior uveitis, inflammatory bowel disease (IBD), and psoriasis.2-11
The timely recognition of axSpA – especially in an early disease stage – is challenging as the 
disease is heterogeneous in its presentation and diagnostic criteria including a formal gold 
standard for diagnosis are lacking. The diagnosis of axSpA is therefore usually made after a 
thorough diagnostic work-up which includes a clinical assessment of all typical SpA features, 
laboratory tests (HLA-B27 and acute phase reactants), and imaging findings (sacroiliitis on 
radiographs or MRI) while excluding other more likely causes of chronic back pain.3, 12-16 
An important tool in assisting clinicians with the (early) diagnosis of axSpA and increasing 
diagnostic confidence is the modified Berlin algorithm.17 This algorithm was developed to 
minimize the number of unnecessary diagnostic tests in chronic back pain patients eventually 
leading to fewer costs for patients and for the health care system. The algorithm combines 
multiple clinical and laboratory indices of patients with chronic back pain (duration of at least 
three months) with an age of onset ≤45 years to advise rheumatologists in their next diagnostic 
step after initial radiography. In the absence of radiographic sacroiliitis the algorithm, 
depending on the number of SpA features present in a patient, guides the diagnostician with 
regard to which patients require subsequent testing, such as determining HLA-B27 and/or 
performing an MRI of the sacroiliac joints (MRI-SI). Importantly, the diagnostic algorithm is 
an aid and does not suffice to make a definite diagnosis in an individual patient.
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Next to this diagnostic tool for axSpA several classification criteria sets have been developed 
for the purpose of conducting clinical trials or cohort studies. In 2009, the Assessment of 
Spondyloarthritis international Society (ASAS), an international group of experts in the field 
of SpA, developed new classification criteria covering the full spectrum of axSpA.18 These 
classification criteria combine clinical, laboratory, and imaging features for classification of 
axSpA patients. However, it is important to note that these classification criteria should only 
be applied to patients in whom a diagnosis of axSpA has already been established. Classification 
criteria are used for research purposes (i.e. creating a homogenous group of patients) with a 
clear dichotomous (yes or no) result. This is in contrast to clinical diagnosis making, where 
differential diagnoses have to be considered and negative findings are also taken into account 
in the diagnostic work-up. 
One of the most important aspects in the (early) diagnosis (and classification) of axSpA is 
the use of imaging (conventional radiography and MRI) to assess active inflammation and/
or structural damage highly suggestive of axSpA. For several years clinicians, have relied 
on radiography of the sacroiliac joints (X-SI) to detect sacroiliitis.1 However, an important 
disadvantage of X-SI is that it only captures structural damage (i.e. erosions, sclerosis, and 
ankylosis), which usually takes months to years to develop.19, 20 Furthermore, not all patients 
will develop structural bone lesions in the sacroiliac joints or spine, which jeopardises the 
early detection of axSpA patients. MRI-SI can be used to visualize both inflammation and 
structural damage and can therefore be used to detect axSpA in patients who have not (yet) 
developed radiographic sacroiliitis.21-24 There have been studies investigating the presence of 
spinal inflammatory and structural lesions (i.e. fatty lesions, erosions, and syndesmophytes) on 
MRI in axSpA patients.25-27 However, currently only radiographic sacroiliitis and sacroiliitis 
on MRI based on inflammation are considered in the ASAS classification criteria for axSpA. 
Information on the use of structural lesions on MRI-SI and spinal (inflammatory and structural) 
lesions on MRI in axSpA diagnosis and classification is still limited.
Outline of this thesis 
The continued challenge of early diagnosis of axSpA in patients presenting with chronic back 
pain has led to the research presented in this thesis. 
In general terms, the aims of this thesis were as follows:
1. To gain better insight into how a diagnosis of early axSpA is made in common clinical 
practice.
2. To assess the potential value of adding spine MRI to the classification criteria for axSpA.
3. To evaluate the role of imaging findings in early axSpA diagnosis and classification.
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To address the aims of this thesis data from two cohorts were used: The Spondyloarthritis 
Caught Early (SPACE) and DEvenir des Spondylarthropathies Indifférenciées Récentes 
(DESIR) cohorts. 
The SPACE cohort is an ongoing observational study which was initiated in 2009 at the 
Leiden University Medical Center (LUMC, the Netherlands). Patients with a minimum age 
of 16 years referred to Rheumatology outpatient clinics with short term chronic back pain (of 
unknown origin) for at least three months but not longer than two years, and age at onset of 
back pain <45 years, were included. In addition to not meeting the minimum age and duration 
of back pain criteria, the presence of other painful conditions not associated with axSpA that 
could interfere with the evaluation of disease activity, or any reason invalidating the informed 
consent or limiting the ability of the subject to comply with the protocol requirements, led 
to exclusion. Patients had been recruited from multiple rheumatology centres in Europe; 
the Netherlands (Leiden, Amsterdam and Gouda), Norway (Oslo), Italy (Padova), Portugal 
(Lisbon) and Sweden (Göteborg, Malmö, Falun, Skövde, Västerås, Huddinge, Stockholm). A 
detailed description of the SPACE cohort has been published elsewhere.28
DESIR is a longitudinal cohort for which the inclusion period was between December 2007 
and April 2010 in 25 participating centres in France. Patients between 18 and 50 years old 
with inflammatory back pain (thoracic, lumbar or buttock region) according to the Calin 
or Berlin criteria, persisting for at least three months but not longer than three years, were 
included.2, 4 Moreover, the symptoms had to be highly suggestive of axSpA according to the 
treating rheumatologist expressed in a score of five or more on a numerical rating scale from 
zero to ten. Exclusion criteria were (1) the presence of a clearly defined spinal disease, (2) history 
of treatment with any biological drug, (3) corticosteroid intake of a dose higher than 10 mg 
prednisone per day and unstable intake for at least 4 weeks prior to baseline, and (4) history 
or current disorders which might interfere with the validity of the informed consent and/or 
prevent an optimal compliance of the patient to the cohort (e.g. alcoholism, psychological 
disorders). A detailed description of the DESIR cohort has also been published before.29
As part of both study protocols patients underwent a full diagnostic work-up to assess disease 
characteristics and the presence of all SpA features, however small but important differences 
exist between the two cohorts. The SPACE cohort is a multicentre, multinational study whilst 
the DESIR cohort is a strictly French cohort with multiple participating centres across the 
country. Furthermore, the SPACE cohort includes patients with chronic back pain of short 
duration (between three months and two years), and with an age of onset <45 years. DESIR, 
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however, included patients between the ages of 18 and 50 years with IBP (between three 
months and three years) and a substantial suspicion of axSpA (measured by the physician’s 
level of confidence in diagnosis of at least five on a zero to ten scale). 
The first aim of this thesis focuses on getting better insight into how chronic back pain 
patients are diagnosed with axSpA in clinical practice. Since the development of the ASAS 
classification criteria for axSpA, and the lack of diagnostic criteria, experts have raised concerns 
about ‘overdiagnosis’ when using the classification criteria as a checklist in the diagnosis 
of chronic back pain patients. In Chapter 2 we investigated in the SPACE cohort whether 
the presence of multiple SpA features in a chronic back pain patient always leads to axSpA 
diagnosis, and looked into the agreement between the rheumatologist’s diagnosis and ASAS 
classification. An important question is what the alternative diagnoses were in the patients 
who were not diagnosed with axSpA but who did have at least four SpA features. In Chapter 
3 we briefly discuss the clinical characteristics of these patients and their alternative diagnosis. 
The diagnosis of axSpA is complex and is therefore accompanied by a certain diagnostic 
uncertainty. It is unclear whether the development of SpA features over time may possibly 
lead to more confidence in diagnosis. Therefore, we investigated diagnostic uncertainty in 
patients with recent onset CBP at baseline and after one-year follow-up in Chapter 4. In 
addition, we systematically investigated SpA feature accrual in one year and the influence on 
diagnosis and level of certainty. One of the SpA features which can be assessed in chronic back 
pain patients is a positive family history of SpA (i.e. the presence of AS, acute anterior uveitis, 
reactive arthritis, IBD, and psoriasis in first- or second-degree relatives). The definition of a 
positive family history was constructed by a panel of SpA experts, but was never validated. 
Chapter 5 discusses the usefulness of the current definition in identifying axSpA in both the 
SPACE and DESIR cohorts. 
MRI is an important tool in the assessment of inflammation in both clinical practice for 
diagnosis and in scientific studies for classification using the ASAS criteria. The ASAS 
classification criteria have only incorporated inflammatory lesions according to a specific 
definition on MRI and structural lesions on radiography in the sacroiliac joints to define 
positive imaging. Several studies however have shown that spinal inflammatory lesions occur in 
chronic back pain patients either together with abnormalities in the SI joints or independently. 
Chapter 6 focuses on the second aim of this thesis, which is to evaluate the additional value 
of MRI-spine, with the use of different definitions of a positive MRI-spine, as an imaging 
criterion in the ASAS classification criteria in both SPACE and DESIR. 
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The last part of this thesis describes the influence of imaging and its interpretation in the 
diagnosis and classification of chronic back pain patients. Previous studies have already shown 
that the interpretation of sacroiliac joint imaging may result in different interpretations in a 
significant number of patients. In Chapter 7 we investigated the influence of different readings 
by local assessors and central readers on the classification of chronic back pain patients in the 
SPACE cohort. The aim was to validate the findings of the DESIR cohort on this topic. From 
previous work in the SPACE cohort it is known that rheumatologists highly value the presence 
of HLA-B27 and sacroiliitis on imaging when making a diagnosis of axSpA. However, there 
is limited knowledge on how imaging is used in the diagnostic process of axSpA, and – more 
specifically – to what extent rheumatologists are influenced by imaging results in diagnosing 
chronic back pain patients. Chapter 8 finally looks into the impact of sacroiliac imaging on 
axSpA diagnosis and the diagnostic confidence of rheumatologists. Chapter 9 consists of a 
summary and a general discussion on the findings of this thesis with future perspectives for 
clinical practice and research. A summary in Dutch is provided in Chapter 10. 
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ABSTRACT
Objectives
Concerns have been raised about overdiagnosis of axial spondyloarthritis (axSpA). We 
investigated whether patients with chronic back pain (CBP) of short duration and multiple 
SpA-features are always diagnosed with axSpA by the rheumatologist, and to what extent 
fulfilment of the ASAS axSpA criteria is associated with an axSpA diagnosis.
Methods
Baseline data from 500 patients from the SPondyloArthritis Caught Early (SPACE)-cohort 
which includes CBP patients ( ≥ 3 months, ≤ 2 years, onset < 45 years) were analysed. All 
patients underwent full diagnostic work-up including MRI-SI and X-SI. For each patient, the 
total number of SpA-features excluding sacroiliac imaging and HLA-B27 status was calculated. 
Results
Before sacroiliac imaging and HLA-B27 testing, 32% of patients had ≤1 SpA-feature, 29% had 
2 SpA-features, 16% had 3 SpA-features and 24% had ≥4 SpA-features. A diagnosis of axSpA 
was made in 250 (50%) of the patients: 24% with ≤1 SpA-feature, 43% with 2 SpA-features, 
62% with 3 SpA-features and 85% with ≥4 SpA-features. Of the 230 patients with a positive 
ASAS classification 40 (17.4%) did not have a diagnosis of axSpA. HLA-B27 positivity (OR 
5.6; 95% CI 3.7 to 8.3) and any (MRI-SI and/or X-SI) positive imaging (OR 34.3; 95% CI 
17.3 to 67.7) were strong determinants of an axSpA diagnosis
Conclusion
In this cohort of CBP patients, neither the presence of numerous SpA-features nor fulfilment of 
the ASAS classification criteria did automatically lead to a diagnosis axSpA. Positive imaging 
was considered particularly important in making a diagnosis of axSpA. 
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INTRODUCTION
Axial spondyloarthritis (axSpA) has a heterogeneous clinical presentation and does not have a 
single pathognomonic feature that distinguishes the disease from other conditions with similar 
symptoms.1, 2 Therefore, it is a challenge to identify axSpA early in patients with chronic 
back pain (CBP). In daily rheumatologic practice, a diagnosis of axSpA is generally made in 
patients with CBP on the basis of a combination of symptoms from medical history, physical 
examination, laboratory investigations, and findings on imaging.3, 4
In 2009 the Assessment of SpondyloArthritis international Society (ASAS) developed 
classification criteria for axSpA. The criteria combine information from several sources such 
as medical history, physical examination, laboratory testing, and imaging.5 In a secondary or 
tertiary care setting the fulfilment of the ASAS-criteria is strongly associated with a clinical 
diagnosis of axSpA at the group level, but the criteria cannot be used for diagnosing axSpA 
in individual patients.6, 7 Classification criteria can only be applied in patients in whom a 
diagnosis of axSpA has been established (not vice versa).8-10 The recognition of axSpA therefore 
requires the physician’s knowledge about SpA, as well as expertise in aggregating information 
obtained during the diagnostic work-up and a differential diagnosis. 
In order to assist physicians in the diagnosis of axSpA the ASAS modified Berlin algorithm 
has been developed, which can be applied in CBP patients with age of onset <45 years (Figure 
1). As a first step the algorithm advises a radiograph of the sacroiliac joints (X-SI) in all 
patients. According to the algorithm CBP patients with indisputable radiographic sacroiliitis 
may be readily diagnosed with axSpA. Patients without clear sacroiliitis on radiographs are 
subsequently stratified according to the number of spondyloarthritis (SpA)-features they 
have after patient history, physical examination and measuring C-reactive protein (CRP) and 
erythrocyte sedimentation rate (ESR). A important feature of the algorithm is that it allows 
a diagnosis of axSpA in patients with ≥4 SpA-features without further imaging (MRI of the 
sacroiliac joints (MRI-SI)) or HLA-B27 testing. Moreover, HLA-B27 positive patients with 
normal radiographs and 2 or 3 SpA-features may also be diagnosed with axSpA without 
performing MRI-SI. Van den Berg et al. have already shown that an axSpA diagnosis according 
to the modified Berlin algorithm is not necessarily the same as an expert’s (i.e. rheumatologist’s) 
clinical diagnosis, so false-positive and false-negative diagnoses may occur if the algorithm 
is followed blindly.11 Therefore, it should be stressed again that the ASAS modified Berlin 
algorithm is only a tool in aiding rheumatologists in diagnosing axSpA and can and should 
not replace a differential diagnostic procedure in patients with CBP. 
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Figure 1 ASAS modification of the Berlin algorithm* for diagnosing axial spondyloarthritis. Adapted 
from: van den Berg R et al. Ann Rheum Dis 2013;72;1646-53 (with permission). *Rudwaleit M et 
al. Ann Rheum Dis 2004;63:535-43.
Nevertheless, several concerns have been raised about the risk of overdiagnosis of axSpA 
when the diagnosis is made by counting the number of SpA-features without paying 
attention to an alternative diagnosis that may be more likely.12 Similarly, the use of ASAS 
classification as diagnostic criteria may lead to misdiagnosis. These issues are of particular 
concern in patients with non-inflammatory conditions in whom overdiagnosis may 
inappropriately lead to the start of anti-inflammatory treatments that will not be effective 
but are associated with side-effects and costs. Concerns like these have contributed to the 
United States Food and Drug Administration (FDA) formal disproval of adalimumab and 
certolizumab for the treatment of non-radiographic axSpA in the United States, while both 
drugs have been approved by the European Medicines Agency (EMA) for this indication 
in the European Union.13
The diagnostic process of early axSpA in patients presenting with CBP is not well studied. 
Cohort studies typically include patients with an established diagnosis of axSpA. The 
multicenter SPondyloArthritis Caught Early (SPACE)-cohort is a study that has included 
2
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patients presenting with CBP but without a formal diagnosis who have been referred to 
a rheumatologist. Consequently, the SPACE-cohort contains patients with and without a 
diagnosis of axSpA. 
The main objectives of our study were to investigate 1) which SpA-features contribute most 
to a diagnosis of axSpA; 2) if the presence of multiple SpA-features automatically leads to 
a diagnosis of axSpA in patients presenting with CBP; and 3) how positive classification 
according to the ASAS-criteria relates to a diagnosis of axSpA.
METHODS
Study design and population
The SPACE-cohort is a prospective multicenter study, which was initiated in January 2009. 
The study has been described elsewhere.14 In brief, patients with CBP (≥3 months and ≤ 2 
years) of unknown origin and age of onset <45 years were included. Patients were recruited for 
the study from five different rheumatology outpatient clinics in the Netherlands (Amsterdam, 
Gouda, Leiden), Norway (Oslo) and Italy (Padua). 
Approval for the study was obtained from all local medical ethics committees. All patients 
provided written informed consent. Data of 157 patients from the LUMC in Leiden have 
previously been published as part of the validation of the modified Berlin algorithm. 
Imaging of the sacroiliac joints
Plain radiographs of the pelvis (X-SI) were performed in anteroposterior view. MRI-SI were 
also performed: the acquired sequences were coronal oblique T1-weighted turbo spin echo 
(TSE) and short tau inversion recovery (STIR) with a slice thickness of 4 mm. Each center 
interpreted the radiographs and MRI-SI on the presence of sacroiliitis using global assessment 
as part of routine clinical practice (local reading) with radiologists specifically asked whether 
there was evidence of sacroiliitis. 
Clinical measurements 
Patients underwent a full diagnostic work-up including the assessment of SpA-features 
according to the ASAS-criteria: CRP and ESR, HLA-B27, imaging (X-SI and MRI-SI), and 
the actual presence or a history of all other SpA-features: inflammatory back pain (IBP), 
good response to non-steroidal anti-inflammatory drugs (NSAIDs), positive family history 
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of SpA, peripheral arthritis, dactylitis, enthesitis, acute anterior uveitis, inflammatory bowel 
disease (IBD), psoriasis. Rheumatologists provided a diagnosis of axSpA based on all collected 
information, including imaging and HLA-B27 status. In case of ‘no axSpA’ rheumatologists 
were asked to provide a most likely alternative diagnosis. In addition, rheumatologists were 
requested to provide a level of confidence about the diagnosis on a 11-point numerical rating 
scale (NRS) ranging from 0 (not confident at all) to 10 (very confident) after imaging was 
performed. Independently of the clinical diagnosis the ASAS axSpA classification criteria were 
used to classify patients using the local imaging results. The rheumatologists were not formally 
informed about the patients’ classification status at the time of diagnosis.
Statistical analysis
For the present analyses baseline data were available (n=522). Patients with missing values for 
≥1 SpA-feature, including imaging and HLA-B27 status, and those with missing information 
on clinical diagnosis, were excluded from the analyses (n=22). Total number of SpA-features 
was determined without taking HLA-B27 and imaging into account. Next, patients were 
stratified according to the number of SpA-features present: ≤1 feature, 2 features, 3 features, 
and ≥4 features. Patient characteristics are presented for the total patient group and for each 
subgroup as mean ± SD or number (%). The rheumatologist’s diagnosis was the main outcome. 
Sensitivity and specificity were calculated to assess the agreement between the clinical diagnosis 
and the ASAS axSpA classification criteria. Where zeroes caused problems with computation of 
odds ratios or their standard errors, 0.5 were added to all cells. Multivariable logistic regression 
analysis was performed to assess independent determinants of clinical diagnosis. Data analysis 
was performed using STATA SE V.14. P values less than 0.05 were considered significant.
RESULTS
A total of 500 patients with CBP of short duration and complete data were analysed. Of these 
patients 37% were male, mean age (SD) was 29.3 (8.3) years and mean symptom duration (SD) 
was 13.4 (7.4) months (Table 1). Of all patients, 159 (32%) had ≤1 feature, 143 (29%) had 2 
features, 79 (16%) had 3 features and 119 (24%) had ≥4 features. Age at onset of back pain, sex, 
and disease duration were similar across subgroups. Of the 159 patients in the ≤1 SpA-feature 
subgroup 24% was diagnosed with axSpA; for patients with 2 SpA-features this was 43%, for 
patients with 3 SpA-features 62%, and for patients with ≥4 SpA-features this was 85%. When 
stratifying for each participating center the same trend - higher percentages of diagnosis with 
increasing numbers of features - in clinical diagnosis was observed (supplementary data Table S1).
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In patients with ≤1 SpA-feature 9/159 (6%) had radiographic sacroiliitis and 26/159 (16%) 
had a positive MRI-SI (Table 2). Of the patients with normal radiographs 99/150 (66%) had 
neither a positive MRI-SI nor HLA-B27 and only 2/99 (2%) were diagnosed with axSpA (both 
CBP patients had 1 SpA-feature which were IBP and positive family history, respectively). 
In total, 38/159 (24%) patients were diagnosed with axSpA. One patient with radiographic 
sacroiliitis was not diagnosed with axSpA. When the ASAS axSpA classification criteria were 
applied, 5 patients without a diagnosis of axSpA fulfilled the ASAS-criteria. In addition, 13 
patients with an axSpA diagnosis did not fulfil the ASAS classification criteria.
In patients with 2 SpA-features 16/143 (11%) had radiographic sacroiliitis and 35/143 (24.5%) 
patients had a positive MRI-SI. Of the patients with normal radiographs 70/127 (55%) had 
neither a positive MRI-SI nor HLA-B27 and 11/127 (9%) were diagnosed with axSpA. In 
total, 62/143 (43%) patients were diagnosed with axSpA. All patients with radiographic 
sacroiliitis were diagnosed with axSpA. When the ASAS axSpA classification criteria were 
applied, 22 patients without a diagnosis of axSpA fulfilled the ASAS-criteria and 11 patients 
with an axSpA diagnosis did not fulfil the ASAS-criteria and. 
In patients with 3 SpA-features 5/79 (6%) had radiographic sacroiliitis and 29/79 (38%) had a 
positive MRI-SI. Of the patients with normal radiographs 29/74 (39%) had neither a positive 
MRI-SI nor HLA-B27 and 8/74 (11%) were diagnosed with axSpA. In total, 49/79 (62%) patients 
were diagnosed with axSpA. All patients with radiographic sacroiliitis were diagnosed with axSpA. 
When the ASAS axSpA classification criteria were applied, 9 patients without a diagnosis of axSpA 
fulfilled ASAS-criteria and 8 patients with an axSpA diagnosis did not fulfil the ASAS-criteria.
In patients with ≥4 SpA-features 28/119 (24%) had radiographic sacroiliitis and 47/119 (40%) 
had a positive MRI-SI. Of the 91 patients with normal radiographs 42 (46%) had neither a 
positive MRI-SI nor HLA-B27 and 28/91 (31%) were diagnosed with axSpA. In total, 101/119 
(85%) patients were diagnosed with axSpA. Again, all patients with radiographic sacroiliitis 
(28/28) were diagnosed with axSpA. Remarkably, 18/119 patients (15%) with ≥4 SpA-features 
but with negative imaging were not given the diagnosis axSpA, 4 of whom were HLA-B27 
positive. When the ASAS axSpA classification criteria were applied, 4 patients without a 
diagnosis of axSpA fulfilled ASAS-criteria and 28 patients with an axSpA diagnosis did not 
fulfil the ASAS-criteria. Moreover, patients with ≥4 features not diagnosed with axSpA were 
mostly given the diagnosis non-specific back pain and degenerative disc disease (data not 
shown). In these patients the most common SpA-features were a positive family history for 
SpA (67%), good response to NSAIDs (82%), and IBP (94%). 
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Table 1 Baseline characteristics of patients with chronic back pain in the SPACE-cohort and stratified 
by total number of SpA-features after medical history taking, physical examination and measurement 
of acute phase reactants but before HLA-B27 testing and imaging.
Characteristic All patients, 
n=500
Patients with ≤1 features, 
n=159
Patients with 2 features, 
n=143
Patients with 3 features, 
n=79
Patients with ≥ 4 features, 
n=119
Age, years 29.3 (8.3) 29.7 (8.8) 28.8 (8.3) 29.1 (8.0) 29.5 (7.9)
Symptom duration, months 13.4 (7.4) 12.9 (7.3) 14.6 (7.7) 13.3 (7.0) 12.7 (7.4)
Male 185 (37) 51 (32) 56 (39) 24 (30) 54 (45)
IBP 329 (66) 43 (27) 103 (72) 71 (90) 112 (94)
Good response to NSAIDs a 208 (42) 13 (8) 50 (35) 47 (60) 98 (82)
Positive family history SpA b 206 (41) 26 (16) 57 (40) 43 (54) 80 (67)
Peripheral arthritis ¥ 74 (15) 2 (1) 15 (11) 11 (14) 46 (39)
Dactylitis ¥ 26 (5) 0 (0) 1 (1) 3 (4) 22 (19)
Enthesitis ¥ 108 (22) 4 (3) 12 (8) 15 (19) 77 (65)
Anterior uveitis ¥ 38 (8) 2 (1) 9 (6) 6 (8) 21 (18)
IBD ¥ 35 (7) 8 (5) 7 (5) 7 (9) 13 (11)
Psoriasis ¥ 57 (11) 2 (1) 7 (5) 8 (10) 40 (34)
Elevated CRP (mg/L) / ESR (mm) c 132 (26) 12 (8) 25 (18) 26 (33) 69 (58)
HLA-B27 positive 198 (40) 36 (23) 65 (46) 41 (52) 56 (47)
Imaging°













Results are presented as mean ± SD or number (%). ¥ Past or present condition, either confirmed or 
diagnosed by a physician. IBP, inflammatory back pain; NSAIDs, non-steroidal anti-inflammatory 
drugs; SpA, spondyloarthritis; IBD, inflammatory bowel disease; CRP, C-reactive protein; ESR, 
erythrocyte sedimentation rate; HLA-B27, human leucocyte antigen B27; °According to global 
assessment radiologist (local reading). ** X-SI, radiograph of sacroiliac joints; 
MRI-SI, magnetic resonance imaging of sacroiliac joints. AxSpA, axial spondyloarthritis. a Back pain 
not present anymore or is much better 24–48 hours after a full dose of NSAID. b Presence in first- or 
second degree relatives of any of the following: ankylosing spondylitis, psoriasis, acute anterior uveitis, 
reactive arthritis, or inflammatory bowel disease. c Values greater than the upper limit of normal. d 
Diagnosis based on information after full diagnostic work-up: medical history, physical examination, 
imaging, and laboratory testing.
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diagnosed by a physician. IBP, inflammatory back pain; NSAIDs, non-steroidal anti-inflammatory 
drugs; SpA, spondyloarthritis; IBD, inflammatory bowel disease; CRP, C-reactive protein; ESR, 
erythrocyte sedimentation rate; HLA-B27, human leucocyte antigen B27; °According to global 
assessment radiologist (local reading). ** X-SI, radiograph of sacroiliac joints; 
MRI-SI, magnetic resonance imaging of sacroiliac joints. AxSpA, axial spondyloarthritis. a Back pain 
not present anymore or is much better 24–48 hours after a full dose of NSAID. b Presence in first- or 
second degree relatives of any of the following: ankylosing spondylitis, psoriasis, acute anterior uveitis, 
reactive arthritis, or inflammatory bowel disease. c Values greater than the upper limit of normal. d 
Diagnosis based on information after full diagnostic work-up: medical history, physical examination, 
imaging, and laboratory testing.
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Table 2 Diagnosis and classification of patients (n=500) with ≤1, 2, 3 and ≥4 spondyloarthritis (SpA)-
features after medical history taking, physical examination and measurement of acute phase reactants, 
followed by sacroiliac imaging and HLA-B27 testing.
Number of 
SpA-features






















HLA-B27+/MRI+ 6 1 7
HLA-B27+/MRI- 7 16 23
HLA-B27-/MRI+ 15 6 14 7
HLA-B27-/MRI- 2 97 99












HLA-B27+/MRI- 15 20 35
HLA-B27-/MRI+ 5 2 7
HLA-B27-/MRI- 11 59 70












HLA-B27+/MRI- 11 9 20
HLA-B27-/MRI+ 8 8
HLA-B27-/MRI- 8 21 29
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Table 2 Diagnosis and classification of patients (n=500) with ≤1, 2, 3 and ≥4 spondyloarthritis (SpA)-
features after medical history taking, physical examination and measurement of acute phase reactants, 
followed by sacroiliac imaging and HLA-B27 testing.
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HLA-B27+/MRI- 21 4 25
HLA-B27-/MRI+ 8 8
HLA-B27-/MRI- 28 14 42
Mean level of confidence regarding diagnosis (SD) 8.0 (2.0) 7.3 (1.7)
X-SI, radiograph of sacroiliac joints; HLA-B27, human leucocyte antigen B27; MRI-SI, magnetic 
resonance imaging of sacroiliac joints; Imaging according to global assessment radiologist (local 
reading). Diagnosis based on information after full diagnostic work-up: medical history, physical 
examination, imaging, and laboratory testing.
ASAS axSpA criteria, Assessment of SpondyloArthritis international Society criteria for axial 
spondyloarthritis. Mean level of confidence regarding diagnosis: 0 (not confident at all) through 10 
(very confident). 
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Overall, the mean levels of confidence (SD) regarding a diagnosis of axSpA and no axSpA 
were 7.7 (2.0) and 7.2 (2.3), respectively. Mean levels of confidence of axSpA diagnosis for 
the different patient subgroups rose with the presence of more SpA-features; ≤1 feature, mean 
6.9 (2.3); 2 features, mean 7.6 (1.9); 3 features, mean 8.0 (1.9); ≥4 features, mean 8.0 (2.0) 
(Table 2). 
With the clinical diagnosis of the rheumatologist as the gold standard, sensitivity and 
specificity of the ASAS classification criteria for axSpA were 76% (190/250) and 84% 
(210/250), respectively (Table 3).
In univariable analysis, HLA-B27 positivity and any positive imaging were associated with an 
axSpA diagnosis (OR 5.6, 95% CI 3.7 to 8.3 and OR 34.3, 95% CI 17.3 to 67.7 respectively). 
These associations were similar across subgroups (Table 4 and 5). In multivariable logistic 
regression analysis with clinical diagnosis as the dependent variable and SpA-features from the 
ASAS-criteria as independent variables HLA-B27 and positive imaging were both independent 
determinants of diagnosis (data not shown). 
Table 3 Concordance between clinical axSpA diagnosis and meeting the ASAS classification criteria 
for axSpA in CBP patients with the physician’s diagnosis as the gold standard in the SPACE-cohort 
(n=500). Sensitivity 76% (190/250) and specificity 84% (210/250). Positive predictive value (PPV): 




Yes 190 40 230
No 60 210 270
Total 250 250 500
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Table 4 Concordance between clinical axSpA diagnosis and presence of HLA-B27 for all patients and 
stratified for total number of SpA-features.
All patients Clinical axSpA diagnosis
HLA-B27 positive Yes No Total
Yes 147 51 198
No 103 199 302
Total 250 250 500
OR (95% CI) 5.6 (3.7-8.3)
≤1 feature Clinical axSpA diagnosis
HLA-B27 positive Yes No Total
Yes 18 18 36
No 20 103 123
Total 38 121 159
OR (95% CI) 5.2 (2.3-11.6)
2 features Clinical axSpA diagnosis
HLA-B27 positive Yes No Total
Yes 45 20 45
No 17 61 78
Total 62 81 143
OR (95% CI) 8.1 (3.8-17.1)
3 features Clinical axSpA diagnosis
HLA-B27 positive Yes No Total
Yes 32 9 41
No 17 21 38
Total 49 30 79
OR (95% CI) 4.4 (1.7-11.7)
≥4 features Clinical axSpA diagnosis
HLA-B27 positive Yes No Total
Yes 52 4 56
No 49 14 63
Total 101 18 119
OR (95% CI) 3.7 (1.1-12.1)
HLA-B27, human leucocyte antigen B27; axSpA, axial spondyloarthritis; OR = odds ratio; 95% CI 
= 95% confidence interval.
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Table 5 Concordance between clinical axSpA diagnosis and any positive imaging (MRI-SI and/or X-SI) 
for all patients and stratified for total number of SpA-features.
All patients Clinical axSpA diagnosis
Any positive imaging Yes No Total
Yes 147 10 157
No 103 240 343
Total 250 250 500
OR (95% CI) 34.3 (17.3-67.7)
≤1 feature Clinical axSpA diagnosis
Any positive imaging Yes No Total
Yes 29 8 37
No 9 113 122
Total 38 121 159
OR (95% CI) 45.5 (16.1-128.3)
2 features Clinical axSpA diagnosis
Any positive imaging Yes No Total
Yes 36 2 38
No 26 79 105
Total 62 81 143
OR (95% CI) 54.7 (12.3-243)
3 features Clinical axSpA diagnosis
Any positive imaging Yes No Total
Yes 30 0 * 30
No 19 30 49
Total 49 30 79
OR (95% CI) 95.4 (5.5-1652.2)
≥4 features Clinical axSpA diagnosis
Any positive imaging Yes No Total
Yes 52 0 * 52
No 49 18 67
Total 101 18 119
OR (95% CI) 39.2 (2.3-668.8)
axSpA, axial spondyloarthritis; X-SI, radiograph of sacroiliac joints; MRI-SI, magnetic resonance 
imaging of sacroiliac joints; OR, odds ratio; 95% CI, 95% confidence interval. * For computation of 
odds ratios in case of zeroes, 0.5 were added to all cells.
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DISCUSSION
Prompted by concerns regarding overdiagnosis of axSpA we investigated whether in patients 
referred with recent onset CBP and a suspicion of axSpA, the presence of several SpA-features 
suffices for a diagnosis of axSpA. While, as expected, an increasing number of SpA-features was 
associated with an increased likelihood of axSpA diagnosis this association was not absolute. 
Numerous patients with multiple SpA-features did not get a diagnosis of axSpA. Among 
them are half of the HLA-B27 positive patients with 3 SpA-features but without imaging 
abnormalities. This example clearly shows that a clinical diagnosis is based on more than 
simply a sum of features. 
In this cohort the ASAS classification criteria had an overall sensitivity and specificity of 76% 
and 84%, respectively. This is comparable to those found in the original ASAS-cohort. In line 
with the finding that patients with multiple SpA-features are not always diagnosed with axSpA 
17% of patients that on paper met the ASAS classification criteria, which requires presence of 
at least two SpA-features, were not diagnosed with axSpA. 
An important finding is the prominent -if not dominant- role of imaging and HLA-B27 testing 
in diagnosing axSpA in rheumatology clinics. The statistically stronger association between 
positive imaging and axSpA diagnosis as compared to HLA-B27 and axSpA diagnosis (or 
any other SpA-feature) should be interpreted with caution. The prevalence of axSpA in this 
cohort of patients specifically referred to the rheumatologist (50%) is much higher than the 
prevalence of axSpA in unselected CBP patients, and we do not know which screening tools 
were applied to select patients for referral. In our cohort X-SI was positive in only a minority 
of patients whilst an analysis of 204 referral letters indicated that HLA-B27 positivity was 
mentioned four times more often than a positive MRI-SI as a reason for referral (unpublished 
data). This difference in absolute prevalence implies that the impact of different ORs (OR=5.6 
for HLA-B27 and OR=35 for imaging) may be far more similar than the ORs suggest. 
Nevertheless, our findings stress the dominance of imaging in establishing an axSpA diagnosis 
and add to the importance of a proper interpretation of the images.15-17 
At first sight, some of the diagnoses may raise suspicion. For instance, a diagnosis of axSpA 
may not be expected in HLA-B27 negative patients that have normal imaging tests, and 
only a few other SpA-features. In such patients, a diagnosis may still be justifiable because of 
features or symptoms that are not part of the ASAS-criteria, e.g. buttock pain, IBP according 
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to Calin or Berlin criteria, presence of structural (but not active) lesions on MRI-SI or spinal 
inflammatory lesions, even though the latter two manifestations are rare in the absence of bone 
marrow edema on MRI-SI.18
Furthermore, differences in the interpretation of imaging may also have contributed to 
unexpected diagnoses. Even though the assessment of the radiologist was used for the analyses, 
the rheumatologist has provided the diagnosis and may -based on the clinical symptoms- 
have overruled the radiologist’s report, for instance by taking structural lesions or spinal 
inflammatory lesions into account.18, 19
A possible limitation of this study is that the clinical diagnosis - as is usual in clinical practice - 
was provided by only one rheumatologist. Each rheumatologist may consider different features, 
apart from positive imaging and presence of HLA-B27, being most informative for axSpA 
diagnosis. Even though this was not assessed it is conceivable this might have influenced the 
diagnosis. Future studies should definitely assess interobserver variance in clinical diagnosis. 
The ASAS modified Berlin algorithm can be used by rheumatologists in the clinical decision 
making process when diagnosing CBP patients. But blindly applying the ASAS modified 
Berlin algorithm will also result in false-positive and false-negative diagnoses. As has become 
clear in our study, in patients without radiographic sacroiliitis but with multiple SpA-features 
(and/or presence of HLA-B27), the algorithm immediately leads to an axSpA diagnosis, while 
in clinical practice this is not always clear. In 15% of the patients with ≥4 SpA-features and 
13% of the HLA-B27 positive patients with 2-3 SpA-features that should have a clinical 
diagnosis of axSpA according to the algorithm, such a diagnosis was not confirmed by the 
clinician.
While the SPACE-cohort is running in different countries and settings (academic and non-
academic), we did not find an important center effect. In all centers the likelihood of axSpA 
diagnosis similarly increased by an increasing number of SpA-features, which adds to the 
credibility of our data. Nevertheless, patients were diagnosed by hospital-based rheumatologists 
with an expertise in diagnosing patients with axSpA, and results of this study cannot be 
extrapolated to different clinical settings such as primary care and common rheumatology 
practices or those of other medical specialities. 
In conclusion, in clinical practice the mere presence of SpA-features does not automatically 
result in a clinical diagnosis of axSpA. Furthermore, this study confirms that the ASAS modified 
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Berlin algorithm could be used as a guidance tool but that a thorough diagnostic work-up with 
ample consideration for alternative diagnoses is still mandatory. Preferably, all information 
including imaging of sacroiliac joints and presence of HLA-B27 should be available to the 
rheumatologist to come to a final diagnosis. 
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Diagnosis based on information after full diagnostic work-up: medical history, physical examination, 
imaging, and laboratory testing. Patient data available from the following centers: Leiden University 
Medical Center (LUMC), Leiden, the Netherlands; 
University of Padova, Padova, Italy; Diakonhjemmet hospital, Oslo, Norway; Academic Medical 
Center, Amsterdam, The Netherlands; Groene Hart ziekenhuis, Gouda, the Netherlands.
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with axial spondyloarthritis: data from the SPACE cohort.
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We recently published a study investigating whether the mere presence of multiple spondyloarthritis 
(SpA) features is sufficient for an axial spondyloarthritis (axSpA) diagnosis.1 Patients (n=500) with 
chronic back pain (CBP) suspected of axSpA were stratified according to their number of SpA 
features into four subgroups: ≤1, 2, 3 and ≥4 SpA features based on medical history taking, physical 
examination and measurement of acute phase reactants, but before sacroiliac imaging and HLA-B27 
testing. In total, 24% (38/159), 43% (62/143), 62% (49/79), and 85% (101/119) of CBP patients 
with ≤1, 2, 3 and ≥4 SpA features respectively were diagnosed with axSpA. In particular, HLA-B27 
positivity and imaging findings highly suggestive of axSpA were strongly associated with an axSpA 
diagnosis. So although the likelihood of axSpA diagnosis increased with an increasing number of 
SpA features, not all patients with multiple SpA features were diagnosed as having axSpA. 
In the News and Views section of Nature Reviews Rheumatology, Braun and Kiltz raised the 
question what diagnoses were made in CBP patients who were not diagnosed with axSpA. 
This information was not provided in the manuscript.2 The question is relevant since we agree 
with these authors that it is unlikely that a patient with 4 or more SpA features does not have 
SpA. This reasoning follows the modified Berlin algorithm in which patients with CBP and 
≥4 SpA features are readily diagnosed with axSpA.3
In our study, rheumatologists were first asked to provide a diagnosis (i.e. presence of axSpA 
yes/no). In all patients this question was answered with 250 patients diagnosed with axSpA 
after full diagnostic work-up. Secondly, in case of ‘no axSpA’ rheumatologists were requested 
to provide a most likely alternative diagnosis. 
In 76% (189/250) of patients who were not diagnosed as having axSpA, the alternative 
diagnosis for the chronic back pain was recorded in the study database. Across all subgroups 
based on the number of SpA features most common diagnoses were nonspecific back pain, 
mechanical back pain, degenerative disc disease, and (fibro)myalgia (Table 1). Not surprisingly, 
in these patients almost no positive imaging (sacroiliitis on either radiographs or MRI) was 
observed and HLA-B27 positivity was infrequent.1 Especially in the 18 patients not diagnosed 
with axSpA, but with at least 4 SpA features, none of the patients had imaging abnormalities 
suggestive of axSpA on MRI or radiography and only 4 of them were HLA-B27 positive. The 
most frequent SpA features in these patients were: IBP (16/18), a positive family history of 
SpA (16/18), a good response to NSAIDs (11/18), elevated CRP or ESR (8/18) and enthesitis 
(8/18). Overall, these findings show that rheumatologists in clinical practice rightly dispute a 
diagnosis of axSpA even when there is a high number of SpA features, especially when imaging 
is normal and patients are negative for HLA-B27.
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Table 1 Alternative diagnoses in CBP patients not diagnosed with axSpA (n=250) stratified by 
total number of SpA features after medical history taking, physical examination and measurement of 
acute phase reactants but before HLA-B27 testing and imaging.
Number of SpA features¥ Alternative diagnoses N (%)
0-1
n=121
Nonspecific back pain 32 (26)
Mechanical back pain 5 (4)
IBP 4 (3)
Degenerative disc disease/HNP a 14 (12)
Myalgia 17 (14)
Fibromyalgia 8 (7)
Hypermobility syndrome 3 (2)
Other* 12 (10)
Missing diagnosis 29 (24)
2
n=81
Nonspecific back pain 15 (19)
Mechanical back pain 8 (9)
IBP 3 (4)
Degenerative disc disease/HNP a 9 (11)
Myalgia 14 (17)
Fibromyalgia 4 (5)
Hypermobility syndrome 1 (1)
Other** 12 (15)
Missing diagnosis 16 (20)
3 
n=30
Nonspecific back pain 6 (20)
Mechanical back pain 3 (10)
IBP 1 (3)
Degenerative disc disease/HNP a 3 (10)
Myalgia 2 (7)
Fibromyalgia 3 (10)
Hypermobility syndrome 0 (0)
Other*** 2 (7)
Missing diagnosis 10 (33)
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Table 1 Continued.
Number of SpA features¥ Alternative diagnoses N (%)
≥ 4 
n=18
Nonspecific back pain 4 (22)
Mechanical back pain 0 (0)
IBP 1 (6)
Degenerative disc disease/HNP a 4 (22)
Myalgia 1 (6)
Fibromyalgia 0 (0)
Hypermobility syndrome 1 (6)
Other**** 1 (6)
Missing diagnosis 6 (33)
¥ Total patient group: 0-1 SpA feature, n=159; 2 SpA features, n=143; 3 SpA features, n=79; ≥ 4 
SpA features, n=119. CBP, chronic back pain; axSpA, axial spondyloarthritis; SpA, spondyloarthritis. 
a Herniated Nucleus Pulposus. *Arthralgia, n=1; local pain syndrome, n=1; Diffuse idiopathic 
skeletal hyperostosis (DISH), n=1; ileitis condensans, n=1; osteoarthritis, n=2; Tarlov cyst, n=1; 
undifferentiated arthritis, n=1; uterus myomatosus, n=1. **Arthritis, n=3; functional complaints, 
n=2; osteoarthritis, n=2; pelvic instability, n=1; uterus myomatosus, n=1; tendinopathy, n=2. *** 
Undifferentiated oligoarthritis, n=1; tendinopathy, n=1. **** Osteoarthritis, n=1.
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Diagnostic uncertainty is common in patients with chronic back 
pain suspected of axial spondyloarthritis but is reduced by one-
year follow-up.
52   |   Chapter 4
ABSTRACT
Objectives
To investigate diagnostic uncertainty in patients suspected of axial spondyloarthritis (axSpA). 
Methods
SPACE is an inception cohort of chronic back pain (CBP) patients (≥ 3 months, ≤ 2 years, onset 
< 45 years) suspected of axSpA. Baseline and one-year visits, both including sacroiliac MRI 
and radiography, were analysed. Diagnosis was provided by the treating rheumatologist with 
level of confidence ≤6 defined as uncertain. 
Results
At baseline, 127/245 (52%) patients were diagnosed as axSpA, 46 (19%) as no axSpA, and 
72 patients (29%) had an uncertain diagnosis. Of the 72 patients with an uncertain diagnosis 
at baseline, at one year 17 (24%) received a diagnosis of axSpA, in 29 (40%) axSpA was 
excluded (no axSpA), and in 26 (36%) the diagnosis remained uncertain. In the patients with 
an uncertain baseline diagnosis 39/72 (54%) had gained at least one SpA feature after one-
year follow-up with a good response to NSAIDs (21%), and elevated CRP/ESR (15%) being 
the two most commonly gained features. Sacroiliac MRI became positive in 11% of these 
patients. At year one, 112/127 (88%) of patients with axSpA and 37/46 (80%) of patients 
with no axSpA had an unchanged diagnosis. Over one year, the percentage of patients with an 
uncertain diagnosis decreased from 72/245 (29%) to 47/245 (19%).
Conclusion
Diagnostic uncertainty is common in CBP patients suspected of having axSpA. Nevertheless, 
despite the limited accrual of SpA features, the overall decrease in uncertain diagnoses after 
one year justifies an expert approach of “wait and see” in cases of diagnostic uncertainty.
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INTRODUCTION
In spite of the efforts to facilitate earlier diagnosis, it is unclear if the reported diagnostic 
delay in axial spondyloarthritis (axSpA) has improved during the past decade.1-5 After relying 
on conventional imaging of the sacroiliac joints for many years, magnetic resonance imaging 
(MRI) was introduced as an imaging tool for the early recognition of axSpA. Not all patients 
develop structural bone damage (i.e. radiographic sacroiliitis) and it may take months to years 
before this occurs. MRI, however, can depict both inflammation and structural damage and is 
therefore potentially useful in the diagnostic work-up of early onset chronic back pain (CBP) 
patients with a suspicion of axSpA. Since a positive MRI of the sacroiliac joints was considered 
specific for axSpA it was added as an imaging criterion to the Assessment of Spondyloarthritis 
international Society (ASAS) classification criteria for axSpA.6 However, several studies have 
shown that inflammation in the sacroiliac joints can also occur in healthy individuals.7-9
Next to optimizing the use of imaging in the diagnostic process of (early) axSpA several 
studies have been conducted with the aim to help clinicians in diagnosing CBP patients with 
axSpA. The modified Berlin algorithm is a tool to assist clinicians in diagnosing patients 
presenting with CBP as axial spondyloarthritis.10 The algorithm is based on the number of 
spondyloarthritis (SpA) features and its use may result in extra diagnostic confidence.
AxSpA is a heterogeneous disease and may present with very different signs and symptoms. 
There is no single feature that reliably distinguishes axSpA from other conditions with CBP. In 
daily practice, a diagnosis of axSpA is usually based on a combination of signs and symptoms, 
imaging and laboratory testing. However, axSpA is a chronic disease and patients may develop 
additional SpA features over time so in patients where a certain diagnosis cannot be made, 
despite a full diagnostic work-up, a ‘wait and see policy’ has been recommended.11, 12
However, it is not known to what extent follow-up suffices to accrue a sufficient number of SpA 
features to reliably make a diagnosis of axSpA. We have recently shown already that repeating 
sacroiliac MRI after three months or one year is not useful.13 However, this study did not 
consider the development of other SpA features. In this study, we investigated if diagnostic 
uncertainty in patients with recent onset CBP improves after one-year follow-up. In addition, 
we systematically investigated SpA feature accrual in one year. 
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PATIENTS AND METHODS
Study design and population
The SPACE cohort is an ongoing multinational study of which the details have been published 
before.14 In summary, patients with chronic back pain (duration of ≥3 months but <2 years) of 
unknown origin and age of onset between 16 and 45 years are included. Patients are recruited 
from several rheumatology outpatient clinics in Europe. Patients signed informed consent 
before participation in the study and approval for the study was obtained from all local medical 
ethics committees.
Clinical assessments
All patients underwent a full work-up at baseline and one year follow-up, including physical 
examination, imaging of the sacroiliac joints (magnetic resonance imaging (MRI-SI) and 
radiographs (X-SI)), laboratory testing (acute phase reactants and HLA-B27), and assessment 
of all other SpA features: inflammatory back pain (IBP), good response to NSAIDs, positive 
family history of SpA, peripheral arthritis, dactylitis, heel enthesitis, acute anterior uveitis, 
inflammatory bowel disease (IBD), and psoriasis all according the definitions of the ASAS 
SpA criteria.6
Imaging assessments
Plain radiographs of the pelvis were performed in anteroposterior view. MRI acquired sequences 
were coronal oblique T1-weighted TSE and STIR with a slice thickness of 4 mm. The presence 
of sacroiliitis (yes/no) on radiographs and MRI of the sacroiliac joints was interpreted by the 
participating centres using global assessment as part of routine clinical practice (local reading). 
Diagnosis
At baseline and after one-year follow-up rheumatologists were asked to provide a diagnosis 
based on all collected information, including imaging (local reading) and HLA-B27 status. 
Rheumatologists were asked to provide a most likely alternative diagnosis in case of ‘no axSpA’. 
Regardless of the diagnosis (i.e. axSpA or no axSpA) rheumatologists were requested to state 
a level of confidence regarding the diagnosis on a numerical rating scale ranging from 0 (not 
confident at all) to 10 (very confident). Patients were labelled according to the following 
diagnosis groups with arbitrary cut-off values: (1) axSpA diagnosis with a level of confidence 
(LoC) ≥7, (2) no axSpA diagnosis with a LoC ≥7, and (3) axSpA or no axSpA diagnosis with a 
LoC ≤6 (‘no certain diagnosis’ group).
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Data analysis
Patients with baseline and one-year follow-up visits were analysed. The used database was 
locked in March 2016. Descriptive analyses were performed on the total patient group with 
visits at both time points and with available diagnosis. Total number of SpA features was 
determined after the full work-up, but without taking HLA-B27 and sacroiliac imaging into 
account. Furthermore, for the purpose of this study, SpA features were considered positive 
according to the principle of “once a feature always a feature”. This implies that patients can 
only gain but not lose features over time. For example, a patient with a positive sacroiliac 
MRI at baseline remained MRI positive even if the repeated sacroiliac MRI was not positive 
at one-year follow-up. Patient characteristics are presented for all defined diagnosis subgroups 
as frequencies (%) for categorical variables or as means and standard deviations (±SD) for 
continuous variables. Data analysis was performed using Stata SE V.14 (StataCorp LP, College 
Station, (TX, USA)). 
RESULTS
After database lock 257 patients with baseline and one-year follow-up visits were available. 
A total of 245 patients with CBP of short duration and complete information on diagnosis 
and corresponding LoC at both baseline and one-year follow-up were analysed. Of these, 38% 
were male, mean age (SD) was 30.6 (7.8) years, and mean symptom duration was 13.1 (7.1) 
months. Mean number of SpA features (SD) at baseline was 2.9 (1.6) and approximately half 
of the patients (n=121, 49%) gained ≥1 SpA feature after one year (Table 1). At baseline, 173 
patients already had a certain diagnosis (LoC ≥7): 127 (52%) of them were diagnosed with 
axSpA and 46 (19%) were definitely considered not having axSpA but another diagnosis. In 
72 (29%) patients a diagnosis could not be established with sufficient certainty (i.e. LoC ≤6) 
(Table 2). The mean (SD) LoC was 8.6 (1.0) in the axSpA group, 7.9 (0.7) in the non-axSpA 
group and 4.5 (1.5) in the uncertain diagnosis group. 
AxSpA diagnosis at baseline
Of the 127 patients at baseline with a diagnosis of axSpA, 112 (88%) were still diagnosed as 
such after one year (Table 3). In 3 (2%) axSpA patients rheumatologists changed the diagnosis 
to no axSpA, and in 12 (10%) patients the LoC regarding the axSpA diagnosis decreased to 
≤6. After one year, in the axSpA diagnosis group the most frequently gained SpA features were 
‘good response to NSAIDs’ (+29%), ‘elevated CRP/ESR’ (+12%), and ‘sacroiliitis on imaging’ 
(+6% and +11% for sacroiliitis on MRI and radiographs, respectively) (supplementary table 
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S1). Within the group of patients who changed from axSpA diagnosis to no axSpA (n=3) or 
uncertain diagnosis (n=12) feature gain after one year was limited (supplementary table S1). In 
the group of patients with axSpA the mean number of SpA features rose with 0.9 after one year. 
Table 1 Baseline demographic and clinical characteristics of CBP patients suspected of having axSpA, 
n= 245. 
Characteristic Baseline
Male, n (%) 94 (38)
Age at baseline (years), mean (SD) 30.6 (7.8)
Symptom duration (months), mean (SD) 13.1 (7.2)
IBP, n (%) 188 (78)
Good response to NSAIDs, n (%)¥ 115 (48)
Positive family history of SpA, n (%) 123 (50)
Past history or current symptoms
Peripheral arthritis, n (%) 46 (19)
Dactylitis, n (%) 22 (9)
Enthesitis, n (% 63 (26)
AAU, n (%) 24 (10)
IBD, n (%) 19 (8)
Psoriasis, n (%) 34 (14)
Elevated CRP/ESR, n (%) 74 (30)
Number of SpA features, mean (SD) º 2.9 (1.6)
Presence of 2 or more SpA features, n (%) 205 (84)
HLA-B27 positive, n (%) 131 (53)
Sacroiliitis radiographs, n (%)¥ 39 (16)
Sacroiliitis MRI, n (%)¥¥ 90 (38)
Mean (SD) LoC ‘axSpA diagnosis’ 8.6 (1.0)
Mean (SD) LoC ‘no axSpA diagnosis’ 7.9 (0.7)
Mean (SD) LoC ‘no certain diagnosis’ 4.5 (1.5)
IBP, inflammatory back pain; NSAIDs, non-steroidal anti-inflammatory drugs; SpA, spondyloarthritis; 
AAU, acute anterior uveitis; IBD, inflammatory bowel disease; CRP, C-reactive protein; ESR, 
erythrocyte sedimentation rate; HLA-B27, human leukocyte antigen B27; MRI, magnetic resonance 
imaging; LoC, level of confidence regarding diagnosis on a 1 to 10 scale with 1 implying little certainty 
and 10 implying great certainty about diagnosis. ºTotal number of SpA features after medical history 
taking, physical examination and measurement of acute phase reactants but before HLA-B27 testing 
and imaging. *axSpA diagnosis defined as LoC ≥7, n=127; no axSpA defined as LoC ≥7, n= 46, and 
no certain diagnosis defined as any diagnosis (axSpA or no axSpA) with a LoC ≤6, n= 72. n/a, not 
applicable. ¥ n= 242 CBP patients, ¥¥n= 236 CBP patients. n/a, not applicable. 
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Table 2 Baseline characteristics of CBP patients stratified according to certain and uncertain axSpA 





















Age (years), mean ±SD 30.3 (7.7) 31.0 (7.8) 31.0 (8.2)
Male, n (%) 59 (46) 11 (24) 24 (33)
IBP, n (%) 104 (82) 36 (78) 48 (67)
Good response to NSAIDs, n (%) 66 (53) 24 (53) 25 (35)
Positive family history of SpA, n (%) 57 (45) 25 (54) 41 (57)
Past history or current symptoms
Peripheral arthritis, n (%) 30 (24) 2 (4) 14 (19)
Dactylitis, n (%) 18 (14) 0 (0) 4 (6)
Enthesitis, n (%) 43 (34) 7 (15) 13 (18)
AAU, n (%) 16 (13) 2 (4) 6 (8)
IBD, n (%) 10 (8) 3 (7) 6 (8)
Psoriasis, n (%) 26 (20) 4 (9) 4 (6)
Elevated CRP/ESR, n (%) 53 (42) 8 (17) 13 (18)
Mean (SD) number of SpA features º 3.3 (1.7) 2.4 (1.0) 2.4 (1.3)
Presence of 2 or more SpA features, n (%) 122 (96) 38 (83) 55 (76)
HLA-B27 positive, n (%) 88 (69) 9 (20) 34 (47)
Sacroiliitis MRI, n (%) ¥ 82 (67) 0 (0) 8 (12)
Sacroiliitis radiography, n (%) 36 (29) 1 (2) 2 (3)
*No certain diagnosis defined as any diagnosis (axSpA or no axSpA) with a level of confidence (LoC) 
≤6. SpA features in this case are accumulated according to the principle of “once a feature always a 
feature”. AxSpA, axial spondyloarthritis; IBP, inflammatory back pain; NSAIDs, non-steroidal anti-
inflammatory drugs; SpA, spondyloarthritis; AAU, acute anterior uveitis; IBD, inflammatory bowel 
disease; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HLA-B27, human leukocyte 
antigen B27; MRI, magnetic resonance imaging. ºTotal number of SpA features after medical history 
taking, physical examination and measurement of acute phase reactants but before HLA-B27 testing 
and imaging. Level of certainty regarding diagnosis on a 1 to 10 scale with 1 implying little certainty 
and 10 implying great certainty about diagnosis. n/a, not applicable. ¥ n= 123 for patients with axSpA 
diagnosis, n= 68 for patients with no certain diagnosis. 
58   |   Chapter 4
No axSpA diagnosis at baseline
Of the 46 patients who were not diagnosed as having axSpA, 37 (80%) patients remained 
as ‘no axSpA’ after one-year follow-up (Table 3). In 9 (20%) patients the LoC changed to 
≤6. Remarkably, none of the patients ‘without axSpA’ changed into an axSpA diagnosis. 
In the no axSpA diagnosis group the most frequently gained SpA features after one year 
were: ‘IBP’ (+14%), ‘good response to NSAIDs’ (+10%), and ‘elevated CRP/ESR’ (+10%). 
Within the group of patients with an uncertain diagnosis (n=9) ‘elevated CRP/ESR’ was the 
most frequently acquired feature (+45%) (supplementary table S2). Most common diagnoses 
within the group of patients without axSpA were ‘non-specific back pain’, ‘(fibro)myalgia’ and 
degenerative disc disease’. 
Uncertain diagnosis at baseline
Of the 72 patients with uncertain diagnosis (i.e. LoC ≤6 for either axSpA or no axSpA), 17 
(24%) patients were diagnosed with axSpA after one-year follow-up (LoC ≥7) (Table 4). In 29 
(40%) patients rheumatologists changed their initial diagnosis to no axSpA with a LoC ≥7, and 
in 26 (36%) patients the LoC regarding diagnosis remained ≤6. In the patients diagnosed with 
axSpA after one year ‘IBP’ (+17%), ‘good response to NSAIDs’ (+30%), and ‘sacroiliitis on MRI’ 
(+24%) were the most prevalent SpA features gained. Although patients in the no axSpA and 
the uncertain diagnosis groups frequently gained new SpA features (‘good response to NSAIDs’ 
(+14% and +23% respectively), ‘elevated CRP/ESR’ (+11% and +31%), and ‘sacroiliitis on MRI’ 
(+7% and +8%)), they remained in the ‘no axSpA’ or ‘uncertain diagnosis’ groups. 
The mean (SD) diagnostic confidence increased at one-year follow-up: 8.8 (1.0) (vs. baseline 
8.6 (1.0)) in the axSpA group, 8.3 (1.0) (vs. baseline 7.9 (0.7)) in the no axSpA group and in 
the uncertain diagnosis group the LoC was 4.7 (1.4) (vs baseline 4.5 (1.5)).
Table 3 Diagnosis at baseline and after one-year follow-up in patients with chronic back pain suspected 
of axSpA.
Diagnosis at follow-up
Diagnosis at baseline AxSpA No axSpA No certain diagnosis* Total
AxSpA 112 3 12 127
No axSpA 0 37 9 46
No certain diagnosis* 17 29 26 72
Total 129 69 47 245
* No certain diagnosis defined as any diagnosis (axSpA or no axSpA) with a level of confidence (LoC) 
≤6. AxSpA, axial spondyloarthritis. 
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Table 4 Feature gain of baseline ‘no certain diagnosis’ patients at one-year follow-up stratified for 
their follow-up diagnosis status (n=72).
Diagnosis at one-year follow-up









IBP, n (%) +10 (14) +3 (17) +1 (3) +6 (23)
Good response to NSAIDs, n (%) +15 (21) +5 (30) +4 (14) +6 (23)
Positive family history of SpA, n (%) +2 (3) 0 (0) +1 (3) +1 (4)
Past history or current symptoms
Peripheral arthritis, n (%) 0 (0) 0 (0) 0 (0) 0 (0)
Dactylitis, n (%) +1 (1) +1 (6) 0 (0) 0 (0)
Enthesitis, n (%) +4 (6) +1 (6) +2 (7) +1 (4)
AAU, n (%) +1 (1) 0 (0) +1 (3) 0 (0)
IBD, n (%) +2 (3) +1 (6) 0 (0) +1 (4)
Psoriasis, n (%) +2 (3) 0 (0) +1 (3) +1 (4)
Elevated CRP/ESR, n (%) +11 (15) 0 (0) +3 (11) +8 (31)
Number of SpA features gained, mean º +0.7 +0.7 +0.5 +0.9
Sacroiliitis MRI, n (%) +8 (11) +4 (24) +2 (7) +2 (8)
Sacroiliitis radiography, n (%) 0 (0) 0 (0) 0 (0) 0 (0)
* No certain diagnosis defined as any diagnosis (SpA or no SpA) with a level of confidence (LoC) 
≤6. SpA features in this case are accumulated according to the principle of “once a feature always a 
feature”. AxSpA, axial spondyloarthritis; IBP, inflammatory back pain; NSAIDs, non-steroidal anti-
inflammatory drugs; SpA, spondyloarthritis; AAU, acute anterior uveitis; IBD, inflammatory bowel 
disease; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HLA-B27, human leukocyte 
antigen B27; MRI, magnetic resonance imaging. ºTotal number of SpA features after medical history 
taking, physical examination and measurement of acute phase reactants but before HLA-B27 testing 
and imaging. Level of certainty regarding diagnosis on a 1 to10 scale with 1 implying little certainty 
and 10 implying great certainty about diagnosis. n/a, not applicable.
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DISCUSSION 
In this study we have evaluated the evolution of diagnostic uncertainty in CBP patients 
with a suspicion of axSpA in relation to the accrual of SpA features during one-year 
follow up. In only about 1% of patients with axSpA at baseline rheumatologists changed 
a diagnosis from axSpA into ‘no axSpA’ or in an ‘uncertain diagnosis’. Interestingly, 
none of the patients with ‘no axSpA’ at baseline were diagnosed as axSpA at follow-up. 
Nevertheless, in some of these cases rheumatologists were less certain about ‘no axSpA’. We 
found that standardized follow-up led to a decrease of patients with uncertain diagnosis, 
however, despite an extensive work-up some uncertainty regarding the diagnosis remained 
at follow-up. Remarkably, around two-third of patients with an uncertain diagnosis at 
baseline received a definite diagnosis (either ‘no axSpA’ or ‘ axSpA’) after one-year follow-
up. In addition, approximately half of the patients had developed at least one new SpA 
feature after one year but this did in most instances not lead to a change in diagnosis or 
level of certainty. 
In all diagnosis subgroups the most frequently acquired SpA features were ‘good response to 
NSAIDs’, ‘IBP’, ‘positive family history of SpA’, and ‘elevated acute phase reactants’. Most of 
these are relatively subjective SpA features and reporting may differ between the baseline and 
follow-up visits. For example, patients may have had a better understanding of their symptoms 
after their visit to the rheumatologist thus leading to a positive answer at follow-up. The 
acquisition of these features may not really reflect a newly developed SpA feature, but rather 
a better comprehension of the SpA feature in question. Although half of the patients acquired 
at least one SpA feature, it did not lead to major diagnosis changes. A possible explanation is 
that rheumatologists may base their diagnosis and their diagnostic certainty on different SpA 
features. Certain SpA features may bear more “weight” when considering an axSpA diagnosis. 
For example, rheumatologists may mistrust the feature ‘good response to NSAIDs’ when 
considering a diagnosis of axSpA but may put more weight on ‘inflammation on MRI-SI’. 
These relative differences could not be assessed in this study and should be evaluated in future 
research on the diagnostic process of early axSpA. 
An important limitation of this study is that there is no gold standard for diagnosing axSpA 
and that rheumatologists might base their diagnosis on different considerations, which may 
have influenced the diagnostic LoCs. In addition, patients were not necessarily seen by the 
same rheumatologist at follow-up, which might have influenced the LoCs because of inter-
observer variability. Moreover, patients were diagnosed by hospital-based rheumatologists with 
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an affinity for axSpA, and as such, findings from this study cannot be extrapolated to different 
clinical settings such as primary care and common rheumatology practices or those of other 
medical specialities. A strength of the study, however, is that all patients received the same 
protocolized work-up at baseline and one-year follow-up. 
Another aspect -as often in daily practice- is that differences may be attributed to different 
levels of clinical expertise. A more experienced rheumatologist may feel more confident in 
diagnosing axSpA, thus giving a higher validation, than one with less experience. We have, 
however, not made this distinction in our study as these data are not available. Furthermore, 
the cut-off value for the level of confidence to stratify the different diagnosis groups was 
chosen arbitrarily as it is unclear what defines an uncertain or definite diagnosis. It is 
plausible that the number of diagnosis changes after one-year follow-up is different with 
another cut-off value. 
As earlier mentioned, diagnostic uncertainty in this study was defined arbitrarily by choosing 
a cut-off value of the LoC regarding diagnosis. There is, however, no clear definition of 
diagnostic uncertainty nor a scientific method to measure diagnostic uncertainty in daily 
clinical practice.15, 16 In this study we have shown that diagnostic uncertainty is quite common 
in CBP patients suspected of axSpA. Arguably, this diagnostic uncertainty is multifactorial. 
AxSpA has a heterogeneous clinical presentation in CBP patients and remains difficult to 
diagnose, even after excluding all other differential diagnoses. In addition, diagnostic criteria 
do not exist and recognition of axSpA may also depend on the clinician’s experience (i.e. 
the ability of pattern recognition) in axSpA. Although follow-up in the SPACE cohort is 
performed according to a standard protocolized work-up, diagnostic uncertainty (outside of a 
research cohort context) may lead to over-testing and thus excessive use of health care resources. 
Diagnostic uncertainty is inherent to the practise of medicine. From the data of this study 
we may conclude that at baseline rheumatologists formed a hypothesis rather than a definite 
diagnosis which may evolve over time. Future research should focus on the clinical reasoning of 
axSpA diagnosis to truly identify what makes an axSpA diagnosis according to rheumatologists 
and which patients might benefit from regular outpatient visits.
In conclusion, diagnostic uncertainty is common in CBP patients suspected of axSpA and 
persists in a substantial number of patients after one-year follow-up. Nevertheless, despite the 
limited accrual of SpA features, the overall decrease in number of patients with an uncertain 
diagnosis after one year favours the experts’ recommendation of pursuing a “wait and see 
approach” in cases of diagnostic uncertainty.
62   |   Chapter 4
REFERENCES
1. Feldtkeller E, Khan MA, van der Heijde D, et al. Age at disease onset and diagnosis delay in 
HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 2003;23:61-6.
2. Salvadorini G, Bandinelli F, Delle Sedie A, et al. Ankylosing spondylitis: how diagnostic and ther-
apeutic delay have changed over the last six decades. Clin Exp Rheumatol 2012;30:561-5.
3. Sorensen J, Hetland ML. Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis 
and ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 
2015;74:e12.
4. Sykes MP, Doll H, Sengupta R, et al. Delay to diagnosis in axial spondyloarthritis: are we improving 
in the UK? Rheumatology (Oxford) 2015;54:2283-4.
5. Masson Behar V, Dougados M, Etcheto A, et al. Diagnostic delay in axial spondyloarthritis: A 
cross-sectional study of 432 patients. Joint Bone Spine 2017;84:467-71.
6. Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloAr-
thritis international Society classification criteria for axial spondyloarthritis (part II): validation and 
final selection. Ann Rheum Dis 2009;68:777-83.
7. Weber U, Maksymowych WP. Sensitivity and specificity of magnetic resonance imaging for axial 
spondyloarthritis. Am J Med Sci 2011;341:272-7.
8. de Winter J, de Hooge M, van de Sande M, et al. Magnetic Resonance Imaging of the Sacroiliac 
Joints Indicating Sacroiliitis According to the Assessment of SpondyloArthritis international Society 
Definition in Healthy Individuals, Runners, and Women With Postpartum Back Pain. Arthritis 
Rheumatol 2018;70:1042-8.
9. Weber U, Jurik AG, Zejden A, et al. Frequency and Anatomic Distribution of Magnetic Resonance 
Imaging Features in the Sacroiliac Joints of Young Athletes: Exploring “Background Noise” Toward 
a Data-Driven Definition of Sacroiliitis in Early Spondyloarthritis. Arthritis Rheumatol 2018;70:736-
45.
10. van den Berg R, de Hooge M, Rudwaleit M, et al. ASAS modification of the Berlin algorithm for 
diagnosing axial spondyloarthritis: results from the SPondyloArthritis Caught Early (SPACE)-cohort 
and from the Assessment of SpondyloArthritis international Society (ASAS)-cohort. Ann Rheum Dis 
2013;72:1646-53.
11. Deodhar A, Mease PJ, Reveille JD, et al. Frequency of axial spondyloarthritis diagnosis among pa-
tients seen by United States rheumatologists for evaluation of chronic back pain. Arthritis Rheumatol 
2016.
12. Diagnosis and differential diagnosis of axial spondyloarthritis (ankylosing spondylitis and 
nonradiographic axial spondyloarthritis) in adults. [https://www.uptodate.com/contents/diag-
nosis-and-differential-diagnosis-of-axial-spondyloarthritis-ankylosing-spondylitis-and-nonradio-
graphic-axial-spondyloarthritis-in-adults]
13. Bakker PAC, Ramiro S, Ez-Zaitouni Z, et al. Is it Useful to Repeat Magnetic Resonance Imaging 
of the Sacroiliac Joints After Three Months or One Year in the Diagnosis of Patients With Chronic 
Back Pain and Suspected Axial Spondyloarthritis? Arthritis Rheumatol 2019;71:382-91.
4
Diagnostic uncertainty in patients with chronic back pain   |   63
14. van den Berg R, de Hooge M, van Gaalen F, et al. Percentage of patients with spondyloarthritis in 
patients referred because of chronic back pain and performance of classification criteria: experience 
from the Spondyloarthritis Caught Early (SPACE) cohort. Rheumatology (Oxford) 2013;52:1492-9.
15. Simpkin AL, Schwartzstein RM. Tolerating Uncertainty - The Next Medical Revolution? N Engl 
J Med 2016;375:1713-5.
16. Bhise V, Rajan SS, Sittig DF, et al. Defining and Measuring Diagnostic Uncertainty in Medicine: 
A Systematic Review. J Gen Intern Med 2018;33:103-15.
64   |   Chapter 4
SUPPLEMENTARY MATERIAL
Table S1. Feature gain of baseline axSpA patients at one-year follow-up stratified for their follow-up 
diagnosis status (n=127).
Diagnosis at one-year follow-up







IBP, n (%) +12 (11) 0 0
Good response to NSAIDs, n (%) +33 (29) +2 (67) +7 (59)
Positive family history of SpA, n (%) +5 (4) 0 +1 (8)
Past history or current symptoms
Peripheral arthritis, n (%) +4 (3) 0 +1 (8)
Dactylitis, n (%) +8 (7) 0 0
Enthesitis, n (%) +5 (4) 0 +1 (8)
AAU, n (%) +2 (2) 0 +1 (8)
IBD, n (%) +1 (1) 0 0
Psoriasis, n (%) +6 (5) 0 0
Elevated CRP/ESR, n (%) +14 (12) 0 0
Number of SpA features, mean º +0.9 +0.7 +0.9
Presence of 2 or more SpA features, n (%) +12 (11) +2 (67) 0
HLA-B27 positive, n (%) n/a n/a n/a
Sacroiliitis MRI, n (%)¥ +9 (6) 0 +1 (8)
Sacroiliitis radiography, n (%) +13 (11) 0 0
* No certain diagnosis defined as axSpA diagnosis with a level of confidence (LoC) ≤6 or no axSpA 
diagnosis with LoC ≤6. SpA features in this case are accumulated according to the principle of “once 
a feature always a feature”. AxSpA, axial spondyloarthritis; IBP, inflammatory back pain; NSAIDs, 
non-steroidal anti-inflammatory drugs; SpA, spondyloarthritis; AAU, acute anterior uveitis; IBD, 
inflammatory bowel disease; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HLA-B27, 
human leukocyte antigen B27; MRI, magnetic resonance imaging. ºTotal number of SpA features after 
medical history taking, physical examination and measurement of acute phase reactants but before 
HLA-B27 testing and imaging. LoC, Level of certainty regarding diagnosis on a 1 to10 scale with 1 
implying little certainty and 10 implying great certainty about diagnosis. n/a, not applicable. ¥ n= 
108 for axSpA patients with LoC ≥7.
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Table S2. Feature gain of baseline ‘no axSpA’ patients (LoC>6) at one-year follow-up stratified for 
their follow-up diagnosis status (n=46).
Diagnosis at one-year follow-up







IBP, n (%) - +5 (14) +1 (11)
Good response to NSAIDs, n (%) - +4 (10) 0
Positive family history of SpA, n (%) - 0 +1 (11)
Past history or current symptoms
Peripheral arthritis, n (%) - 0 0
Dactylitis, n (%) - +1 (3) 0
Enthesitis, n (%) - +1 (3) 0
AAU, n (%) - 0 0
IBD, n (%) - 0 0
Psoriasis, n (%) - 0 0
Elevated CRP/ESR, n (%) - +4 (10) +4 (45)
Number of SpA features, mean º - +0.4 +0.6
Presence of 2 or more SpA features, n (%) - +2 (5) +1 (11)
HLA-B27 positive, n (%) n/a n/a n/a
Sacroiliitis MRI, n (%) - 0 0
Sacroiliitis radiography, n (%) - 0 0
* No certain diagnosis defined as axSpA diagnosis with a level of confidence (LoC) ≤6 or no axSpA 
diagnosis with LoC ≤6. SpA features in this case are accumulated according to the principle of “once 
a feature always a feature”. AxSpA, axial spondyloarthritis; IBP, inflammatory back pain; NSAIDs, 
non-steroidal anti-inflammatory drugs; SpA, spondyloarthritis; AAU, acute anterior uveitis; IBD, 
inflammatory bowel disease; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HLA-B27, 
human leukocyte antigen B27; MRI, magnetic resonance imaging. ºTotal number of SpA features after 
medical history taking, physical examination and measurement of acute phase reactants but before 
HLA-B27 testing and imaging. Level of certainty regarding diagnosis on a 1 to10 scale with 1 implying 
little certainty and 10 implying great certainty about diagnosis. n/a, not applicable. 
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Arthritis Res Ther, 2017. 19(1): p. 118.
5
Is the current ASAS expert definition of a positive family 
history useful in identifying axial spondyloarthritis? 
Results from the SPACE and DESIR cohorts.
68   |   Chapter 5
ABSTRACT
Background
The Assessment of SpondyloArthritis international Society (ASAS) definition of a positive 
family history (PFH) of spondyloarthritis (SpA) includes the following diseases in first- or 
second-degree relatives: ankylosing spondylitis (AS), acute anterior uveitis (AAU), reactive 
arthritis (ReA), inflammatory bowel disease (IBD), and psoriasis. However, it is not known 
if a PFH for each of these diseases contributes to making a diagnosis of axSpA, sacroiliitis on 
imaging or fulfilling the ASAS criteria in patients presenting with chronic back pain (CBP). 
Therefore, the aim was to assess which SpA diseases in family members are associated with 
HLA-B27 and axial spondyloarthritis (axSpA) in CBP patients.
Methods
CBP patients suspected of axSpA from the SPACE (n=438) and the DESIR (n=647) cohort 
were asked about the presence of SpA diseases in first- or second-degree relatives (AS, AAU, 
ReA, IBD, and psoriasis). The associations between a PFH and HLA-B27, sacroiliitis on 
imaging (MRI or radiographs), axSpA diagnosis, and ASAS classification in CBP patients 
were assessed. 
Results 
In the SPACE and the DESIR cohort, a PFH of AS (odds ratio (OR) 5.9 (3.5-9.9) and OR 3.3 
(2.1-5.2)) and a PFH of AAU (OR 9.8 (3.3-28.9) and OR 21.6 (2.9-160.1)) were significantly 
associated with presence of HLA-B27. Furthermore, in both cohorts a PFH of AS and a PFH of 
AAU were positively associated with fulfilment of the ASAS criteria, but not with sacroiliitis 
on imaging. In SPACE but not in DESIR a PFH of AAU was positively associated with axSpA 
diagnosis. In both cohorts, a PFH of ReA, IBD, or psoriasis was not positively associated with 
HLA-B27 positivity, sacroiliitis on imaging, axSpA diagnosis or meeting the ASAS criteria 
for axSpA.
Conclusions 
In our cohorts, a PFH of AS or AAU is useful for case-finding of axSpA as this is correlated 
with HLA-B27 carriership. However, as a PFH of ReA, IBD, or psoriasis does not contribute 
to identifying axSpA in CBP patients, these data suggest that the widely used ASAS definition 
of a PFH of SpA should be updated.
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BACKGROUND
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease mainly involving the spine 
and sacroiliac joints. Genetic risk factors play a role in axSpA with human leukocyte antigen 
B27 (HLA-B27) by far the strongest genetic risk factor for disease. 1 A positive family history 
(PFH) of SpA has been reported in up to 40% of ankylosing spondylitis (AS) patients and the 
risk to develop AS in HLA-B27 positive first-degree relatives of HLA-B27 positive AS patients 
has been estimated to be 16 times higher than that of HLA-B27 positive individuals in the 
general population.2-5 As a result, familial aggregation of SpA is considered a risk indicator 
for the presence of axSpA in patients with chronic back pain (CBP) and is part of several SpA 
classification criteria sets.6-8 
In the Assessment of SpondyloArthritis international Society (ASAS) classification criteria 
for axSpA, a PFH of SpA is defined as the presence of any of the following diseases in 
first- or second-degree relatives: AS, acute anterior uveitis (AAU), reactive arthritis (ReA), 
inflammatory bowel disease (IBD), and psoriasis.8. This PFH definition is also recommended 
in diagnosing axSpA, and is incorporated in several referral strategies for CBP patients used 
by non-rheumatologists.9, 10
However, only three of these diseases have a documented HLA-B27 association (i.e. AS, AAU, 
ReA) and two are not HLA-B27 associated (i.e. IBD, psoriasis). 11-13 So, even though a PFH 
of SpA is a common finding in axSpA patients, it is unknown whether a PFH of each of these 
diseases contributes equally well to making a diagnosis of axSpA in patients presenting with 
CBP.
In this study, we present data from two unique early axSpA cohorts: the multinational 
multicenter SPondyloArthritis Caught Early (SPACE) cohort and the French multicenter 
DEvenir des Spondylarthropathies Indifférenciées Récentes (DESIR) cohort. In these cohorts 
of CBP patients with a suspicion of axSpA we have investigated which of the SpA diseases 
present among family members were associated with HLA-B27, sacroiliitis on imaging, a 
clinical diagnosis of axSpA, and meeting the ASAS classification criteria for axSpA.
70   |   Chapter 5
METHODS
Patient cohorts
The SPACE cohort is a prospective study which includes patients with short term CBP (≥3 
months, ≤2 years, and an onset <45 years) at a minimum age of 16 years from five Rheumatology 
outpatient clinics in the Netherlands, Norway, and Italy. DESIR is a prospective longitudinal 
cohort running in 25 centers in France (clinicaltrials.gov NCT01648907). Patients between 
the ages of 18 and 50 years with inflammatory back pain (IBP) according to the Calin14 or 
Berlin15 criteria, persisting ≥3 months but <3 years, were included. In addition, the treating 
rheumatologist had to have a substantial suspicion of axSpA (level of confidence ≥5 on a 
0-10 rating scale, where 0=not confident and 10=very confident). A detailed description of 
both cohorts is provided elsewhere. 16, 17 Both studies were approved by local medical ethics 
committees. All participants provided written informed consent beforehand. 
Clinical data collection 
All patients underwent a diagnostic work-up according to a fixed protocol which includes 
physical examination, laboratory assessments (HLA-B27, C-reactive protein (CRP), and 
erythrocyte sedimentation rate (ESR)), and magnetic resonance imaging (MRI) as well as 
radiographs of sacroiliac joints. The presence and history of clinical SpA features were assessed: 
inflammatory back pain (IBP), good response to non-steroidal anti-inflammatory drugs 
(NSAIDs), peripheral arthritis, dactylitis, enthesitis, AAU, IBD, and psoriasis. Patients were 
inquired about the presence of any of the following SpA diseases in first- or second-degree 
relatives: AS, AAU, ReA, IBD, and psoriasis. For each SpA disease possible answers were “yes”, 
“no” or “unknown/uncertain”. A PFH was defined as the presence of ≥1 SpA related disease 
in first- (mother, father, sister, brother, daughter, son) or second-degree relatives (aunt, uncle, 
niece, nephew, grandmother, and grandfather) reported by the patient. 8 
In the SPACE cohort, axSpA was diagnosed by the treating rheumatologist. In the DESIR 
cohort axSpA diagnosis was defined as the level of confidence regarding diagnosis of ≥8 on a 
0–10 numerical rating scale (where 0=not confident at all and 10=very confident). The ASAS 
axSpA classification criteria were used to classify patients. 
Data analysis
Baseline demographic and clinical characteristics are presented using descriptive statistics 
for both the SPACE and DESIR cohorts. The association between each PFH disease 
and HLA-B27 in patients was assessed using the Chi-squared test. Similar analyses 
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were performed for the assessment of the association between each PFH disease and a 
clinical diagnosis of axSpA, sacroiliitis on imaging (defined as either sacroiliitis on MRI, 
radiographs or on both modalities by local reading), and the fulfilment of the ASAS axSpA 
classification criteria. Statistical testing was performed using Stata SE v.14 (StataCorp LP, 
College Station, Texas, USA).
RESULTS
For the current analyses, 438 patients from the SPACE cohort and 647 patients from the DESIR 
cohort with complete data at baseline were used (Table 1). Several baseline characteristics 
differed between the two cohorts, mainly reflecting differences in inclusion criteria. In both 
cohorts, the distribution of all PFH diseases (AS, AAU, ReA, IBD, and psoriasis) in first- or 
second-degree relatives were similar. 
In both the SPACE and DESIR cohort, any PFH, a PFH of AS, and a PFH of AAU were 
significantly associated with HLA-B27 in CBP patients (Table 2). In multivariable analyses, a 
PFH of AS or AAU were independently associated with HLA-B27 positivity (data not shown). 
However, in neither cohort a PFH of ReA, IBD, or psoriasis was associated with HLA-B27 
positivity. 
To investigate whether the presence of any of the PFH diseases in relatives is associated with 
sacroiliitis, a clinical diagnosis of axSpA or a positive ASAS classification similar analyses were 
performed. In both cohorts, neither ‘any PFH’ nor a separate PFH disease were associated 
with sacroiliitis (see online Supplementary Table S1). In SPACE but not in DESIR a PFH of 
AAU was positively associated with axSpA diagnosis (see online Supplementary Table S2). 
While a PFH of AS or AAU had a significant positive association with fulfilment of the ASAS 
criteria, such an association was not found for a PFH of ReA, IBD or psoriasis in the SPACE 
and DESIR cohorts (Table 3).
In addition, the relative contribution of HLA-B27 was investigated among patients who were 
classified according to the ASAS criteria. A total of 203 (46%) patients from the SPACE cohort 
and 410 (63%) patients from the DESIR cohort fulfilled the ASAS criteria for axSpA, and 156 
(77%) and 347 (85%) patients were HLA-B27 positive, respectively (Table 4). A PFH was 
reported more frequently in HLA-B27 positive patients than in HLA-B27 negative patients 
meeting the ASAS classification criteria (SPACE 45% vs 7% and DESIR 35% vs 6%).
72   |   Chapter 5
Table 1 Baseline characteristics and clinical features of CBP patients in the SPACE (n=438) and 





Age, years 31.3 (8.3) 33.6 (8.6)
Symptom duration, months 13.4 (7.4) 18.1 (10.5)
Male 165 (38) 305 (47)
IBP 286 (66) 647 (100)*
Good response to NSAIDs a 181/420 (43) 515/643 (80)
Past history or current symptoms
Peripheral arthritis 64 (15) 363 (56)
Dactylitis 24 (6) 83 (13)
Enthesitis 89 (20) 312 (48)
AAU 34 (8) 51 (8)
IBD 34 (8) 23 (4)
Psoriasis 51 (12) 97 (15)
Elevated CRP (mg/L) / ESR (mm) b 123 (28) 254 (39)
HLA-B27 positive 174/436 (40) 376/646 (58)
Sacroiliitis, radiography¥ 48/434 (11) 172 (27)
Sacroiliitis, MRI¥ 135/431 (31) 207/636 (33)
ASAS criteria for axSpA 203 (46) 410/634 (65)
Any positive family history c 185 (42) 249 (39)
PFH of AS 90 (21) 127 (20)
PFH of AAU 27 (6) 29 (5)
PFH of ReA 14 (3) 6 (1)
PFH of IBD 33 (8) 32 (5)
PFH of Psoriasis 83 (19) 129 (20)
Total number of SpA diseases in first- or second-degree relatives 
Number of patients with 1 disease 135 (73) 189 (76)
Number of patients with 2 diseases 39 (21) 47 (19)
Number of patients with ≥3 diseases 11 (6) 13 (5)
Unless specified otherwise, results are presented as mean ± SD or number (%). * Inclusion criterion. CBP, 
chronic back pain; IBP, inflammatory back pain; NSAIDs, non-steroidal anti-inflammatory drugs; SpA, 
spondyloarthritis; AS, ankylosing spondylitis; AAU, acute anterior uveitis; ReA, reactive arthritis; IBD, 
inflammatory bowel disease; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HLA-B27, 
human leucocyte antigen B27; ASAS axSpA criteria, Assessment of Spondyloarthritis international 
Society criteria for axial Spondyloarthritis; PFH, positive family history. ¥Imaging based on local reading. 
MRI, magnetic resonance imaging of sacroiliac joints. a Back pain not present anymore or is much better 
24–48 hours after a full dose of NSAID. b Values greater than the upper limit of normal. c Presence in 
first- or second-degree relatives of any of the following: AS, AAU, ReA, IBD, or psoriasis. 
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Table 2 Association of family history manifestations with HLA-B27 in CBP patients in the SPACE 









n= 270 OR (95% CI) P- value
Any PFH 97 87 2.5 (1.7-3.8) <0.001 158 91 1.4 (1.0-2.0) 0.032
AS 65 24 5.9 (3.5-9.9) <0.001 100 27 3.3 (2.1-5.2) <0.001
AAU 23 4 9.8 (3.3-28.9) <0.001 28 1 21.6 (2.9-160.1) 0.003
ReA 5 9 0.8 (0.3-2.5) 0.745 1 5 0.1 (0.01-1.2) 0.075
IBD 12 21 0.9 (0.4-1.8) 0.666 17 15 0.8 (0.4-1.6) 0.551
Psoriasis 34 48 1.1 (0.6-1.8) 0.750 69 60 0.8 (0.5-1.2) 0.225
HLA-B27, human leukocyte antigen B27; CBP, chronic back pain; Any PFH, any family history 
manifestation in first- or second-degree relatives; AS, ankylosing spondylitis; AAU, acute anterior uveitis; 
ReA, reactive arthritis; IBD, inflammatory bowel disease; OR, odds ratio; 95% CI, 95% confidence 
interval. * 2 patients with unknown HLA-B27 status; **1 with patient unknown HLA-B27 status.
Table 3 Association of family history manifestations with the fulfilment of ASAS axSpA criteria in 
the SPACE cohort and DESIR cohorts. 
Fulfilment of ASAS axSpA criteria
SPACE DESIR
OR (95% CI) P- value OR (95% CI) P- value
Any PFH 2.1 (1.4-3.1) <0.001 1.3 (1.0-1.9) 0.091
AS 3.3 (2.0-5.3) <0.001 2.1 (1.3-3.3) <0.001
AAU 7.4 (2.5-21.7) <0.001 5.0 (1.5-16.7) 0.009
ReA 0.6 (0.2-1.9) 0.421 0.3 (0.05-1.5) 0.132
IBD 1.1 (0.5-2.2) 0.798 0.8 (0.4-1.6) 0.521
Psoriasis 1.2 (0.8-2.0) 0.388 1.2 (0.8-1.8) 0.464
Any PFH, any family history manifestation in first- or second-degree relatives; AS, ankylosing 
spondylitis; AAU, acute anterior uveitis; ReA, reactive arthritis; IBD, inflammatory bowel disease; 
OR, odds ratio; 95% CI, 95% confidence interval. 
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Table 4 PFH diseases in first- or second-degree relatives of CBP patients meeting the ASAS axSpA 







HLA-B27+ HLA-B27- HLA-B27+ HLA-B27-
Any PFH 90 (45%) 14 (7%) 145 (35%) 24 (6%)
AS 59 (29%) 2 (1%) 92 (23%) 5 (1%)
AAU 22 (11%) 1 (1%) 26 (6%) 0 (0)
ReA 4 (1%) 1 (1%) 1 (0.2%) 1 (0.2%)
IBD 11 (6%) 5 (3%) 14 (3%) 5 (1%)
Psoriasis 32 (16%) 9 (5%) 65 (16%) 20 (5%)
ASAS axSpA criteria, Assessment of Spondyloarthritis international Society criteria for axial 
Spondyloarthritis; HLA-B27, human leucocyte antigen B27; Any PFH, any family history manifestation 
in first- or second-degree relatives; AS, ankylosing spondylitis; AAU, acute anterior uveitis; ReA, 
reactive arthritis; IBD, inflammatory bowel disease.*203 patients fulfilled ASAS-criteria, 2 with 
unknown HLA-B27 status; **410 patients fulfilled ASAS-criteria, 1 with unknown HLA-B27 status.
Table 2 Association of family history manifestations with HLA-B27 in CBP patients in the SPACE 









n= 270 OR (95% CI) P- value
Any PFH 97 87 2.5 (1.7-3.8) <0.001 158 91 1.4 (1.0-2.0) 0.032
AS 65 24 5.9 (3.5-9.9) <0.001 100 27 3.3 (2.1-5.2) <0.001
AAU 23 4 9.8 (3.3-28.9) <0.001 28 1 21.6 (2.9-160.1) 0.003
ReA 5 9 0.8 (0.3-2.5) 0.745 1 5 0.1 (0.01-1.2) 0.075
IBD 12 21 0.9 (0.4-1.8) 0.666 17 15 0.8 (0.4-1.6) 0.551
Psoriasis 34 48 1.1 (0.6-1.8) 0.750 69 60 0.8 (0.5-1.2) 0.225
HLA-B27, human leukocyte antigen B27; CBP, chronic back pain; Any PFH, any family history 
manifestation in first- or second-degree relatives; AS, ankylosing spondylitis; AAU, acute anterior uveitis; 
ReA, reactive arthritis; IBD, inflammatory bowel disease; OR, odds ratio; 95% CI, 95% confidence 
interval. * 2 patients with unknown HLA-B27 status; **1 with patient unknown HLA-B27 status.
Table 3 Association of family history manifestations with the fulfilment of ASAS axSpA criteria in 
the SPACE cohort and DESIR cohorts. 
Fulfilment of ASAS axSpA criteria
SPACE DESIR
OR (95% CI) P- value OR (95% CI) P- value
Any PFH 2.1 (1.4-3.1) <0.001 1.3 (1.0-1.9) 0.091
AS 3.3 (2.0-5.3) <0.001 2.1 (1.3-3.3) <0.001
AAU 7.4 (2.5-21.7) <0.001 5.0 (1.5-16.7) 0.009
ReA 0.6 (0.2-1.9) 0.421 0.3 (0.05-1.5) 0.132
IBD 1.1 (0.5-2.2) 0.798 0.8 (0.4-1.6) 0.521
Psoriasis 1.2 (0.8-2.0) 0.388 1.2 (0.8-1.8) 0.464
Any PFH, any family history manifestation in first- or second-degree relatives; AS, ankylosing 
spondylitis; AAU, acute anterior uveitis; ReA, reactive arthritis; IBD, inflammatory bowel disease; 
OR, odds ratio; 95% CI, 95% confidence interval. 
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DISCUSSION 
To our knowledge, this is the first study to investigate the usefulness of the separate SpA 
diseases in a PFH as defined for the ASAS classification criteria. In two independent cohorts 
of predominantly Caucasoid Europeans, we found that in CBP patients suspected of axSpA 
a PFH of ReA, IBD or psoriasis were neither associated with HLA-B27 positivity, nor with 
sacroiliitis, a diagnosis of axSpA or fulfilment of the ASAS criteria. In contrast, a PFH of AS 
or AAU was strongly correlated with HLA-B27 carriership. 
IBD and psoriasis are generally not HLA-B27 associated diseases, but ReA has been reported to 
be associated with HLA-B27 in a secondary care setting, although in population-based studies 
the prevalence of HLA-B27 in ReA was comparable to that of the general population.12, 18 A 
possible explanation for the absence of the association between ReA and HLA-B27 in our study 
is that the (self)reported prevalence of ReA in family members of patients in the SPACE and 
DESIR cohort was low, suggesting underreporting. 
It is important to emphasize that the current study is done in patients with predominantly axial 
symptoms. Although only a PFH of AS or AAU have shown to be independently associated 
with HLA-B27, this does not mean that a PFH of the other SpA diseases is always irrelevant.19 
For example, presence of psoriasis in relatives could be relevant in a patient with peripheral 
symptoms suspected of psoriatic arthritis.20
A strength of this study is the use of two large early axSpA cohorts in which all patients were 
assessed following a similar protocol which allowed for replication of findings. Strikingly 
similar prevalences of PFH were found in both cohorts which adds to the credibility of the 
data. The major limitation of this study, however, is that the diagnosis in relatives (the PFH) 
is solely based on patients’ information which may have led to either under- or overestimation 
of a PFH. However, this is similar to most clinical settings in which PFH is mostly based on 
self-reporting too. Moreover, subdividing a PFH into five different diseases meant that a PFH 
of for instance AAU or ReA was uncommon. 
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CONCLUSIONS
In conclusion, in our two cohorts a PFH of ReA, IBD, and psoriasis does not contribute to 
diagnosing axSpA in CBP patients suspected of axSpA. A PFH of AS or AAU may be useful 
in case-finding in low prevalence settings, such as general practice, as these are correlated with 
HLA-B27 carriership. When replicated, preferably in other regions of the world in patients 
with a different genetic background, it is justified to remove a PFH of ReA, IBD, and psoriasis 
from the current ASAS definition of a positive PFH relevant for axSpA. 
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SUPPLEMENTARY MATERIAL
Table S1. Association of family history manifestations with any positive imaging (sacroiliitis on MRI 
or radiographs) in the SPACE cohort and DESIR cohorts. 
Sacroiliitis on imaging (local reading)
SPACE DESIR
OR (95% CI) P- value OR (95% CI) P- value
Any PFH 0.9 (0.6-1.3) 0.597 0.9 (0.7-1.3) 0.753
AS 0.8 (0.5-1.4) 0.452 1.0 (0.7-1.5) 0.928
AAU 1.7 (0.8-3.8) 0.164 1.2 (0.6-2.6) 0.566
ReA 0.2 (0.02-1.2) 0.075 0.8 (0.1-4.2) 0.749
IBD 0.8 (0.4-1.7) 0.530 0.7 (0.3-1.5) 0.318
Psoriasis 0.9 (0.6-1.6) 0.851 0.9 (0.6-1.4) 0.652
Any PFH, any family history manifestation in first- or second-degree relatives; AS, ankylosing 
spondylitis; AAU, acute anterior uveitis; ReA, reactive arthritis; IBD, inflammatory bowel disease; 
OR, odds ratio; 95% CI, 95% confidence interval. 




OR (95% CI) P- value OR (95% CI) P- value
Any PFH 1.5 (1.0-2.2) 0.053 1.0 (0.7-1.4) 0.900
AS 1.3 (0.8-2.1) 0.282 1.2 (0.8-1.7) 0.461
AAU 3.4 (1.3-8.6) 0.010 1.4 (0.7-3.0) 0.350
ReA 0.2 (0.1-0.9) 0.035 1.1 (0.2-5.7) 0.870
IBD 1.0 (0.5-2.1) 0.960 1.0 (0.5-2.1) 0.982
Psoriasis 1.6 (1.0-2.6) 0.064 0.9 (0.6-1.3) 0.526
*Diagnosis defined as level of confidence of axSpA diagnosis ≥8. Any PFH, any family history 
manifestation in first- or second-degree relatives; AS, ankylosing spondylitis; AAU, acute anterior 
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ABSTRACT
Objectives
To assess the prevalence of spinal inflammation on MRI in patients with chronic back pain 
(CBP) of maximally three years duration, and to evaluate the yield of adding a positive MRI-
spine as imaging criterion to the ASAS classification criteria for axSpA.
Methods
Baseline X-SI, MRI-SI, and MRI-spine were scored by ≥2 experienced central readers per 
modality in the SPACE and DESIR cohorts. Inflammation suggestive of axSpA was assessed in 
the entire spine. A positive MRI-spine was defined by the presence of ≥5 inflammatory lesions. 
Alternative less strict definitions were also tested.
Results
In this study 541 and 650 CBP patients from the SPACE and DESIR cohorts were included. 
Sacroiliitis on X-SI and MRI-SI was found in 40/541(7%) and 76/541(14%) patients in SPACE, 
and in DESIR in 134/650(21%) and 231/650(36%) patients, respectively. In SPACE and 
DESIR, a positive MRI-spine was seen in 4/541(1%) and 48/650(7%) patients. Of the patients 
without sacroiliitis on imaging, 3/447(1%) (SPACE) and 8/382(2%) (DESIR) patients had a 
positive MRI-spine. Adding positive MRI-spine as imaging criterion led to new classification 
in only one patient in each cohort, as the other patients already fulfilled the clinical arm. Other 
definitions of a positive MRI-spine yielded similar results.
Conclusion
In two cohorts of CBP patients with a maximum symptom duration of three years, a positive 
MRI-spine was rare in patients without sacroiliitis on MRI-SI and X-SI. Addition of MRI-
spine as imaging criterion to the ASAS axSpA criteria had a low yield of newly classified 
patients and is therefore not recommended. 
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INTRODUCTION 
Magnetic resonance imaging (MRI) has become of great interest as a diagnostic tool 
in the evaluation of patients suffering from chronic back pain (CBP) suspected of axial 
spondyloarthritis (axSpA).1-8 For years, clinicians (and researchers) relied on conventional 
imaging of the sacroiliac joints (X-SI) to detect abnormalities suggestive of axSpA.9 However, 
X-SI only captures structural damage, which generally takes months to years to develop, 
leaving aside that not all patients will develop structural bone damage in the axial skeleton. 
This jeopardises the early recognition of patients with axSpA. MRI, however, can visualize both 
inflammation and structural damage, and therefore may help in recognizing axSpA patients 
that do not (yet) have radiographic sacroiliitis. 
The Assessment of SpondyloArthritis international Society (ASAS) classification criteria 
for axSpA comprise a criteria set combining the information obtained from patient history 
taking, physical examination, laboratory testing, and imaging (X-SI and MRI of the sacroiliac 
joints).10 A pivotal aspect of these criteria is the “two arms” concept, commonly referred to 
as the ‘imaging arm’ and the ‘clinical arm’. According to the ASAS classification criteria, 
CBP patients with the onset of back pain <45 years of age are classified via the imaging 
arm when 1) radiographic sacroiliitis plus ≥1 spondyloarthritis (SpA)-feature is present or 2) 
sacroiliitis on MRI plus ≥1 additional SpA-feature is present also defined as ‘positive MRI’. 
Currently, a positive MRI in the ASAS classification criteria is solely based on the presence 
of inflammatory lesions in the sacroiliac joints and positive findings are defined according to 
the ASAS definition: 1 bone marrow edema (BME) lesion highly suggestive of axSpA present 
on ≥2 consecutive slices, or ≥2 BME lesions highly suggestive of axSpA on a single slice.11, 12
Several studies have shown that besides inflammation on MRI of the sacroiliac joints (MRI-
SI), inflammatory lesions in the spine on MRI (MRI-spine) may also occur.8, 13 Remarkably, 
in one study spinal inflammation - in the absence of sacroiliitis on MRI - was observed in 
about half of the patients with longer disease duration.14 A consensus definition for a positive 
MRI-spine was developed by the ASAS/Outcome Measures in Rheumatology (OMERACT) 
MRI working group.8 In this consensus definition a positive MRI-spine is described as the 
presence of ≥3 inflammatory lesions in the vertebrae, whereas each lesion needs to be present 
on ≥2 consecutive slices. De Hooge et al recently proposed a cut-off value of ≥5 inflammatory 
lesions that defines a positive MRI-spine with higher specificity of ≥95% (i.e. <5% patients 
without axSpA with a positive MRI-spine).15 
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The main objectives of this study were to evaluate the presence of spinal inflammatory lesions 
on MRI in patients with a maximum CBP duration of 3 years in two different cohorts, the 
SPondyloArthritis Caught Early (SPACE) cohort and the DEvenir des Spondylarthropathies 
Indifférenciées Récentes (DESIR) cohort. In addition, we assessed the added value of spinal 
inflammatory lesions on MRI, represented in various definitions of a positive MRI-spine, as 
imaging criterion in the ASAS classification criteria for axSpA. 
METHODS
Cohorts and clinical assessments
For this analysis baseline data from the SPACE and the DESIR cohorts were used which have 
been described in detail before.16, 17In summary, SPACE is an ongoing observational cohort in 
which patients with a minimum age of 16 years with short term CBP (≥3 months, ≤2 years, 
and an onset <45 years) are included. Patients are recruited from multiple Rheumatology 
centres in Europe; the Netherlands, Norway, Italy, and Sweden. The clinical database used 
for the current study was locked on September 30th 2016.
DESIR is a longitudinal cohort for which the inclusion period was from December 2007 
until April 2010 in 25 centres in France. Patients aged 18-50 years with inflammatory back 
pain (IBP) according to the Calin18 or Berlin19 criteria, persisting ≥3 months but <3 years, 
suggestive of axSpA according to the treating rheumatologist, were included. The clinical 
database used for the current study was locked on April 30th 2015.
As part of both study protocols and to determine fulfilment of the ASAS-criteria, presence 
of all SpA-features was assessed. These include Human Leukocyte Antigen B27 (HLA-B27), 
positive family history of SpA, IBP, psoriasis, peripheral arthritis, dactylitis, heel enthesitis, 
acute anterior uveitis, inflammatory bowel disease (IBD), good response to non-steroidal 
anti-inflammatory drugs (NSAIDs), elevated C-reactive protein (CRP) and erythrocyte 
sedimentation rate (ESR), sacroiliitis on X-SI and MRI-SI, all according to the published 
definitions. In both cohorts informed consent forms from all study participants as well as 
approval from all local medical ethical committees were obtained beforehand. 
Imaging
Detailed descriptions of the applied scoring methods in both cohorts have been published 
previously. In brief, all available baseline imaging modalities were scored by experienced 
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central readers. In the SPACE cohort each imaging modality was scored by three central 
readers. In the DESIR cohort each imaging modality was scored by two central readers and an 
adjudicator in case of disagreement. The readers were blinded for all clinical and laboratory 
data as well as the other imaging modalities, and the various modalities were scored separately.
Imaging assessments 
Sacroiliac joints were evaluated on pelvic radiographs using the mNY criteria in which 
sacroiliitis is defined as grade ≥2 bilaterally or grade 3-4 unilaterally.9 MRI-SI and MRI-spine 
were performed on a 1T-1.5T scanner. For both modalities, Short Tau Inversion Recovery 
(TR2500-4000/TE600) and T1-weighted Turbo Spin-Echo (TR500-700/TE10-55) sequences 
were acquired. MRI-SI were performed in coronal oblique plane and MRI-spine in sagittal 
plane with a slice thickness of 4 mm. Readers provided an overall judgement on a positive 
MRI-SI (yes/no) according to the ASAS definition.11 X-SI and MRI-SI were considered positive 
if ≥2 readers agreed. 
MRI-spine
In the SPACE cohort, a positive MRI-spine was defined by the presence of ≥5 corner BME 
lesions highly suggestive of axSpA each visible on ≥2 consecutive slices and if ≥2 readers 
agreed.15 A positive MRI-spine was also defined by the ASAS consensus definition (≥3 corner 
BME lesions on ≥2 consecutive slices) and if ≥2 readers agreed.8
In addition, spinal inflammation suggestive of axSpA was scored according to the 
Spondyloarthritis Research Consortium of Canada (SPARCC) method. Presence of BME 
was marked on three consecutive sagittal slices per vertebral unit (VU).20 In case of BME 
lesions on more than three slices, the three most affected consecutive slices were selected. 
The 23 VUs each are divided into 4 quadrants and assessed for the presence (score of 1) or 
absence (score of 0) of inflammatory lesions (maximum possible score 276). In addition, for 
each VU a score of 1 could be assigned to the presence of an “intense” signal (maximum 
possible score of 69), defined as a signal as intense as a blood vessel, and a “deep” lesion 
(maximum possible score of 69), defined as a homogeneous, unequivocal increase in STIR 
signal extending at least 1 cm from the vertebral end plate. In total, the maximum possible 
total SPARCC-score is 414. We tested two additional definitions of a positive MRI-spine 
using the SPARCC-score (including intensity and depth of a lesion). The first, in which a 
positive MRI-spine was defined by a SPARCC-score ≥5 by ≥2 readers, and the second, in 
which a positive MRI-spine was defined by a mean SPARCC-score ≥5 of all 3 readers. All four 
of the described definitions of a positive MRI-spine (i.e. ≥5 BME lesions on ≥2 consecutive 
88   |   Chapter 6
slices; ≥3 BME lesions on ≥2 consecutive slices (ASAS definition); SPARCC score ≥5 by ≥2 
readers, and mean SPARCC score ≥5 of 3 readers) were applied to assess the added value of 
a positive MRI-spine in the ASAS classification criteria. 
In the DESIR cohort spinal inflammation suggestive of axSpA was scored according to the 
Berlin method.21 In total, the maximum possible total Berlin-score is 69. Additionally, the 
23 VUs were each divided into 4 quadrants and assessed for the presence (score of 1) or 
absence (score of 0) of inflammatory lesions. Inflammatory lesions were scored when present 
on ≥2 consecutive slices. When central readers disagreed on the presence of inflammation, an 
adjudicator provided scores for all 23 VUs. A positive MRI-spine was defined by the presence of 
≥5 corner inflammatory lesions and if ≥2 readers agreed. A positive MRI-spine was also defined 
by the ASAS consensus definition (i.e. ≥3 inflammatory lesions) and when ≥2 readers agreed. 
Only these two definitions were used to assess the additional value of a positive MRI-spine in 
the ASAS classification criteria, as the SPARCC method was not applied.
Data analysis 
Baseline demographic and clinical characteristics are presented using descriptive statistics for 
both the SPACE and DESIR cohort (reported in this order). Results are presented as mean 
and standard deviation (SD) or numbers and percentages (%). Agreement (Cohen’s kappa, ƙ) 
between readers regarding a positive MRI-SI and MRI-spine was calculated. 
Stata 14 (StataCorp. College Station (TX, USA)) was used for data analysis. 
RESULTS
For 541/639 and 650/708 patients from the SPACE and DESIR cohorts complete scores of 
MRI-SI, MRI-spine, X-SI, and clinical data were available for analyses. Of these, 34% and 
46% were male, mean symptom duration (SD) was 13.0 (7.1) and 18.2 (10.5) months, and 
mean age was 29.1 (8.4) and 33.7 (8.7) years (Table 1), respectively.
Interreader reliability The agreement between the readers in the SPACE and DESIR cohorts 
regarding a positive MRI-spine according to the ASAS definition was ƙ=0.66 and ƙ=0.58, 
respectively. Interreader agreement for a positive MRI-spine according to the cut-off of ≥5 BME 
lesions in SPACE was ƙ=0.60 and in DESIR ƙ=0.49. For MRI-SI the reliability between the 
readers in the SPACE cohort was ƙ=0.76 and in the DESIR cohort ƙ=0.73. 
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Table 1 Baseline clinical and demographic characteristics of patients with CBP suspected of axSpA 





Male 186 (34) 301 (46)
Age (years) at onset of back pain 29.1 (8.4) 33.7 (8.7)
Symptom duration, months 13.0 (7.1) 18.2 (10.5)
HLA-B27 positive 211 (39) 381 (59)
Number of SpA-features, mean (SD) 2.4 (1.6) 4.0 (1.4)
IBP 358 (66) 650 (100)*
Good response to NSAIDs
 
a 217/521 (42) 518 (80)
Positive family history of SpA b 235 (43) 248 (38)
Peripheral arthritis 76 (14) 366 (56)
Dactylitis 28 (5) 82 (13)
Enthesitis 105 (19) 322 (50)
Acute anterior uveitis 42 (8) 55 (8)
IBD 35 (6) 29 (4)
Psoriasis 57 (11) 103 (16)
Elevated CRP/ESR 138 (26) 257 (40)
ASAS axSpA classification 207 (38) 411 (63)
Imaging arm (with/without clinical arm)
Sacroiliitis on MRI (mNY-MRI+) 53 (10) 115 (21)
Sacroiliitis on radiograph (mNY+MRI+/MRI-) 39 (7) 121 (21)
Clinical arm only 115 (21) 175 (31)
Results are presented as mean (±SD) or number (%). CBP, chronic back pain; axSpA, axial 
spondyloarthritis; HLA-B27, human leukocyte antigen B27; IBP, inflammatory back pain; NSAIDs, 
non-steroidal anti-inflammatory drugs; SpA; spondyloarthritis; IBD, inflammatory bowel disease; 
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; ASAS, Assessment of Spondyloarthritis 
international Society. mNY, modified New York; MRI, magnetic resonance imaging. * Inclusion 
criterion. a Back pain not present anymore or is much better 24–48 hours after a full dose of NSAID. 
b Patient reported presence in first- or second-degree relatives of any of the following: ankylosing 
spondylitis, acute anterior uveitis, reactive arthritis, IBD, or psoriasis. 
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In both cohorts, the majority of patients did not show abnormalities on MRI-SI, MRI-spine, and 
X-SI (444/541 (82%) and 374/650 (58%), SPACE and DESIR respectively) (Table 2). In total, 
40/541 (7%) and 134/650 (21%) patients in the SPACE and DESIR cohorts had radiographic 
sacroiliitis (Figure 1). Of the remaining patients without radiographic sacroiliitis, 447/501 (89%) 
and 382/516 (74%) in SPACE and DESIR had no evidence of inflammation on MRI-SI. In both 
cohorts, an isolated positive MRI-spine (without sacroiliitis on either MRI-SI or X-SI), applying 
the cut-off of ≥5 BME lesions, was found in 3/447 (1%) and 8/382 (2%) patients (Table 2).
Table 2 Cross-tabulations of baseline sacroiliac imaging (MRI-SI and X-SI) and MRI-spine of CBP 
patients suspected of axSpA in the SPACE (n=541) and DESIR cohorts (n=650).
SPACE 




Positive 1 3 4
Negative 93 444 537
Total 94 447 541
DESIR




Positive 40 8 48
Negative 228 374 602
Total 268 382 650
SI, sacroiliac joints; MRI, magnetic resonance imaging; X, radiography; CBP, chronic back pain; 
axSpA, axial spondyloarthritis; BME, bone marrow edema.
Two of the three patients in the SPACE cohort with a positive MRI-spine (definition of ≥5 BME 
lesions) but without sacroiliitis on MRI-SI and X-SI, already fulfilled the clinical arm of the 
ASAS-criteria, were male and their mean (SD) number of SpA-features was 3.5 (0.7) (Table 3). 
When hypothetically adding a positive MRI-spine as imaging criterion to the ASAS-criteria for 
axSpA, the remaining patient could be additionally classified via the imaging arm. Therefore, 
447 MRIs of the spine have to be performed to additionally classify this single patient. This 
patient was a male with one SpA-feature (i.e. good response to NSAIDs). 
In the DESIR cohort eight patients had a positive MRI-spine (definition of ≥5 BME lesions) 
without having any signs of inflammation or structural damage suggestive of axSpA on MRI-
SI and X-SI (Figure 1). As patients within the DESIR cohort are included until the age of 50 
and the ASAS-criteria are, in principle, to be applied to CBP patients ≤45 years, we report this 
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separately. In total, 7 out of 8 patients already fulfilled the clinical arm of the ASAS-criteria: 
6/8 patients ≤45 years and 1/8 >45 years (Table 3). Of these seven patients, one was male and 
the mean (SD) number of SpA-features was 3.7 (2.0). When hypothetically adding a positive 
MRI-spine as imaging criterion to the ASAS-criteria for axSpA, the remaining patient could 
be additionally classified via the imaging arm. Therefore, 382 MRI of the spine have to be 
performed to additionally classify this single patient. This was a HLA-B27 negative male 
patient with the following 6 SpA-features: positive family history of SpA, IBP, good response 
to NSAIDs, heel enthesitis, IBD, and peripheral arthritis. 
Figure 1 ASAS classification of CBP patients with negative MRI-SI and positive MRI-spine defined 
by ≥5 inflammatory lesions, and the effect of adding positive MRI-spine as an imaging criterion to the 
ASAS axSpA criteria on classification of patients. A. Additional classification of CBP patients in the 
SPACE cohort. B. Additional classification of CBP patients in the DESIR cohort. ASAS, Assessment 
of SpondyloArthritis international Society; axSpA, axial spondyloarthritis; CBP, chronic back pain; 
SPACE, SPondyloArthritis Caught Early.
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Table 3 Baseline clinical characteristics and disease activity of CBP patients additionally classified 
according to the ASAS axSpA criteria by baseline presence of sacroiliitis on MRI and spinal inflammation 






Male, n (%) 1 (100) 2 (100)
HLA-B27 positive, n (%) 0 2 (100)
Number of SpA features 1 3.5 (0.7)
SPARCC spine score, 0-414 13.3 14 (2.4)
Disease activity
BASDAI¥ 3.4 2.9 (0)
CRP ≥5 mg/l, n (%) 0 1 (50)
CRP, mg/l 3 30 (41)






Male, n (%) 1 (100) 1 (14)
HLA-B27 positive, n (%) 0 7 (100)
Number of SpA features 6 3.7 (2)
Berlin spine score, 0-69 9.5 8.5 (2)
Disease activity
BASDAI 2.9 5 (1.4)
CRP ≥5 mg/l, n (%) 0 2 (29)
CRP, mg/l 4 5.3 (4.2)
ASDAS-CRP 1.8 2.8 (0.8)
Unless stated otherwise, results are presented as mean ± SD (range). CBP, chronic back pain; axSpA, 
axial spondyloarthritis; MRI-SI, magnetic resonance imaging sacroiliac joints; HLA-B27, Human 
Leukocyte Antigen B27; SpA-features, total number of spondyloarthritis features without taking 
imaging and HLA-B27 into account; SPARCC, Spondyloarthritis Research Consortium of Canada; 
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; NRS, numerical rating scale; CRP, 
C-reactive protein; ASDAS, Ankylosing Spondylitis Disease Activity Score. ¥¥n=1 for patients already 
fulfilling the clinical arm. ¥¥n=1 for patients already fulfilling the clinical arm. *Patients already 
fulfilling the clinical arm of the ASAS-criteria, 1/7 patients was >45 years of age.
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Alternative definitions of a positive MRI-spine
SPARCC-score
Two other definitions of a positive MRI-spine were tested in the SPACE cohort using the 
SPARCC-score (Table 4). When a positive MRI-spine was defined as a SPARCC-score of ≥5 
by ≥2 central readers, a total of 21/447 (5%) patients without sacroiliitis on MRI-SI and X-SI 
had a positive MRI-spine (see online supplementary Figure S1). Eight patients (38%) already 
fulfilled the clinical arm and when adding MRI-spine to the ASAS-criteria, 13/21 (62%) patients 
could be additionally classified via the imaging arm. Of these 13 patients almost half had ≥2 
SpA-features. Most frequently reported SpA-features were good response to NSAIDs, positive 
family history of SpA, and IBP (data not shown). When a positive MRI-spine was defined as a 
mean SPARCC-score ≥5 of all 3 readers, a total of 13/447 (3%) patients had a positive MRI-spine 
(see online supplementary Figure S2). Of these, 7/13 (54%) already fulfilled the clinical arm 
and the remaining six (46%) patients could be additionally classified via the imaging arm when 
adding positive MRI-spine to the ASAS-criteria. Half of these patients had ≥2 SpA-features and 
positive family history of SpA and IBP were amongst the frequent features (data not shown).
ASAS consensus definition
According to the ASAS consensus definition (≥3 spinal inflammatory lesions on ≥2 consecutive 
slices) 5/447 (1%) patients from the SPACE cohort and 25/382 (7%) patients from the DESIR 
cohort had a positive MRI-spine without sacroiliitis on MRI-SI and X-SI (Table 4). Of these, 
3/5 (60%) patients and 18/25 (72%) patients (16 patients ≤45 years and 2 patients >45 years) 
already fulfilled the clinical arm (see online supplementary Figure S3). The addition of a 
positive MRI-spine as a criterion in the ASAS-criteria would have resulted in the additional 
classification of 2/5 (40%) and 7/25 (28%) patients (6 patients ≤45 years and 1 patient >45 
years) for SPACE and DESIR, respectively.
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Table 4 Patients additionally classified through positive MRI-spine according to 4 different definitions, 
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Already classified by clinical arm 8 (38%) 7 (54%) 3 (60%) 2 (67%)
axSpA diagnosis 7/8 7/7 3/3 2/2
Additionally classified by imaging arm 13 (62%) 6 (46%) 2 (40%) 1 (33%)
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≥2 consecutive slices 
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Already classified by clinical arm* - - 18 (72%) 7 (88%)
axSpA diagnosis¥ - - 13/18 5/7
Additionally classified by imaging arm* - - 7 (28%) 1 (12%)
axSpA diagnosis¥ - - 3/7 1/1
MRI, magnetic resonance imaging; axSpA, axial spondyloarthritis; HLA-B27, Human Leukocyte 
Antigen B27; SPARCC, Spondyloarthritis Research Consortium of Canada; 
BME, bone marrow edema; n/a, not assessed. *Classification for all patients <50 years. ¥ Diagnosis 
based on rheumatologist’s level of confidence regarding axSpA diagnosis ≥8.
DISCUSSION 
In patients with CBP of a maximum duration of 3 years and suspected of axSpA from two 
different cohorts (SPACE and DESIR), the overall prevalence of spinal inflammation is low. 
In addition, spinal inflammation in the absence of sacroiliitis on MRI-SI and X-SI occurred in 
a very small proportion of patients. Consequently, adding a positive MRI-spine (represented 
in various definitions) as an imaging criterion to the ASAS-criteria resulted in a very low 
percentage of newly classified patients. Considering the number of MRI-spine needed to 
additionally classify a few patients, the longer scanning time for the patient and higher costs, 
we conclude that the yield of adding MRI-spine to the ASAS-criteria is unacceptably low in 
relation to the number of MRI-spine needed to be performed in patients with early disease.
Multiple studies assessed the presence of spinal inflammation in different patient groups (e.g. 
nonradiographic axSpA), however, to the best of our knowledge this is the first study to report 
on the value of a positive MRI-spine in classifying patients according to the ASAS-criteria 
using different definitions in patients with recent onset CBP. Our findings are in line with 
a recent study by Weber et al in which they state that the combination of MRI-spine and 
MRI-SI has little incremental value compared to MRI-SI alone.22 Using global assessment in 
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percentage of newly classified patients. Considering the number of MRI-spine needed to 
additionally classify a few patients, the longer scanning time for the patient and higher costs, 
we conclude that the yield of adding MRI-spine to the ASAS-criteria is unacceptably low in 
relation to the number of MRI-spine needed to be performed in patients with early disease.
Multiple studies assessed the presence of spinal inflammation in different patient groups (e.g. 
nonradiographic axSpA), however, to the best of our knowledge this is the first study to report 
on the value of a positive MRI-spine in classifying patients according to the ASAS-criteria 
using different definitions in patients with recent onset CBP. Our findings are in line with 
a recent study by Weber et al in which they state that the combination of MRI-spine and 
MRI-SI has little incremental value compared to MRI-SI alone.22 Using global assessment in 
patients with nonradiographic axSpA and normal MRI-SI, approximately 20% of MRI-spine 
were judged as being consistent with axSpA. However, reading of MRI-spine in nonspecific 
back pain patients and healthy controls yielded similar percentages. 
In the SPACE and DESIR cohorts, the majority of patients with only spinal inflammation 
(≥5 BME lesions and normal MRI-SI and X-SI) already fulfilled the clinical arm of the ASAS-
criteria (2/3 and 6/7, respectively). The remaining patients, hypothetically classified via the 
imaging arm solely because of a positive MRI-spine, can either be misclassified or truly ‘missed’ 
cases. We did not formally investigate the role of MRI-spine in diagnosis making in routine 
clinical practice and this may still be considered as an imaging tool in the differential diagnosis 
of CBP patients or in the confirmation of the diagnosis in specific patients.
This study has several strengths. Two independent early axSpA cohorts were examined in which 
CBP patients have been assessed according to a similar standardized protocol. Both cohorts were 
rather complete in terms of images being present and scored by multiple readers, and the findings 
in both cohorts were similar providing credit to the robustness of our data. Furthermore, the 
observation that in both cohorts several definitions of a positive MRI-spine in the ASAS-criteria 
for axSpA yielded comparable misclassifications strengthens the validity of the findings. 
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It can be seen as a limitation that we only used patients with short symptom duration. 
Consequently, the results can only be extrapolated to this group of patients. However, we feel 
that this is the most applicable group to test the usefulness of MRI-spine as part of the ASAS 
classification criteria as abnormalities on imaging of the sacroiliac joints are more likely to 
become positive with longer symptom duration. Moreover, our data are very much in line with 
the data from Weber et al in a study with more established disease.
In summary, in both the SPACE and the DESIR cohorts a positive MRI-spine in CBP patients 
suspected of early axSpA was infrequent. Furthermore, spinal inflammation in the absence 
of sacroiliitis was observed in very few patients. In this early disease stage, the addition of a 
positive MRI-spine as imaging criterion to the ASAS classification criteria for axSpA yielded a 
very low number of newly classified patients in both cohorts. Therefore, the use of MRI-spine 
is not recommended in the classification of CBP patients suspected of axSpA.
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Sacroiliitis on imaging is important in the diagnosis and classification of axial spondyloarthritis 
(axSpA) patients. In the Assessment of SpondyloArthritis international Society (ASAS) 
classification criteria for axSpA, sacroiliitis is defined as either radiographic sacroiliitis (X-
SI) according to the modified New York (mNY) criteria or active inflammation on magnetic 
resonance imaging (MRI-SI) highly suggestive of axSpA (ASAS definition).1-4 According to the 
ASAS-criteria chronic back pain patients are classified via the imaging arm when sacroiliitis 
on MRI-SI or X-SI plus ≥1 spondyloarthritis (SpA)-feature is present, or via the clinical arm 
where ≥2 SpA-features in addition to HLA-B27 have to be present.
While local clinicians can interpret imaging of the sacroiliac joints in the context of clinical 
information, central readers of research studies are not aware of the clinical data. If local and 
central readers disagree about the presence of sacroiliitis, a patient may be erroneously classified. 
The clinical arm of the ASAS-criteria may substitute for discrepant reads, so that the effect of 
discrepant reads on classification may be mitigated: In the DEvenir des Spondylarthropathies 
Indifférenciées Récentes (DESIR)-cohort, local and central readers disagreed in 28% of the 
cases, but this led to a change in classification in only 7.9% of patients.5, 6 
This is a replication study in the SpondyloArthritisCaughtEarly (SPACE)-cohort.7 In SPACE 
patients with chronic back pain (≥3 months and ≤ 2 years, onset <45 years) are assessed 
following a fixed protocol. Patients with complete imaging were included in this analysis. Local 
assessors interpreted MRI-SI and X-SI (sacroiliitis yes/no) as part of routine clinical practice. 
Three central readers, blinded for all clinical and laboratory data as well as other imaging 
modalities, scored each imaging modality. Positive X-SI was defined according to the mNY 
criteria and positive MRI-SI was defined by the ASAS definition. 
MRI-SI and X-SI were available for 513 patients. MRI-SI results were discordant in 81/513 
(16%) patients and X-SI results were discordant in 55/513 (11%) patients between local 
assessors and central readers (Table 1). In 17% of patients local assessors and central readers 
disagreed either about sacroiliitis on MRI-SI or on X-SI. With central reading as external 
standard, the false-positive rate for MRI-SI was 48% and for X-SI 60% (‘local overcall’). In 
52/513 (10%) patients discrepant reading resulted in a different classification of axSpA: 46 
patients that did not classify as axSpA after central reading were classified as axSpA after 
local assessment and 6 patients classified as axSpA after central reading were not after local 
assessment (Table 2). When fulfilment of the imaging arm was required (irrespective of the 
clinical arm), the discordance increased to 16% (82/513).
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We confirmed the findings in the DESIR-cohort that the classification of axSpA was rather 
insensitive to differences between local and central reading. DESIR is performed in multiple 
French centres and SPACE includes patients from multiple European sites. Our results add 
to the strength of the conclusion that the ASAS classification criteria are rather robust against 
discrepant reading results of images of the sacroiliac joints due to the incorporation of the 
clinical arm. 
Table 1 Cross-tabulation of MRI-SI and X-SI reading by central readers and local assessors in the 




Positive 85 78 163
Negative 3 347 350




Positive 26 39 65
Negative 16 432 448
Total 42 471 513
MRI-SI, magnetic resonance imaging sacroiliac joints. Positive predictive value (PPV): 85/163 (52%), 
negative predictive value (NPV): 347/350 (99%). Concordance positive MRI-SI: 85/513 (17%).
X-SI, radiography sacroiliac joints. PPV: 26/65 (40%), NPV: 432/448 (96%). Concordance positive 
X-SI: 26/513 (5%).
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Table 2 Concordance between central reading and local assessment of imaging according to the 
classification of CBP patients using the ASAS axSpA criteria in the SPACE cohort (n=513).
Central reading
Classification















MRI and mNY 
positive





No SpA 256 n/a 2 4 0 0 0 0 262
Clinical arm only n/a 79 n/a n/a 1 1 0 n/a 81
MRI positive only 32 n/a 17 2 n/a n/a n/a 1 52
mNY positive only 8 n/a 0 2 n/a n/a n/a 0 10
Both arms (clinical arm and MRI positive) 0 18 n/a n/a 27 2 6 0 53
Both arms (clinical arm and mNY positive) 0 2 n/a n/a 0 0 0 0 2
Clinical arm, MRI and mNY positive 0 8 n/a n/a 10 5 15 0 38
MRI and mNY positive 6 n/a 5 2 0 0 0 2 15
Total 302 107 24 10 38 8 21 3 513
CBP, chronic back pain; ASAS, Assessment of SpondyloArthritis international Society; axSpA, axial 
spondyloarthritis; SPACE, SpondyloArthritis Caught Early; MRI, magnetic resonance imaging; mNY, 
modified New York; n/a, not applicable (fulfilment of the clinical arm does not depend on (different) 
reading of imaging). 
For 52/513 (10%) patients different reading resulted in a different classification of axSpA (grey boxes). 
If hypothetically fulfilment of the imaging arm was required (irrespective of the clinical arm), 30 more 
patients (in italic and bold) would be discordant (82/513, 16%).
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ABSTRACT
Objectives 
To evaluate the contribution of the results of sacroiliac imaging on diagnosis and on the level 
of confidence in diagnosis in patients presenting with chronic back pain (CBP) and suspected 
of having axial spondyloarthritis (axSpA).
Methods 
Data from 513 patients from the SPondyloArthritisCaughtEarly (SPACE) cohort with 
CBP (≥3 months, ≤2 years, onset <45 years) were analysed after full diagnostic work-up. 
Rheumatologists were asked not only to provide a diagnosis before- and after the imaging 
results had been provided to them, but also to provide the level of confidence (LoC) of this 
diagnosis on an 11-point numerical scale. 
Results
Before imaging, 317/513 patients were diagnosed with axSpA. Of these patients, 178/317 
(56%) did not have signs of sacroiliitis on either MRI or radiography, which led to the 
rheumatologist refuting the initial diagnosis of axSpA in 81/178 (46%) patients. Of the 
196/513 patients without axSpA before imaging, 35/196 (18%) had signs of sacroiliitis on 
imaging. Subsequently, 28/35 (80%) patients were diagnosed with axSpA. Overall, imaging 
was incongruent with the diagnosis before imaging in 213 patients. This led to a change in 
diagnosis in 109/213 (51%), which corresponds to 21% (109/513) of all patients in the cohort. 
In general, diagnostic confidence increased by having imaging results available (from 6.2 to 
7.4, p<0.001). 
Conclusions
In patients with chronic back pain suspected of having axSpA sacroiliac imaging adds to the 
confidence in the final diagnosis. However, the number of changes in diagnosis suggests that 
imaging is important but not all-decisive in early axSpA diagnosis. 
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INTRODUCTION 
The diagnosis of axial spondyloarthritis (axSpA) in patients presenting with chronic back 
pain (CBP) is a known challenge in clinical practice as there is a broad spectrum in clinical 
presentations.1 Rheumatologists may use information acquired from several sources such as a 
patient’s medical history, physical examination, laboratory tests, and imaging (radiography 
and/or magnetic resonance imaging of sacroiliac joints) to make a diagnosis.2-4 
Several decades ago, conventional radiography was introduced as an imaging tool to detect 
sacroiliitis.5 However, pelvic radiographs can only detect structural changes such as erosions 
and sclerosis. Furthermore, in early axSpA radiography of the sacroiliac joints may not show 
structural abnormalities which can remain absent for many years after disease onset.6 In 
recent years, magnetic resonance imaging (MRI) has become an important instrument in the 
visualisation of both inflammation and structural damage in CBP patients especially without 
radiographic sacroiliitis.7-11
Imaging of the sacroiliac joints plays a pivotal role in the early recognition of axSpA.12, 13 We 
have recently shown that in CBP patients suspected of axSpA positive imaging of the sacroiliac 
joints is highly associated with a diagnosis of axSpA (odds ratio 34.3; 95% confidence interval 
17.3 to 67.7).14 
Unfortunately, recognition of sacroiliitis on radiographs can be difficult. For example, it has 
been shown that agreement on radiographic sacroiliitis between readers is low and that this 
does not improve after training.15 Moreover, bone marrow oedema on MRI suggestive of 
axSpA may not always be due to axSpA.16 Therefore, some axSpA experts have expressed their 
concerns about relying solely on imaging, which may lead to incorrect diagnoses of axSpA. 
In turn, this may lead to unnecessary exposure to anti-inflammatory drugs with potentially 
severe side effects.17, 18 
Given these controversies, surprisingly little is known about how rheumatologists actually 
integrate sacroiliac imaging results in their diagnostic work-up of CBP patients suspected of 
having axSpA. Therefore, the main objectives of this study were to study the contribution 
of sacroiliac imaging to the rheumatologist’s diagnosis, and to quantify the contribution of 
sacroiliac imaging to diagnostic certainty. 
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METHODS
Study design and population
The data used for the current study were obtained from the SPondyloArthritis Caught Early 
(SPACE) cohort. The SPACE cohort is a prospective multicentre study, which has been initiated 
in January 2009. A detailed description of the study design has been published previously.19 
Briefly, patients with chronic back pain (≥3 months and ≤2 years) of unknown origin and age 
of onset <45 years were recruited and included from multiple European rheumatology centres 
in the Netherlands, Norway, Italy, and Sweden. The clinical database used for the current study 
was locked on January 11th 2017. Approval for the study was obtained from all local medical 
ethics committees and patients provided written informed consent before participation. 
Clinical assessments and measurements 
All patients were examined according to a standardized full work-up including the 
assessment of the presence and history of clinical SpA features according to the Assessment 
of SpondyloArthritis international Society (ASAS) definitions3: C-reactive protein (CRP)/
erythrocyte sedimentation rate (ESR), human leukocyte antigen B27 (HLA-B27), inflammatory 
back pain (IBP), good response to non-steroidal anti-inflammatory drugs (NSAIDs), positive 
family history of SpA, peripheral arthritis, dactylitis, heel enthesitis, acute anterior uveitis, 
inflammatory bowel disease (IBD), and psoriasis. 
Imaging of the sacroiliac joints
Plain radiographs of the pelvis (X-SI) were performed in anteroposterior view. MRI of sacroiliac 
joints (MRI-SI) was performed in coronal oblique T1-weighted turbo spin echo (TSE) and short 
tau inversion recovery (STIR) with a slice thickness of 4 mm. Interpretation of the radiographs 
and MRI of the sacroiliac joints (sacroiliitis yes/no) was done by each participating centre as 
part of routine clinical practice (local reading). Patients were classified according to the ASAS 
classification criteria for which data from central reading in the SPACE cohort was used.20 
Diagnosis 
During the diagnostic work-up, rheumatologists were asked to provide a diagnosis twice 
(axSpA, yes/no): (1) based only on information available after medical history, physical 
examination, and laboratory testing, but before taking sacroiliac imaging into account 
(“Diagnosis before imaging”), and (2) based on all previously collected information but after 
taking sacroiliac imaging into account (“Diagnosis after imaging”). In case of ‘no axSpA’, 
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rheumatologists were asked to provide the most likely alternative diagnosis. In addition, 
rheumatologists were requested to provide a level of confidence (LoC) regarding their diagnosis 
(axSpA or no axSpA) on an 11-point numerical rating scale ranging from 0 (not confident at 
all) to 10 (very confident). 
Data analysis 
For the present study baseline patients with complete information on sacroiliac imaging (both 
MRI and radiography) and diagnosis were analysed. Descriptive statistics were used to define 
patient characteristics for the total patient group, for each diagnosis subgroup (axSpA vs no 
axSpA), and for each imaging subgroup (i.e. sacroiliitis positive and negative) as means and 
standard deviations (SD) for continuous variables or frequencies (%) for categorical variables. 
Chi-square and unpaired t tests were used to compare variables between groups. The paired t 
test was used to compare the level of confidence regarding diagnosis before and after imaging 
within each diagnosis subgroup according to their imaging status. Total number of SpA features 
was calculated including HLA-B27 status, but without taking imaging of the sacroiliac joints 
into account. Any positive imaging was defined as either a negative X-SI but positive MRI-SI 
(X-SI-/MRI-SI+), a positive X-SI but negative MRI-SI (X-SI+/MRI-SI-), or sacroiliitis on both 
modalities (X-SI+/MRI-SI+). The rheumatologist’s diagnosis and the LoC regarding diagnosis 
were the main outcomes. Data analysis was performed using Stata SE v.14 software (StataCorp 
LP, College Station, (TX, USA)).
RESULTS
Baseline data of 583 CBP patients were available. A total of 70 (12%) patients were excluded 
because of incomplete or missing data regarding diagnosis or sacroiliac imaging. Baseline 
characteristics of these patients were similar to the remaining 513 patients with complete data 
(not shown). Of these 513 CBP patients suspected of having axSpA, 188 (37%) patients were 
male, mean age (SD) was 31.0 (8.2) years, mean symptom duration was 13.3 (7.0) months, 
and 210 (41%) patients were HLA-B27 positive (Table 1). 
In all patients, rheumatologists provided a diagnosis before- and after taking sacroiliac imaging 
into account (Figure 1). Before imaging, 317 (62%) patients were diagnosed with axSpA (Table 
2). Most common diagnoses in the 196 patients without axSpA were ‘nonspecific back pain’, 
‘degenerative disc disease’, and ‘mechanical back pain’ (data not shown). Diagnostic confidence 
was moderate in patients with- and without an axSpA diagnosis before imaging (mean (SD) LoC 
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‘axSpA’ 6.6 (1.9) and mean LoC ‘no axSpA’ 5.6 (2.0), respectively). Patients diagnosed with axSpA 
before imaging were more often male (41% vs 29%) and were more often HLA-B27 positive 
(53% vs 22%) compared to patients who were not diagnosed with axSpA before imaging. As 
expected, the mean (SD) number of SpA features was twice as high for axSpA patients compared 
to the patients not diagnosed with axSpA (3.1 (1.7) and 1.5 (1.0), respectively). 
Table 1 Baseline characteristics of CBP patients suspected of axSpA in the SPACE cohort, n= 513.
Characteristic
Male 188 (37)
Age, years, mean (SD) 31.0 (8.2)
Symptom duration, months, mean (SD) 13.3 (7.0)
Number of SpA features incl. HLA-B27, mean (SD) 2.9 (1.8)
HLA-B27 positive * 210 (41)
IBP 346 (68)
Peripheral arthritis 78 (15)
Dactylitis 28 (5)
Enthesitis 106 (21)
Acute anterior uveitis 38 (7)
IBD 35 (7)
Psoriasis 58 (11)
Good response to NSAIDs
 
** 216 (43)
Positive family history of SpA 222 (43)
Elevated CRP/ESR 147 (29)
Values are listed as n (%), unless otherwise stated.. CBP, chronic back pain; axSpA, axial 
spondyloarthritis; HLA-B27, human leukocyte antigen B27; IBP, inflammatory back pain; DMARD, 
disease modifying drug; NSAIDs, non-steroidal anti-inflammatory drugs; IBD, inflammatory bowel 
disease; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate;* n=510 patients for HLA-B27,** 
n=499 patients for good response to NSAIDs.
In total, 317/513 (62%) of CBP patients were initially diagnosed with axSpA, and this figure 
decreased to 269/513 (52%) patients with a final diagnosis of axSpA after imaging. Of these 
269 axSpA patients, 55% were male, 59% were HLA-B27 positive, 62% had positive imaging, 
and the mean number of SpA features was 3.2 (1.7). A total of 172/269 (64%) patients fulfilled 
the ASAS classification criteria (52% male, 87% HLA-B27 positive, and mean number of SpA 
features 3.2 (1.5)). Overall, the mean diagnostic confidence increased by having imaging results 
available (from 6.2 to 7.4, p<0.001). This increase in diagnostic confidence was observed in 
both axSpA patients (from 7.1 (1.7) to 7.7 (2.1), p<0.001) and ‘non-axSpA’ patients (from 
5.7 (2.0) to 7.5 (2.3), p<0.001).
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Table 2 Clinical features of CBP patients stratified for diagnosis before taking sacroiliac imaging 
results into account.







LoC regarding diagnosis, mean (SD) 6.6 (1.9) 5.6 (2.0)
Male 131 (41) 57 (29)
Number of SpA features incl. HLA-B27, mean (SD) 3.6 (1.7) 1.7 (1.1)
HLA-B27 positive 168 (53) * 42 (22)
IBP 253 (80) 93 (48)
Peripheral arthritis ¥ 68 (22) 10 (5)
Dactylitis ¥ 27 (9) 1 (1)
Enthesitis ¥ 92 (29) 14 (7)
Acute anterior uveitis ¥ 32 (10) 6 (3)
IBD ¥ 26 (8) 9 (5)
Psoriasis¥ 48 (15) 10 (5)
Good response to NSAIDs
 
¥¥ 176 (57) ** 40 (21) ***
Positive family history of SpA ¥¥¥ 160 (50) 62 (32)
Elevated CRP/ESR 107 (34) 40 (20)
Values are listed as n (%), unless otherwise stated.LoC, level of confidence regarding diagnosis: 0 
(not confident at all) through 10 (very confident); axSpA, axial spondyloarthritis; HLA-B27, human 
leukocyte antigen B27; IBP, inflammatory back pain; NSAIDs, non-steroidal anti-inflammatory drugs; 
IBD, inflammatory bowel disease; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate. ¥ Past 
or present condition, either confirmed or diagnosed by a physician. ¥¥ Back pain not present anymore or 
is much better 24–48 hours after a full dose of NSAID. ¥¥¥ Presence in first- or second-degree relatives 
of any of the following: ankylosing spondylitis, acute anterior uveitis, reactive arthritis, psoriasis, or 
inflammatory bowel disease. * n=315 for patients with axSpA diagnosis before imaging, ** n=310 for 
patients with axSpA diagnosis before imaging, *** n=189 for patients without axSpA diagnosis before 
imaging. 
Of the 317 patients who were diagnosed with axSpA before imaging, 139 (44%) had positive 
imaging (Table 3). In these 139 patients, sacroiliitis was seen in 85 (61%) patients only on 
MRI-SI, in 10 (7%) patients only on X-SI, and in 44 (32%) patients on both modalities 
(X-SI+/MRI-SI+). After imaging, the axSpA diagnosis was maintained in all of these 139 
patients and the mean LoC in the diagnosis of axSpA increased significantly (from 7.4 (1.8) 
to 8.6 (1.7), p<0.001). 
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Of the 317 patients who were diagnosed with axSpA before imaging, 178 (56%) had negative 
imaging. In 97/178 patients the diagnosis axSpA was maintained. In these patients, the LoC 
in the diagnosis somewhat decreased (from 6.7 (1.6) to 6.4 (2.1), p=0.06). In 81/178 patients 
with negative imaging the diagnosis was changed to “no axSpA” after imaging. In these 
patients the LoC increased significantly after imaging (from 5.1 (1.7) to 6.4 (2.0), p<0.001). 
By comparison, the 97/178 patients diagnosed with axSpA after imaging had a higher number 
of SpA features (excluding imaging and HLA-B27) than the 81/178 patients without axSpA 
(mean 3.5 (1.6) vs 2.2 (1.2), p<0.001). Moreover, these 97 axSpA patients were also more often 
HLA-B27 positive than the 81 patients without axSpA (53% vs 33%, p=0.010).
Of the 196 patients not diagnosed with axSpA before imaging, 35 (18%) had positive imaging 
(Table 4). In these 35 patients, sacroiliitis was seen in 24 (68%) patients only on MRI-SI, in 2 
(6%) patients only on X-SI, and in 9 (26%) patients on both modalities (X-SI+/MRI-SI+). In 
28 of these 35 patients (80%) with sacroiliitis the diagnosis was changed into axSpA (18/28 
(64%) patients only MRI-SI+, 1/28 (4%) only X-SI+, and 9/28 (32%) MRI-SI+/X-SI+). 
The mean LoC in diagnosis increased significantly following imaging (from 4.7 (2.0) to 7.6 
(2.3), p<0.001). In 7 of the 35 patients with positive imaging (20%) the diagnosis ‘no axSpA’ 
remained unchanged (6/7 (86%) patients were MRI-SI+ and one (14%) patient was X-SI+). 
In these 7 patients, the mean LoC in diagnosis remained the same after imaging (LoC from 5.0 
(1.3) to 5.0 (2.3)). By comparison, the 28/35 patients diagnosed with axSpA after imaging had 
a higher number of SpA features than the 7/35 patients without axSpA (mean 1.6 (0.9) versus 
1.0 (0.8), p=0.10). Moreover, these 28 patients diagnosed with axSpA were also more often 
HLA-B27 positive than the 7 patients without axSpA (48% vs 29%, p=0.35).
Of the 196 patients not diagnosed with axSpA before imaging, 161 (82%) had negative 
imaging. Despite having negative imaging, the diagnosis changed to axSpA after imaging 
in 5/196 patients (3%). In these 5 patients, LoC in diagnosis increased (from 5.0 (1.9) to 6.4 
(1.9), p=0.43). In 156/161 (97%) patients with negative imaging the diagnosis “no axSpA” 
remained unchanged. The LoC in diagnosis increased after imaging (from 5.8 (2.0) to 7.6 
(2.2), p<0.001). By comparison, the 5/161 patients diagnosed with axSpA after imaging had 
a higher number of SpA features than the 156/161 patients without axSpA (mean 1.8 (0.8) 
versus 1.4 (1.0), p=0.43). Moreover, these 5 axSpA patients were also more often HLA-B27 
positive than the 156 patients without axSpA (40% vs 16%, p=0.16).
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Table 3 Diagnosis and imaging status after sacroiliac imaging in patients with axSpA diagnosis before 
sacroiliac imaging.
AxSpA diagnosis before imaging n=317
Any imaging positive n=139 Negative imaging n=178
Imaging status
Only MRI-SI+ 85 (61) n/a
Only X-SI+ 10 (7) n/a
MRI-SI+/X-SI+ 44 (32) n/a
Diagnosis after imaging Diagnosis after imaging
AxSpA n=139 No axSpA n=0 AxSpA n=97 No axSpA n=81
LoC regarding diagnosis before imaging, mean (SD) 7.4 (1.8) - 6.7 (1.6) 5.1 (1.7)
LoC regarding diagnosis after imaging, mean (SD) 8.6 (1.7)a - 6.4 (2.1)b 6.4 (2.0)c
Imaging status 
Only MRI-SI+ 85 (61) - n/a n/a
Only X-SI+ 10 (7) - n/a n/a
MRI-SI+/X-SI+ 44 (32) - n/a n/a
Clinical features
Male 71 (51) - 32 (33) 28 (35)
Number of SpA features º, mean (SD) 3.4 (1.7) - 3.5 (1.6) 2.2 (1.2)
HLA-B27 positive 90 (66) * - 51 (53) 27 (33)
Values are listed as n (%), unless otherwise stated.LoC, level of confidence regarding diagnosis: 0 (not 
confident at all) through 10 (very confident); MRI-SI, magnetic resonance imaging of sacroiliac joints; 
X-SI, radiographs of sacroiliac joints. axSpA, axial spondyloarthritis; HLA-B27, human leukocyte 
antigen B27. 
ºTotal number of SpA features after medical history taking, physical examination and measurement 
of acute phase reactants but before HLA-B27 testing and imaging. * n=137 for patients with axSpA 
diagnosis before and after imaging. a mean difference 1.2, 95% Confidence Interval (CI) 0.9 to1.6, 
p-value <0.001; b mean difference -0.3, 95% CI -0.5 to 0.01, p-value=0.06; c mean difference 1.3, 95% 
CI 0.7 to 1.8, p-value <0.001. n/a, not applicable.
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Table 3 Diagnosis and imaging status after sacroiliac imaging in patients with axSpA diagnosis before 
sacroiliac imaging.
AxSpA diagnosis before imaging n=317
Any imaging positive n=139 Negative imaging n=178
Imaging status
Only MRI-SI+ 85 (61) n/a
Only X-SI+ 10 (7) n/a
MRI-SI+/X-SI+ 44 (32) n/a
Diagnosis after imaging Diagnosis after imaging
AxSpA n=139 No axSpA n=0 AxSpA n=97 No axSpA n=81
LoC regarding diagnosis before imaging, mean (SD) 7.4 (1.8) - 6.7 (1.6) 5.1 (1.7)
LoC regarding diagnosis after imaging, mean (SD) 8.6 (1.7)a - 6.4 (2.1)b 6.4 (2.0)c
Imaging status 
Only MRI-SI+ 85 (61) - n/a n/a
Only X-SI+ 10 (7) - n/a n/a
MRI-SI+/X-SI+ 44 (32) - n/a n/a
Clinical features
Male 71 (51) - 32 (33) 28 (35)
Number of SpA features º, mean (SD) 3.4 (1.7) - 3.5 (1.6) 2.2 (1.2)
HLA-B27 positive 90 (66) * - 51 (53) 27 (33)
Values are listed as n (%), unless otherwise stated.LoC, level of confidence regarding diagnosis: 0 (not 
confident at all) through 10 (very confident); MRI-SI, magnetic resonance imaging of sacroiliac joints; 
X-SI, radiographs of sacroiliac joints. axSpA, axial spondyloarthritis; HLA-B27, human leukocyte 
antigen B27. 
ºTotal number of SpA features after medical history taking, physical examination and measurement 
of acute phase reactants but before HLA-B27 testing and imaging. * n=137 for patients with axSpA 
diagnosis before and after imaging. a mean difference 1.2, 95% Confidence Interval (CI) 0.9 to1.6, 
p-value <0.001; b mean difference -0.3, 95% CI -0.5 to 0.01, p-value=0.06; c mean difference 1.3, 95% 
CI 0.7 to 1.8, p-value <0.001. n/a, not applicable.
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Table 4 Diagnosis and imaging status after sacroiliac imaging in patients without axSpA diagnosis 
before sacroiliac imaging.
No axSpA diagnosis before imaging n=196
Any imaging positive n=35 Negative imaging n=161
Imaging status 
Only MRI-SI+ 24 (68) n/a
Only X-SI+ 2 (6) n/a
MRI-SI+/X-SI+ 9 (26) n/a
Diagnosis after imaging Diagnosis after imaging
AxSpA n=28 No axSpA n=7 AxSpA n=5 No axSpA n=156
LoC regarding diagnosis before imaging, mean (SD) 4.7 (2.0) 5.0 (1.3) 5.0 (1.9) 5.8 (2.0)
LoC regarding diagnosis after imaging, mean (SD) 7.6 (2.3)a 5.0 (2.3)b 6.4 (1.9)c 7.6 (2.2)d
Imaging status 
Only MRI-SI+ 18 (64) 6 (86) n/a n/a
Only X-SI+ 1 (4) 1 (14) n/a n/a
MRI-SI+/X-SI+ 9 (32) - n/a n/a
Clinical features
Male 15 (54) 2 (29) 2 (40) 38 (24)
Number of SpA features º, mean (SD) 1.6 (0.9) 1 (0.8) 1.8 (0.8) 1.4 (1.0)
HLA-B27 positive 13 (48) 2 (29) 2 (40) 25 (16)
Values are listed as n (%), unless otherwise stated.LoC, level of confidence regarding diagnosis: 0 (not 
confident at all) through 10 (very confident); MRI-SI, magnetic resonance imaging of sacroiliac joints; 
X-SI, radiographs of sacroiliac joints. axSpA, axial spondyloarthritis; HLA-B27, human leukocyte 
antigen B27. 
ºTotal number of SpA features after medical history taking, physical examination and measurement 
of acute phase reactants but before HLA-B27 testing and imaging. a mean difference 2.9, 95% CI 1.6 
to 4.2, p-value <0.001; b mean difference 0; c mean difference 1.4, 95% CI -3.1 to 5.9, p-value=0.43; 
d mean difference 1.8, 95% CI 1.5 to 2.1, p-value <0.001. n/a, not applicable.
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Table 4 Diagnosis and imaging status after sacroiliac imaging in patients without axSpA diagnosis 
before sacroiliac imaging.
No axSpA diagnosis before imaging n=196
Any imaging positive n=35 Negative imaging n=161
Imaging status 
Only MRI-SI+ 24 (68) n/a
Only X-SI+ 2 (6) n/a
MRI-SI+/X-SI+ 9 (26) n/a
Diagnosis after imaging Diagnosis after imaging
AxSpA n=28 No axSpA n=7 AxSpA n=5 No axSpA n=156
LoC regarding diagnosis before imaging, mean (SD) 4.7 (2.0) 5.0 (1.3) 5.0 (1.9) 5.8 (2.0)
LoC regarding diagnosis after imaging, mean (SD) 7.6 (2.3)a 5.0 (2.3)b 6.4 (1.9)c 7.6 (2.2)d
Imaging status 
Only MRI-SI+ 18 (64) 6 (86) n/a n/a
Only X-SI+ 1 (4) 1 (14) n/a n/a
MRI-SI+/X-SI+ 9 (32) - n/a n/a
Clinical features
Male 15 (54) 2 (29) 2 (40) 38 (24)
Number of SpA features º, mean (SD) 1.6 (0.9) 1 (0.8) 1.8 (0.8) 1.4 (1.0)
HLA-B27 positive 13 (48) 2 (29) 2 (40) 25 (16)
Values are listed as n (%), unless otherwise stated.LoC, level of confidence regarding diagnosis: 0 (not 
confident at all) through 10 (very confident); MRI-SI, magnetic resonance imaging of sacroiliac joints; 
X-SI, radiographs of sacroiliac joints. axSpA, axial spondyloarthritis; HLA-B27, human leukocyte 
antigen B27. 
ºTotal number of SpA features after medical history taking, physical examination and measurement 
of acute phase reactants but before HLA-B27 testing and imaging. a mean difference 2.9, 95% CI 1.6 
to 4.2, p-value <0.001; b mean difference 0; c mean difference 1.4, 95% CI -3.1 to 5.9, p-value=0.43; 
d mean difference 1.8, 95% CI 1.5 to 2.1, p-value <0.001. n/a, not applicable.
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In the entire cohort, the diagnosis changed in 21% (109/513) of the CBP patients following 
imaging. In patients with imaging results that were discordant with their primary diagnosis 
(n=213 (178+35)) the diagnosis changed in 109 (51%) patients (Figure 1, boxes in bold). This 
change of diagnosis more often pertained to patients in whom a clinical diagnosis was suspected 
but imaging was negative (81/109 (74%)) than in patients in whom a clinical diagnosis of 
axSpA was not suspected but imaging was positive (28/109 (26%)). 
DISCUSSION 
This study was performed to investigate the contribution of sacroiliac imaging to 
the rheumatologist’s diagnosis and its respective confidence. We have shown that the 
rheumatologist’s confidence in the diagnosis of patients with chronic back pain suspected of 
having axSpA increases after the results of sacroiliac imaging are taken into account. However, 
the number of changes in diagnosis after imaging implies that imaging is indeed an important 
but not the all-decisive factor in axSpA diagnosis. 
Prior to imaging the physician’s confidence in diagnosis was already moderate to high in most 
patients, which corroborates the value of medical history taking, physical examination and 
laboratory tests in the diagnostic work-up of axSpA. Congruent imaging results significantly 
increased the diagnostic confidence of rheumatologists except in axSpA patients (before- and 
after imaging) without sacroiliitis. In general, these findings are in line with results from an 
international survey conducted amongst rheumatologists throughout the world illustrating 
the value rheumatologists place on imaging in the diagnostic work-up of patients suspected 
of axSpA.21 
Nevertheless, there were patients diagnosed as “no axSpA” before imaging in which a positive 
imaging result did not influence the final diagnosis. A few patients were not diagnosed with 
axSpA after imaging, even though they had sacroiliitis (n=6 for MRI-SI and n=1 for X-SI). 
These patients had only few other SpA features and rheumatologists remained uncertain about 
the diagnosis (mean LoC 5.0). Apparently, the diagnosing rheumatologist considered the 
observed lesions -in combination with the clinical presentation- not sufficiently specific for 
an axSpA diagnosis, which is an indication that rheumatologists do not necessarily find that 
imaging is the dominant feature in establishing a diagnosis of axSpA. An even smaller number 
of patients (n=5) without a diagnosis of axSpA before imaging and without signs of sacroiliitis 
were still diagnosed with axSpA after imaging. Since these 5 patients have a low number of 
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SpA features, it is difficult to understand these diagnoses. Moreover, our findings also stress 
the importance of imaging in rejecting an axSpA diagnosis as in 81/178 (46%) patients with 
axSpA before imaging the diagnosis was dismissed when imaging turned out to be negative.
This study has several limitations. First, rheumatologists were asked to provide CBP patients 
with a diagnosis before- and after taking imaging into account. We cannot, however, rule out 
the possibility that rheumatologists may have already looked at the imaging results before 
filling out the diagnosis in the case report form. However, this does not explain why change in 
diagnosis still occurred. More importantly, the overall diagnostic confidence clearly increased 
after taking imaging results into account, which most likely would not have happened (or to a 
lesser extent) if rheumatologists had indeed looked at the imaging results before filling out the 
diagnosis “Before imaging”. Although in line with clinical practice, the fact that each patient 
was diagnosed by one rheumatologist and the imaging was read by one radiologist) might be 
regarded as a limitation. Furthermore, the rheumatologist may also have used information from 
other sources such as spinal imaging in the diagnostic process, which may have (additionally) 
contributed to the LoC regarding the diagnosis. In addition, due to the high overlap of positive 
imaging (i.e. X-SI+/MRI-SI+) we cannot elaborate on the individual value of each modality 
(X-SI or MRI-SI) on the final diagnosis and the diagnostic confidence. 
In conclusion, in chronic back pain patients suspected of having axSpA sacroiliac imaging 
increases diagnostic confidence. However, the number of changes in diagnosis suggests that 
imaging is important but not all-decisive in the early diagnosis of axSpA.
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SUMMARY AND GENERAL DISCUSSION
All studies described in this thesis cover various aspects of the diagnostic work-up of patients 
with chronic back pain suspected of having axial spondyloarthritis (axSpA) and the diagnosis 
and classification (according to the ASAS classification criteria) of axSpA. Moreover, these 
studies are centralized around the same objective, being the early recognition and diagnosis 
of axSpA. 
The following topics were addressed. First, the diagnostic process in chronic back pain 
patients and the final diagnosis of axSpA were elaborately evaluated in a secondary/tertiary 
care setting. Second, the use and potential added value of spinal MRI for the classification of 
axSpA (according to the ASAS criteria) was tested. Finally, we focus on the diagnostic process 
again and evaluated the role of imaging findings as a whole in the diagnosis and classification of 
(early) axSpA: We investigated the use of sacroiliac imaging in clinical practice for diagnosing 
axSpA, but also the influence of different readings by local assessors and central readers on the 
classification of axSpA. 
All studies presented in this thesis were performed in two cohorts: the DEvenir des 
Spondyloarthropathies Indifférenciées Récentes (DESIR)1 and the SpondyloArthritis Caught 
Early (SPACE)2 cohorts. These cohorts were collected with more or less similar study protocols 
as all patients underwent a full (fixed) diagnostic work-up at pre-defined time points to assess 
disease characteristics and the presence of all SpA features. However, there are also important 
differences between the two cohorts. The SPACE cohort is a multicentre, multinational (the 
Netherlands, Norway, Sweden, Italy) observational study, whilst the DESIR cohort is a national 
French observational cohort with multiple (25) participating centres across the country. 
Furthermore, the SPACE cohort includes patients with a minimum age of 16 years who had 
chronic back pain of short duration (between three months and two years), and with an age of 
onset before 45 years. DESIR, however, included patients between the ages of 18 and 50 years 
with chronic inflammatory back pain (IBP, duration between three months and three years) and 
a substantial suspicion of axSpA (measured by a physician’s level of confidence in a diagnosis 
of at least five on a zero to ten scale). In SPACE all patients with chronic back pain (and not 
only those with IBP) can be included, regardless of an existing suspicion of axSpA. In addition, 
inclusion of patients in DESIR is now closed (inclusion took place between December 2007 
and April 2010), whilst SPACE is an ongoing cohort study still actively recruiting patients. 
For this thesis, however, only baseline and one-year follow-up data from the SPACE cohort 
and only baseline data from the DESIR cohort were used. 
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In this final chapter we summarize the main findings of the studies presented in this thesis. 
Thereafter, we will discuss future perspectives and devise research questions that may further 
our knowledge of axSpA. 
Diagnosis of axSpA 
The timely recognition of axSpA – especially in an early disease stage – is challenging as 
the disease is heterogeneous in its presentation and confirmatory signs or symptoms, in 
analogy to for instance urate crystals in the joint in patients with gout, are lacking. An 
important phase in the diagnostic process of patients with continuous chronic back pain is 
the collection of information regarding a patient’s present status and rheumatologic history. 
Patients should be inquired about past or present conditions that are relevant to axSpA 
(i.e. SpA features). Inflammatory back pain (IBP) is a common feature and has several 
definitions.3-5 However, in this thesis IBP is deemed ‘positive’ or present when at least four 
of the following characteristics are present: an onset before the age of 40 years, an insidious 
onset, improvement with exercise, no improvement with rest, and pain at night, i.e. 
fulfilment of the ASAS criteria for IBP.6 Furthermore, patients may complain about heel pain 
suggestive of enthesitis, peripheral arthritis, or swollen and painful toes or fingers suggestive 
of dactylitis.7-10 The concurrent presence or history of extra-articular manifestations, being 
acute anterior uveitis, inflammatory bowel disease (IBD), and psoriasis also increases the 
likelihood of axSpA.11, 12 In addition, a positive family history of SpA (i.e. the presence of AS, 
psoriasis, acute anterior uveitis, reactive arthritis, or IBD in first- or second-degree relatives) 
and a good response (i.e. relief of pain symptoms) to non-steroidal anti-inflammatory 
drugs (NSAIDs) are considered useful characteristics in the diagnostic assessment of CBP 
patients. 13 Next to interviewing the patient, a thorough physical examination is required 
to objectively assess the presence of the aforementioned clinical features. Importantly, there 
is no single laboratory test to diagnose axSpA. However, the presence of human leukocyte 
antigen-B27 (HLA-B27) and/or an elevated acute phase reactant (C-reactive protein (CRP) 
or erythrocyte sedimentation rate (ESR)) that cannot be explained by another condition, 
may further point to a diagnosis of axSpA. Finally, characteristic findings on radiographs or 
MRI of the sacroiliac (SI) joints may frequently be seen.
Neither a formal diagnostic standard for axSpA nor diagnostic criteria exist, so all signs and 
symptoms of axSpA presented by patients – either present or absent – should be appreciated 
and weighted in an aggregated manner (full clinical context) by the diagnostician in a rather 
intuitive process of pattern recognition.14, 15 This implies that the assessing rheumatologist 
has broad expertise in diagnosing axSpA and its differential diagnoses, that he knows about 
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types and has access to relevant laboratory tests and imaging. A previously discussed tool, the 
modified Berlin algorithm, is an example of how a decision tool can support clinicians in such 
a process, but should not be followed blindly. 
If the algorithm would be used strictly as a means to diagnose axSpA, it would result in 
approximately 10 percent false-positive cases but 10 percent of cases will be missed (false-
negative cases) when compared against the rheumatologist’s (i.e. expert’s) diagnosis.16 
The ASAS classification criteria for axSpA are frequently used to define patients for inclusion in 
studies. As the classification criteria were developed in a controlled setting with an artificially 
high prevalence of axSpA, experts have repeatedly warned against the use of these classification 
criteria for diagnosing axSpA.17 Still, as diagnosing axSpA early remains a continuous challenge, 
concerns about inappropriate use of the ASAS classification criteria in clinical practice remain. 
The classification criteria have been developed with the diagnosis of a clinical ‘expert panel’ as 
the external standard in the absence of a real gold standard. Expert opinion includes patient 
characteristics and symptoms at presentation that are combined with results from selected 
laboratory tests and imaging findings. The underlying process is that of ‘pattern recognition’ 
in which physicians (i.e. rheumatologists) conscientiously (or unconscientiously) use their 
clinical experience to try and put all the ‘pieces of the (axSpA) puzzle’ together. The application 
of the classification criteria to diagnose axSpA in clinical practice scenarios with low pre-test 
probability may lead to significant overcall. And especially in low prevalence settings and in 
circumstances with little experience with axSpA, such as primary care settings, it is tempting 
to use classification criteria to make a diagnosis. As a complicating factor, there is a thin line 
between classification and diagnosis since most clinical, laboratory and imaging results are 
used in both classification and diagnosis of axSpA. Nevertheless, the classification criteria 
should be used in patients already diagnosed with axSpA. And part of this diagnostic process 
also includes the exclusion of other, more likely diagnoses.
As said, the sheer counting of SpA features – i.e. ticking boxes of features and symptoms – 
whilst neglecting more likely alternative diagnoses (differential diagnosis) may easily lead 
to overdiagnosis of axSpA, which may in turn invoke inappropriate medical treatment.17-19 
Concerns raised by experts of misdiagnosis and in particular overdiagnosis have led to the 
research in Chapter 2. In this chapter – bearing the aforementioned concerns in mind – we 
investigated whether the presence of multiple SpA features in a chronic back pain patient 
has always led to axSpA diagnosis. We have studied which SpA features contributed most to 
an axSpA diagnosis and we assessed the agreement between the rheumatologist’s diagnosis 
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and the ASAS classification criteria in the SPACE cohort. In this study 500 patients, after 
undergoing a full diagnostic protocol, were stratified according to the number of SpA 
features: 159 (32%) had less than or equal to one feature, 143 (29%) had two features, 
79 (16%) had three features and 119 (24%) had four or more features. Half of the total 
study population was diagnosed with axSpA, and the likelihood of an axSpA diagnosis 
was generally conditional upon the number of SpA features. Still, numerous patients with 
multiple SpA features were not diagnosed with axSpA. These findings show that making a 
clinical diagnosis of axSpA is more than a simple summation of SpA features. Overdiagnosis 
merely based on the presence of multiple SpA features is a concern but likely did not 
occur frequently in centres participating in the SPACE cohort in which experts judged the 
diagnosis. 
There were also encouraging findings showing that rheumatologists are not blindly guided 
by classification criteria. HLA-B27 negative patients without imaging abnormalities (either 
radiography or MRI of sacroiliac joints) and few other SpA features could still receive a 
diagnosis of axSpA without classifying as axSpA. A potential explanation for these diagnoses 
is that other features or symptoms (not part of the ASAS classification criteria), such as 
alternating buttock pain or the presence of spinal inflammatory lesions, were rated as 
relevant features for a diagnosis of axSpA. In addition, rheumatologists may have based 
their diagnosis on their own interpretation of the imaging in combination with the clinical 
picture. Another interesting question raised in this study was which SpA features were most 
contributory to axSpA diagnosis. In both univariable and multivariable analyses we found 
that ‘HLA-B27 positivity’ and ‘any positive imaging’ (i.e. either sacroiliitis on a radiograph 
or MRI) were independent determinants of an axSpA diagnosis. Especially positive imaging 
of the sacroiliac joints was a dominant feature. These results underline the importance 
of proper interpretation of imaging or new imaging modalities (discussed later) in the 
diagnostic process of axSpA. With the concern of just ‘ticking boxes’ for axSpA diagnosis 
in mind, we have also looked at the relation between axSpA diagnosis and classification 
according to the ASAS axSpA criteria. For this, the diagnosis of the treating rheumatologist 
was used as a gold standard to test the performance of the ASAS axSpA classification criteria. 
The ASAS classification criteria had an overall sensitivity and specificity of 76% and 84%, 
respectively. These results were a bit worse than those published in a recent systematic 
literature review and meta-analysis in which the performance of the ASAS axSpA criteria 
was summarized.20 A sensitivity of 82% and a specificity of 88% were reported, which is 
indeed in line with the aforementioned conclusion that not all patients with a diagnosis of 
axSpA are classified as such, and vice versa. 
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The differentiation of the signs and symptoms of axSpA from other conditions which may 
also present with CBP is important in the diagnosis of axSpA. In addition, some conditions 
may well co-exist with axSpA. The differential diagnosis for axSpA includes among others 
mechanical back pain, osteitis condensans ilii, sacroiliac joint infection, diffuse idiopathic 
skeletal hyperostosis (DISH), degenerative disc disease, and fibromyalgia.21-24 During 
follow-up, the clinical presentation of CBP patients might change, which can result in the 
rheumatologist either refuting the initial diagnosis –axSpA or an alternative diagnosis – or 
getting increased confidence in the initial diagnosis. In Chapter 3 we further elaborate on 
the findings in Chapter 2, mainly on the clinical characteristics and alternative diagnoses of 
patients who were not diagnosed with axSpA, especially in those with four or more SpA features 
who are considered as having axSpA by the Berlin algorithm. This study was prompted by the 
comments of Braun et al. in Nature Reviews in which they state that it is unlikely that a patient 
with four or more SpA features does not have SpA.25 In the SPACE cohort rheumatologists are 
asked to provide a clinical diagnosis (axSpA or no axSpA). In case of ‘no axSpA’ rheumatologists 
were requested to provide a better alternative diagnosis. In all patient categories (those with 
no- or only with one- SpA features versus those with two, three, and four or more SpA features) 
the most frequent alternative diagnoses were expectedly non-specific back pain, mechanical 
back pain, degenerative disc disease, and (fibro)myalgia. None of the 18 patients with four 
or more SpA features had imaging abnormalities suggestive of axSpA and only four of them 
were HLA-B27-positive. Furthermore, they had SpA features that are considered less specific, 
such as IBP, a positive family history for SpA, and a good response to NSAIDs. These findings 
reassuringly suggest that – although an axSpA diagnosis is likely in the presence of a high 
number of SpA features – rheumatologists may still discard the diagnosis when they think 
there are not enough arguments in favour of a diagnosis. 
As mentioned before, the definite diagnosis of axSpA is preceded by an elaborate work-up 
of imaging, physical examination, and laboratory testing. However, despite this extensive 
diagnostic approach, uncertainty regarding the diagnosis (diagnostic uncertainty) is not 
uncommon. In Chapter 4 we looked into diagnostic uncertainty at baseline and after one-
year follow-up, and at the possible influence of SpA feature accrual on diagnosis. An important 
finding of this study was that diagnostic uncertainty was common, however standardized 
(one-year) follow-up led to a decrease of patients with uncertain diagnosis. Importantly, some 
uncertainty regarding the diagnosis remained at follow-up. Almost half of the patients had 
developed at least one SpA feature after one year, but this did in most cases not lead to 
changes in diagnosis or level of certainty. These results may reflect certain aspects of clinical 
reasoning in daily rheumatologic practice. First, the finding that the acquisition of new SpA 
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features after one year did not necessarily lead to a switch of diagnosis can be the result 
of rheumatologists ‘weighing’ SpA features in importance. Positive imaging suggestive of 
axSpA might be considered a ‘stronger’ SpA feature than ‘good response to NSAIDs’. Second, 
rheumatologists may base their diagnosis and level of certainty on other features than the 
SpA features defined in the ASAS axSpA criteria. The definition ‘diagnostic uncertainty’ was 
construed by an arbitrarily chosen cut-off value as there is no clear definition nor a way to 
scientifically measure diagnostic uncertainty. An interesting conclusion we may draw from our 
data is that at baseline rheumatologists hypothesize about the possible diagnosis which can 
be influenced by newly acquired information of or from the patient. Diagnostic uncertainty 
is not necessarily a ‘bad thing’ albeit that excessive use of health care resources in the pursuit 
of a diagnosis should be avoided. Therefore, in cases with diagnostic uncertainty a “wait and 
see approach” is justified. 
One of the commonly present SpA features is a positive family history. The definition of a 
positive family history, as is used in daily clinical practice as well as in research studies, has once 
been constructed by a panel of SpA experts, but was never validated. Chapter 5 discusses the 
usefulness of the current definition of a positive family history (PFH) as it is considered a risk 
factor for axSpA, and whether the five diseases that comprise a PFH contribute equally well to 
diagnosing axSpA. For this study data from both the SPACE and DESIR cohorts were used. 
In both cohorts a PFH was defined according to the definition used in the ASAS classification 
criteria: the presence of ankylosing spondylitis (AS), acute anterior uveitis (AAU), reactive 
arthritis, inflammatory bowel disease (IBD), and psoriasis in first- or second-degree relatives 
(first-degree: mother, father, sister, brother, daughter, son); second-degree: aunt, uncle, niece, 
nephew, grandmother, and grandfather).5 Overall, the most common diseases among first-or 
second-degree relatives were AS and psoriasis, followed by IBD, AAU, and reactive arthritis. 
In both univariable and multivariable analyses a PFH of AS or AAU was independently 
associated with HLA-B27 positivity. These results were expected since AS and AAU have a 
known association with HLA-B27.26-28 Furthermore, AAU showed an association with axSpA 
diagnosis in SPACE only. In addition, there was no association of PFH with sacroiliitis on 
imaging. We also looked at the relative contribution of HLA-B27 among patients who were 
classified according to the ASAS axSpA criteria. The majority of these patients were HLA-B27 
positive. Interestingly, a PFH was more often reported in HLA-B27 positive patients compared 
to HLA-B27 negative patients. We concluded that a PFH of AS or AAU may be useful 
for case-finding in low prevalence settings as they are correlated with HLA-B27 carriership. 
However, a PFH of reactive arthritis, IBD, and psoriasis does not contribute to diagnosing 
axSpA in CBP patients suspected of axSpA. A recent study by van Lunteren et al. replicated 
9
Summary and general discussion   |   139
this finding in the ASAS cohort. They expanded their research question to ethnicity and degree 
of family relationship (i.e. first or second degree relatives), and found that a PFH of AS was 
positively associated in all patient subgroups, but that there was no association between a 
PFH of AAU, ReA, IBD or psoriasis with HLA-B27 carriership.29 These findings are well in 
line with ours in that a PFH of AS, and possibly of AAU, may ‘track’ patients who are at risk 
of having axSpA. These patients should subsequently be typed for HLA-B27. Furthermore, 
these findings underscore calls that the current definition of a PFH for this specific population 
should be amended.
Use of imaging in the diagnosis of axSpA
One of the most important aspects in the (early) diagnosis (and classification) of axSpA is the 
use of imaging (conventional radiography and MRI of the sacroiliac joints) to assess active 
inflammation and/or structural changes highly suggestive of axSpA. An important limitation 
is that patients may have symptoms long before abnormalities (i.e. sacroiliitis) are detected on 
radiographs.5, 10, 30 Another important consideration is that not all patients with axSpA will 
develop structural lesions in the sacroiliac joints or the spine. MRI was introduced to overcome 
some of these issues in an early disease phase, since MRI may visualize both structural and 
inflammatory lesions in the sacroiliac joints and the spine.31-34 The introduction of MRI has 
spearheaded the distinction of a fairly new disease entity called ‘non-radiographic axSpA’. 
Numerous studies have investigated this imaging modality in axSpA during the past decade.35 
ASAS has developed several recommendations on how to best perform an MRI of the sacroiliac 
joints and a definition for a positive MRI.14, 33 Because of the widespread use of sacroiliac 
imaging, a correct interpretation of the imaging by either an experienced rheumatologist or 
a radiologist is of crucial importance. There are several concerns, however, regarding the use 
of sacroiliac imaging. The recognition of sacroiliitis on radiographs is unreliable, regardless 
of the experience or training of the assessor(s).36, 37 Inaccurate readings (i.e. false-positive or 
false-negative for sacroiliitis) may lead to wrong diagnoses, especially if a diagnosing physician 
would rate the importance of abnormal imaging higher than the presence or absence of clinical 
symptoms. Subsequently, such falsely diagnosed patients may be enrolled in clinical trials or 
other types of clinical research, since they may erroneously classify as positive using the ASAS 
classification criteria. We do not have much insight into the extent to which rheumatologists 
are led by imaging findings in diagnosing their patients with axSpA.
The ASAS experts, who have developed the ASAS classification criteria for axSpA, did not 
include spinal inflammatory lesions on MRI (MRI-spine) as an imaging criterion in the 
classification of axSpA.5 However, several studies have shown that spinal inflammatory lesions 
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may occur, even in the absence of sacroiliitis on MRI.38-40 Given these observations, it was of 
interest to investigate whether MRI-spine should have a place as an element in the ASAS 
classification criteria. A consensus definition for a positive MRI-spine (i.e. three or more 
spinal inflammatory lesions) had already been developed by the ASAS/Outcome Measures in 
Rheumatology (OMERACT) MRI working group.39 A positive MRI-spine is defined as the 
presence of ≥3 inflammatory lesions in the vertebrae on ≥2 consecutive slices. Recently, a new 
cut-off value (the ‘rule of five’) for spinal inflammatory lesions - positive MRI-spine defined 
as ≥5 inflammatory lesions - was proposed by the Hooge et al. that had a higher specificity (> 
95%).41 In Chapter 6 we wanted to investigate whether it is useful to add a positive MRI-spine 
as an imaging criterion in the ASAS classification criteria for axSpA. Baseline data from both 
the SPACE and DESIR cohorts were used and several definitions of a positive MRI-spine were 
applied: (1) the ASAS consensus definition (≥3 spinal inflammatory lesions); (2) ‘rule of five’ - 
≥5 spinal inflammatory lesions; (3) SPARCC-score of ≥5 by at least two readers (not available 
in DESIR); (4) and SPARCC-score of ≥5 by the mean of three readers (not available in DESIR). 
The majority of chronic back pain patients did not have any imaging abnormalities suggestive 
of axSpA. An isolated positive MRI-spine according to the ‘rule of five’ definition was found 
in only 1% and 2% of patients in the SPACE and DESIR cohorts, respectively. Almost all 
patients already had fulfilled the ASAS-criteria through the clinical arm. In both cohorts only 
one patient could additionally be classified as having axSpA by a putative MRI-spine-enriched 
imaging arm. This implies that a huge number of MRI-spine have to be performed needlessly 
in order to additionally classify one patient. We arrived at similar conclusions when using the 
other definitions for a positive MRI-spine. Therefore, the use of MRI-spine in the classification 
of axSpA is not recommended. An important side note is that this study focused on the effect 
of adding MRI-spine to the ASAS classification criteria. We did not formally assess the role 
of MRI-spine for an axSpA diagnosis in routine clinical practice. Obviously, MRI-spine may 
still be valuable for excluding other diseases with chronic back pain (differential diagnosis). 
We have also not investigated if MRI-spine is of added value in establishing the activity of the 
disease, for instance for monitoring purposes. This remains to be investigated. 
In daily clinical practice the diagnosis of axSpA relies on local reading of images, usually in the 
clinical context, by either the radiologist and/or rheumatologist. In contrast, research studies 
use (blinded) centralized readers who have been trained and calibrated well. In Chapter 7 we 
replicated a previously performed study in DESIR to investigate whether reading discrepancies 
between local assessors and central readers influenced the classification of chronic back pain 
patients in the SPACE cohort.42 In our study we confirmed that local assessors and central 
readers did not agree on the presence of sacroiliitis on MRI in 81/513 (16%) of patients. For 
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sacroiliitis on radiographs this rate of disagreement was 55/513 (11%) patients. Discrepant 
read-results led to a different classification in 52/513 (10%) patients, which is not negligible 
but also not of major impact. With central reading as external standard we found that local 
assessors tended to overrate the presence of sacroiliitis leading to a certain false-positive rate 
(‘local overcall’). These findings were essentially similar to those reported in DESIR and add 
to the conclusion that the ASAS classification criteria are reasonably robust against differences 
invoked by local versus central readers. That read-discrepancy did not have a greater impact 
is mainly due to the inclusion of the clinical arm, which mitigates a wrong classification based 
on the imaging arm only.
Chapter 8 is the last chapter addressing the use of imaging in clinical practice, particularly 
sacroiliac imaging, in the SPACE cohort. Moreover, the effects of imaging results on the 
diagnosis and diagnostic confidence of rheumatologists were studied here. According to a fixed 
protocol rheumatologists were asked to provide a diagnosis before and after imaging results were 
known, and a corresponding level of confidence regarding this diagnosis. Sacroiliac imaging 
was interpreted by local assessors (rheumatologists & radiologists). Before imaging results were 
known to rheumatologists more than half of the patients (62%) had already been diagnosed 
with axSpA. As we have shown before in Chapter 3 most common diagnoses in the patients 
not diagnosed with axSpA were non-specific back pain, degenerative disc disease or mechanical 
back pain. Expectedly, axSpA patients were more often male, HLA-B27 positive, and had more 
SpA features than patients without axSpA. Both in the groups with and without the diagnosis 
of axSpA, the mean (SD) level of confidence (LoC) was moderate at best (axSpA LoC 6.6 (SD 
1.9), no axSpA LoC 5.6 (2.0)). After studying the results of the imaging, rheumatologists 
refuted the previous axSpA diagnosis in a number of cases. In total, after studying the results 
of imaging, 109/513 (21%) patients were assigned a different diagnosis, but the level of 
confidence regarding their (new) diagnosis markedly increased. Our findings suggest that 
imaging results play an important role in the diagnostic considerations of rheumatologists and 
increase the confidence in a diagnosis, regardless of the imaging outcome (positive or negative). 
This observation is in line with the conclusion of Chapter 2, namely that there is a strong 
relation between sacroiliitis on imaging and an axSpA diagnosis. In addition, imaging results 
increase their level of confidence with which they conclude to a certain diagnosis. 
Future perspectives for research and implications of findings
A clear challenge in Rheumatology is making an appropriate diagnosis of axSpA early in 
patients presenting with chronic back pain. The timely presentation of patients to the 
rheumatologist is dependent on primary care physicians and other workers in primary health 
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care (physiotherapists and others). Although not covered in this thesis, an early identification 
and timely referral of chronic back pain patients is pivotal. Increasing awareness of the existence 
of axSpA may guide patient and doctor toward a timely diagnosis. This thesis has provided 
elements that may be of help in this regard. An important limitation of our studies, however, 
is that the conclusions cannot be extrapolated to primary care and common Rheumatology 
practice without further consideration since they have been derived from researching the 
SPACE and DESIR cohorts. These are cohorts with a far higher prevalence of axSpA than any 
clinical setting. It would be interesting to analyse how an axSpA diagnosis is made in settings 
with a lower prior probability, whether the modified Berlin diagnostic algorithm has indeed 
a place in the diagnostic process and whether the number of present SpA features dictates the 
diagnosis. 
We have seen that positive imaging and the presence of HLA-B27 often drive a diagnosis 
of axSpA by rheumatologists in clinical practice. Which SpA features were considered most 
important for a diagnosis by rheumatologists, however, was not assessed. It is, for instance, 
very likely that rheumatologists weigh different SpA features differently and this may have 
(had) impact on the final diagnosis. Analysing such ‘heterogeneity amongst diagnosticians’ 
may give us better insight into how a diagnosis of axSpA is made and what it means. Such a 
process may even lead to considering other or new features or symptoms in diagnosing axSpA. 
As we try to be more efficient in our daily clinical practice we wondered whether several 
aspects of the current definition of a positive family history (PFH) are relevant for case-finding 
(or axSpA diagnosis). Of note, a PFH is usually patient-reported which may both lead to an 
underestimation (patients cannot remember) or to an overestimation (patients misinterpret 
chronic back pain in a family member as a symptom of axSpA). Further clinical research is 
needed here in order to better diagnose axSpA. In addition, the current definition of a PFH 
(in this specific population) in the classification criteria deserves reconsideration and possibly 
modification. Ultimately, an interesting topic for future clinical research will be to investigate 
if certain combinations of SpA features point to axSpA with higher likelihood than others. 
Altogether, this may lead to earlier and more appropriate diagnosis and treatment of axSpA 
in different clinical settings. 
The use of conventional radiography and MRI for an axSpA diagnosis (and subsequent 
classification) remains a point of debate. An important remaining question is when to use 
which modality and whether it does make a difference for the early recognition of axSpA. There 
have been recent studies assessing the course and progression of imaging abnormalities as well 
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as the development of new lesions over time. Ideally, in a few years we may predict which 
patients will develop structural bone lesions or permanent damage. Such a risk-stratification 
may lead to an individualized treatment plan (personalized medicine) and follow-up for each 
patient. Both cohorts used in this thesis (SPACE and DESIR) have longitudinal data and may 
help – in time – provide us with the answers.
Final comments on this thesis
In this thesis the focus was on diagnosing axSpA early using clinical features as well as imaging 
modalities. We have studied multiple elements diagnosing axSpA among patients presenting 
with chronic back pain. We have emphasized two main themes: (1) the importance of clinical 
SpA features; and (2) the contribution of imaging to an axSpA diagnosis and classification. 
We have learned how rheumatologists use imaging results in their diagnostic considerations 
and thereby have helped reduce certain fears regarding the way diagnosis is made in clinical 
practice. We have shown that the use of MRI-spine in classification is not efficient. The 
common thread in all of the studies in this thesis is that axSpA diagnosis is the interaction 
between the clinical aspects of chronic back pain and imaging findings highly suggestive of 
axSpA. Clinicians should be aware of mindlessly ‘stacking up’ SpA features in chronic back 
pain patients in order to avoid unnecessary (biologic) treatment. Additional studies are needed 
to investigate the numerous phenotypes of axSpA and to predict in which chronic back pain 
patient axSpA diagnosis is likely. Overall, we hope the studies reported in this thesis will 
contribute to a better understanding of how we diagnose axSpA in daily clinical practice as 
this is likely an important step towards improving long term outcomes of patients with axSpA.
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De studies beschreven in dit proefschrift omvatten aspecten van de diagnostiek bij patiënten 
met chronische rugpijn (CBP) die verdacht worden van axiale spondylartritis (axSpA) én de 
diagnose en classificatie (volgens de ASAS classificatie criteria) van axSpA. Deze studies zijn 
gecentreerd rondom hetzelfde doel, namelijk de vroege herkenning en diagnose van axSpA. 
Dit proefschrift behandelt een aantal onderwerpen. Eerst wordt het diagnostische proces en de 
uiteindelijke diagnosestelling bij patiënten met chronische rugpijn geëvalueerd. Vervolgens 
is naar de toegevoegde waarde van de MRI van de wervelkolom bij de classificatie van axSpA 
(met gebruik van de ASAS classificatie criteria) gekeken. Daarna gaan we in op het gebruik 
van beeldvormend onderzoek (en de bevindingen) bij de diagnose en classificatie van (vroege) 
axSpA.
Voor dit proefschrift zijn data gebruikt van twee prospectieve cohortstudies: het DEvenir 
des Spondyloarthropathies Indifférenciées Récentes (DESIR) cohort en het SpondyloArthritis 
Caught Early (SPACE) cohort. Deze twee cohorten vertonen gelijkenis op meerdere punten, 
zoals een volledig gestandaardiseerde diagnostische opzet en vooraf gedefinieerde tijdspunten. 
Echter, er zijn ook een paar belangrijke verschillen te noemen. Het SPACE cohort is een 
‘multinational’ cohortstudie in vier Europese landen (Nederland, Noorwegen, Zweden en 
Italië), terwijl DESIR alleen patiënten binnen Frankrijk includeert. In SPACE worden alle 
patiënten van 16 jaar en ouder met chronische rugpijn (≥3 maanden en ≤2 jaar, aanvang <45 
jaar) gerekruteerd en geïncludeerd. De patiënten in DESIR zijn 18-50 jaar oud én hebben 
inflammatoire rugpijn (IBP met een duur van ≥3 maanden en <3 jaar), waarbij de betrokken 
reumatoloog een waarschijnlijkheid voor axSpA van minimaal 50% heeft afgegeven. Het 
SPACE cohort is een doorlopende cohort studie met actieve inclusie van patiënten. De inclusie 
van patiënten in DESIR is inmiddels gesloten, echter wordt wel naar een follow-up van 10 
jaar gestreefd. Voor dit proefschrift zijn alleen de baseline en 1-jaarsdata van beide cohorten 
gebruikt.
Diagnose axSpA
De tijdige herkenning van axSpA, zeker in een vroege fase van de ziekte, is tot op heden een 
uitdaging gebleken vanwege de heterogeniteit van de ziekte en de afwezigheid van echte 
diagnostische criteria. Een belangrijk aspect van het diagnostische proces in patiënten met 
chronische rugpijn is de anamnese. De behandelend arts dient te vragen naar kenmerken van 
- of ziektebeelden die relevant kunnen zijn voor - axSpA, ook wel SpA kenmerken genoemd. 
Een veelvoorkomend symptoom (c.q. SpA kenmerk) is inflammatoire rugpijn (IBP). IBP kent 
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meerdere definities, echter ten behoeve van dit proefschrift hebben wij de ASAS-definitie van 
IBP gebruikt. Volgens deze definitie is er sprake van IBP indien er minstens 4 van de volgende 
kernmerken aanwezig zijn: rugpijn in de ochtend, vermindering van rugpijn bij beweging, 
geen verbetering bij rust, nachtelijke rugpijn, een geleidelijke aanvang van de rugpijn en een 
leeftijd bij aanvang rugpijn van <40 jaar. Patiënten kunnen eveneens klagen over enthesitis 
(ontstoken peesaanhechtingen), perifere artritis (ontstoken gewrichten) of dactylitis (gezwollen 
en pijnlijke vingers of tenen). Extra-articulaire manifestaties (aandoeningen buiten het 
bewegingsapparaat), zoals uveitis, inflammatoire darmziekten (de ziekte van Crohn of colitis 
ulcerosa) en psoriasis, verhogen de kans op het hebben van axSpA (in patiënten met chronische 
rugpijn). Tevens behoren een positieve familieanamnese voor SpA bij eerste- en tweedegraads 
familieleden en een goede respons op non-steroïdale anti-inflammatoire geneesmiddelen 
(NSAIDs) ook tot de SpA kenmerken. Een gedegen lichamelijk onderzoek is een andere pijler 
in het diagnostische proces van de patiënt met chronische rugpijn. Aanvullende diagnostiek in 
de vorm van laboratoriumonderzoek (ontstekingsparameters en HLA-B27 (humaan leukocyten 
antigeen B27)) en beeldvormend onderzoek van de sacroiliacaal (SI) gewrichten kan eveneens 
bijdragen aan de diagnose. 
Aangezien er geen diagnostische criteria voor axSpA bestaan dienen de symptomen van patiënt 
en de bevindingen bij het lichamelijk onderzoek en aanvullende diagnostiek in de volledige 
klinische context te worden geplaatst (patroonherkenning). Dit betekent dat de behandelend 
reumatoloog ruime ervaring moet hebben opgedaan in het herkennen van axSpA en gedegen 
kennis moet hebben van de uitgebreide differentiaaldiagnose van chronische rugpijn. Het 
Berlijn-algoritme is een goed voorbeeld van een beslissingsboom waarin de clinicus begeleid 
kan worden in het diagnostische proces van patiënten met chronische rugpijn. Voorzichtigheid 
is echter wel geboden bij het gebruik van dit algoritme. Het blindelings volgen van het 
algoritme leidt namelijk tot ongeveer 10% fout-positieve diagnoses en 10% fout-negatieve 
diagnoses. 
De ASAS classificatie criteria voor axSpA worden gebruikt om patiënten voor wetenschappelijke 
studies te includeren. Deze classificatie criteria zijn ontwikkeld in een gecontroleerde setting, 
waarbij de axSpA prevalentie duidelijk hoger is dan in de algemene populatie. Derhalve 
is binnen de axSpA onderzoeksgemeenschap meermalen gewaarschuwd tegen het gebruik 
van deze classificatie criteria om de diagnose axSpA te stellen. Desondanks blijven er zorgen 
bestaan over het oneigenlijke gebruik van de classificatie criteria voor de diagnosestelling in 
de dagelijkse praktijk. Een ander relevant aspect is dat de classificatie criteria zijn ontwikkeld 
door een ‘expert panel’ van reumatologen die als externe standaard (in afwezigheid van een 
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gouden standaard) fungeerde. Een ‘expert opinion’ houdt in dat alle klinische relevante 
informatie wordt gecombineerd en afgewogen om tot een eventuele diagnose te komen. 
Het onderliggende proces is wederom patroonherkenning waarin behandelend artsen (in dit 
geval reumatologen) hun klinische ervaring gebruiken om tot een diagnose te komen. Heel 
belangrijk in dit proces is ook het uitsluiten van andere, meer waarschijnlijke diagnoses. De 
applicatie van de classificatie criteria in situaties waarin reeds een lage ‘pre-test probability’, ofwel 
een lage vooraf-kans, kan leiden tot significante overdiagnose. Zeker als er weinig ervaring is met 
axSpA, zoals in een huisartsenpraktijk, kan het verleidelijk zijn om de classificatie criteria te 
gebruiken. Een complicerende factor is dat er een dunne scheidslijn bestaat tussen classificatie 
en diagnose daar de meeste klinische-, laboratorium- en beeldvormend onderzoeksuitslagen 
zowel bij de classificatie als bij de diagnostiek van axSpA worden gebruikt. Desalniettemin 
dienen de classificatie criteria slechts te worden gebruikt bij patiënten met de diagnose axSpA, 
waarbij andere minder waarschijnlijke diagnoses zijn geëxcludeerd. 
Zoals eerder besproken, kan het optellen van SpA kenmerken en het negeren van andere meer 
waarschijnlijke diagnoses leiden tot aanmerkelijke overdiagnose van axSpA, mogelijk leidend 
tot foutieve behandeling. De geuite zorgen over verkeerde diagnoses dan wel overdiagnose 
van axSpA hebben geleid tot het onderzoek in hoofdstuk 2. In dit hoofdstuk hebben wij 
onderzocht of de aanwezigheid van meerdere SpA kenmerken inderdaad automatisch leidt tot 
de diagnose axSpA. Eveneens werd onderzocht welke SpA kenmerken het meest bijdragen aan 
de diagnose axSpA en de overeenkomst tussen de diagnose van de reumatoloog en de ASAS 
classificatie criteria in het SPACE cohort. Er werden in totaal 500 patiënten geanalyseerd en 
gestratificeerd naar het aantal aanwezige SpA kenmerken: 159 (32%) patiënten hadden geen of 
maximaal 1 SpA kenmerk, 143 (29%) hadden 2 SpA kenmerken, 79 (16%) 3 SpA kenmerken 
en 119 (24%) minimaal 4 SpA kenmerken. De helft van de studiepopulatie had axSpA en 
de kans op de diagnose axSpA was in het algemeen gecorreleerd aan het aantal aanwezige 
SpA kenmerken. Echter, een deel van de patiënten met multipele SpA kenmerken hadden 
geen diagnose axSpA. Deze bevindingen laten zien dat de diagnose axSpA niet alleen wordt 
bepaald door het aantal aanwezige SpA kenmerken. Overdiagnose is een reële zorg, maar heeft 
zich zeer waarschijnlijk niet vaak voorgedaan in het SPACE-cohort waar experts de diagnose 
hebben gesteld. 
Enkele bevindingen in deze studie lieten eveneens zien dat reumatologen zich niet blindelings 
laten leiden door de classificatie criteria. HLA-B27 negatieve patiënten zonder afwijkingen 
op beeldvormend onderzoek (MRI of röntgenonderzoek van de SI-gewrichten) met enkele 
SpA kenmerken konden ook de diagnose axSpA krijgen zónder aan de classificatie criteria 
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van axSpA te voldoen. Een mogelijke verklaring voor deze diagnoses is dat andere kenmerken 
of symptomen (niet in de ASAS criteria geïncorporeerd), zoals alternerende bilpijn of de 
aanwezigheid van inflammatoire laesies in de wervelkolom, zijn meegenomen in de 
diagnosestelling. In aanvulling hierop kunnen reumatologen hun diagnose hebben gebaseerd 
op hun eigen interpretatie van het verrichte beeldvormend onderzoek in combinatie met de 
klachtenpresentatie. Een andere interessante onderzoeksvraag was welke SpA kenmerken het 
meeste bijdragen aan een axSpA diagnose. Zowel in uni- als multivariabele analyses waren de 
aanwezigheid van HLA-B27 en positief beeldvormend onderzoek (sacroiliitis op röntgen of 
MRI) onafhankelijke determinanten van axSpA diagnose. Met name positief beeldvormend 
onderzoek bleek een dominant kenmerk te zijn. Deze resultaten onderschrijven nogmaals 
het belang van correcte interpretatie van de verschillende modaliteiten in het diagnostisch 
proces. In deze studie werd ook gekeken naar de relatie tussen axSpA diagnose en de ASAS 
classificatie criteria voor axSpA. De diagnose van de reumatoloog werd als gouden standaard 
gebruikt. De classificatie criteria hadden een sensitiviteit van 76% en een specificiteit van 
84%. Deze resultaten verschillen enigszins met de waarden uit andere studies, maar zijn 
wel in overeenstemming met de conclusie dat niet alle patiënten met axSpA voldoen aan de 
classificatie criteria en vice versa. 
Het stellen van de diagnose axSpA bij patiënten met chronische rugpijn is een proces waarin 
de differentiaaldiagnose een belangrijke rol speelt. De differentiaaldiagnose voor axSpA 
omvat onder andere mechanische rugpijn, osteitis condensans ilii, DISH (diffuse idiopathic 
skeletal hyperostosis), degeneratieve discopathie en fibromyalgie. Tijdens de follow-up 
van patiënten kan de klinische presentatie veranderen hetgeen weer kan leiden tot het 
veranderen van de initieel gestelde diagnose of juist tot een toename van het vertrouwen in 
de gestelde diagnose. In hoofdstuk 3 gaan we verder in op de bevindingen in hoofdstuk 
2, in het bijzonder kijken we naar de alternatieve diagnoses bij patiënten met meerdere 
SpA kenmerken die volgens het Berlijn algoritme (naar verwachting) wél axSpA hebben. 
Deze aanvulling is gekomen na een commentaar van Braun et al. in Nature Reviews waarin 
zij beweren dat het onwaarschijnlijk is dat een patiënt met 4 of meer SpA kenmerken 
géén axSpA heeft. In het SPACE-cohort worden reumatologen gevraagd een diagnose te 
geven (axSpA of geen axSpA). Indien een patiënt geen axSpA heeft, wordt om een (meest 
waarschijnlijke) alternatieve diagnose gevraagd. In alle patiëntgroepen (0-1, 2, 3 en 4 
SpA kenmerken) waren de meest voorkomende alternatieve diagnoses aspecifieke rugpijn, 
mechanische rugpijn, degeneratieve discopathie en fibromyalgie. Geen van de 18 patiënten 
met 4 of meer SpA kenmerken had afwijkingen op beeldvormend onderzoek en maar 4 
waren HLA-B27 positief. De meest voorkomende SpA kenmerken waren IBP, een positieve 
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familieanamnese en een goede respons op NSAIDs, die alle als minder specifiek worden 
beschouwd. De (geruststellende) conclusie die hieruit getrokken kan worden, is dat een hoog 
aantal SpA kenmerken alleen niet voldoende is voor de diagnose axSpA.
Ondanks de uitgebreide diagnostische work-up in de diagnosestelling van axSpA is er vaak 
onzekerheid over de diagnose (diagnostische onzekerheid). Hoofdstuk 4 behandelt de 
diagnostische onzekerheid op baseline en na 1 jaar follow-up, en de mogelijke invloed daarop 
van een toename van SpA kenmerken. Een belangrijke bevinding van deze studie is dat 
diagnostische onzekerheid normaal is. Hoewel enige diagnostische onzekerheid tijdens follow-
up blijft bestaan, leidt gestandaardiseerde follow-up wel tot een afname van patiënten met een 
onzekere diagnose. Ongeveer de helft van de patiënten ontwikkelde minimaal één nieuw SpA 
kenmerk na 1 jaar follow-up, maar dit leidde in de meeste gevallen niet tot een verandering 
van diagnose of niveau van zekerheid. Deze resultaten geven enig inzicht in het klinisch 
redeneren in de dagelijkse praktijk. De bevinding dat toename van het aantal SpA kenmerken 
bij follow-up niet noodzakelijkerwijs leidt tot diagnoseverandering kan het resultaat zijn van 
het ‘wegen’ van de verschillende SpA kenmerken door reumatologen. Oftewel, de reumatoloog 
vindt sacroiliitis op beeldvormend onderzoek een zwaarder wegend SpA kenmerk dan een 
goede respons op NSAIDs. Ten tweede is het mogelijk dat reumatologen hun diagnose alsmede 
de zekerheid omtrent de diagnose baseren op andere kenmerken dan die zijn gedefinieerd in 
de ASAS criteria. Het is belangrijk te vermelden dat de term ‘diagnostische onzekerheid’ is 
gebaseerd op een arbitrair gekozen afkapwaarde, gezien er geen definitie is van diagnostische 
onzekerheid. Wellicht stellen reumatologen een eerste werkhypothese (diagnose) op, die dan 
na verloop van tijd kan veranderen bij het beschikbaar komen van nieuwe informatie. Een 
afwachtend beleid is in deze gerechtvaardigd, ook al om overdiagnostiek te voorkomen. 
Een van de frequent voorkomende SpA kenmerken is een positieve familieanamnese voor SpA. 
De definitie voor een positieve familieanamnese (PFH) is door een expert panel opgesteld maar 
nooit gevalideerd. In hoofdstuk 5 wordt het nut van een positieve familieanamnese bij de 
diagnose van axSpA behandeld. Een positieve familieanamnese voor SpA wordt in het algemeen 
beschouwd als een risicofactor voor axSpA. In de SPACE en DESIR cohorten werd de volgende 
definitie aangehouden: de aanwezigheid van ankyloserende spondylitis (AS/Bechterew), 
acute uveitis anterior (AAU), reactieve artritis, IBD, en psoriasis in eerste- of tweedegraads 
familieleden (eerstegraads: moeder, vader, zus, broer, zoon, dochter; tweedegraads: oom, tante, 
neef, nicht, grootvader, grootmoeder). Zowel in eerste- als tweedegraads familieleden waren 
AS en psoriasis de meest voorkomende aandoeningen, gevolgd door IBD, AAU en reactieve 
artritis. Zowel uni- als multivariabele analyses laten een onafhankelijk verband tussen een 
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PFH voor AS en AAU met de aanwezigheid van HLA-B27 zien. Deze resultaten waren min 
of meer verwacht gezien de bekende associatie van AS en AUU met HLA-B27. Alleen in het 
SPACE cohort werd een associatie tussen AAU en axSpA diagnose gevonden. Sacroiliitis op 
beeldvormend onderzoek liet echter geen associatie met een PFH zien. In aanvulling hierop 
werd de relatieve bijdrage van HLA-B27 onderzocht bij patiënten die waren geclassificeerd 
volgens de ASAS classificatie criteria. De meerderheid van deze patiënten waren HLA-B27 
positief. Een interessante bevinding was dat een PFH vaker werd gerapporteerd bij HLA-B27 
positieve patiënten dan bij HLA-B27 negatieve patiënten. Wij concludeerden dat een PFH 
voor AS of AAU een nuttig signaal kan zijn bij ‘case-finding’ in een omgeving met een lage kans 
op axSpA gezien de correlatie met HLA-B27 dragerschap. Een PFH voor reactieve artritis, 
IBD of psoriasis draagt niet bij aan de diagnosestelling. Deze bevindingen zijn gerepliceerd in 
een studie door van Lunteren et al. Zij hebben eveneens gekeken naar etniciteit en de bijdrage 
van familiegraad, waarbij een PFH voor AS bij alle patiëntengroepen een positieve associatie 
liet zien met HLA-B27 dragerschap. Een PFH voor AS of AAU kan gebruikt worden bij de 
opsporing van patiënten met een hogere kans op axSpA. Tevens pleiten deze bevindingen voor 
een herziening van de huidige definitie van een PFH binnen deze populatie. 
Het gebruik van beeldvormend onderzoek voor axSpA diagnose
Een van de meest cruciale aspecten bij de (vroege) diagnose (en classificatie) van axSpA is 
het gebruik van beeldvormend onderzoek (conventionele radiografie en MRI van de SI-
gewrichten) om inflammatie en/of structurele afwijkingen die suggestief zijn voor axSpA 
te identificeren. Een belangrijke beperking is dat patiënten al lang klachten kunnen hebben 
vóórdat zij afwijkingen (sacroiliitis) op röntgenfoto’s krijgen. Ten tweede ontwikkelen lang 
niet alle axSpA patiënten afwijkingen in de SI-gewrichten of wervelkolom. De MRI bracht 
verandering in de diagnostiek van de vroege fase van axSpA waarbij vooral ontsteking te zien 
is. MRI is in staat zowel structurele afwijkingen als ontstekingslaesies in de SI-gewrichten en 
de wervelkolom af te beelden. Hiermee werd ook de nieuwe ziekte entiteit ‘non-radiografische 
axSpA’ bepaald. Het gebruik van MRI bij axSpA is de afgelopen 10 jaar frequent onderzocht, 
en diverse aanbevelingen ten aanzien van het gebruik en de interpretatie zagen het licht. De 
toename van het gebruik van beeldvormend onderzoek onderschrijft het belang van correcte 
interpretatie van de bevindingen door een reumatoloog of radioloog. Het (toenemend) 
gebruik van beeldvormend onderzoek roept ook enkele zorgen en bezwaren op. Ten eerste is 
sacroiliitis op röntgenfoto’s lastig te herkennen en is de interpretatie ervan onbetrouwbaar, 
ongeacht ervaring en training van de lezers. Onjuiste interpretaties kunnen leiden tot verkeerde 
diagnoses (fout-positief of fout-negatief), zeker wanneer de behandelend arts afwijkingen op 
beeldvormend onderzoek belangrijker acht dan de klinische verschijnselen van de patiënt. 
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Eveneens kan een onjuiste interpretatie in klinische trials leiden tot verkeerde classificatie. 
Helaas is er weinig bekend over in welke mate reumatologen worden geleid door bevindingen 
op beeldvormend onderzoek voor de diagnose axSpA. 
In de ontwikkeling van de ASAS classificatie criteria werden inflammatoire laesies in de 
wervelkolom op MRI (MRI-rug) niet meegenomen als criterium voor een positieve uitslag. 
Desondanks hebben meerdere studies laten zien dat spinale inflammatoire laesies wel degelijk 
kunnen voorkomen zonder sacroiliitis op MRI. Derhalve werd in hoofdstuk 6 onderzocht of 
een positieve MRI-wervelkolom (inflammatoire laesies suggestief voor axSpA) een toegevoegde 
waarde heeft als criterium voor MRI-positiviteit in de ASAS classificatie criteria. Baseline data 
van de SPACE en DESIR cohorten werden gebruikt voor deze onderzoeksvraag. Verschillende 
definities voor een positieve MRI-wervelkolom werden gebruikt: (1) ASAS consensus definitie 
(≥3 spinale inflammatoire laesies); (2) ‘regel van vijf’ - ≥5 spinale inflammatoire laesies; (3) 
SPARCC-score van ≥5 door minstens 2 lezers (niet in DESIR); (4) en SPARCC-score van ≥5 
berekend uit het gemiddelde van 3 lezers (niet in DESIR). De meerderheid van de patiënten 
met chronische rugpijn had geen afwijkingen op beeldvormend onderzoek. Een geïsoleerde 
positieve MRI-wervelkolom volgens de ‘regel van vijf’ definitie werd respectievelijk in 
slechts 1% en 2% van de patiënten in de SPACE- en DESIR-cohorten gevonden. Echter, 
bijna alle patiënten voldeden reeds aan de klinische arm van de classificatie criteria. In beide 
cohorten zou maar 1 patiënt aanvullend worden geclassificeerd als axSpA door de positieve 
MRI-wervelkolom. Dit suggereert dat een groot aantal MRI’s van de wervelkolom verricht 
moeten worden om één patiënt extra te classificeren. Dezelfde conclusies werden getrokken 
met gebruik van de overige definities van een positieve MRI-rug. Derhalve ontraden wij het 
gebruik van een MRI-wervelkolom bij de classificatie van axSpA. Een belangrijke kanttekening 
is dat in deze studie de rol van de MRI-wervelkolom alleen bij de classificatie van axSpA is 
getoetst en niet bij het stellen van de diagnose. Een MRI-wervelkolom kan zeker nuttig zijn 
voor het excluderen van andere oorzaken van chronische rugpijn. Of de MRI-wervelkolom 
kan worden ingezet voor de evaluatie van ziekteactiviteit dient nog te worden onderzocht. 
In de dagelijkse praktijk wordt voor de diagnose axSpA veelal de interpretatie van beeldvormend 
onderzoek van de radioloog gebruikt dan wel de eigen interpretatie in de klinische context. Dit 
is in tegenstelling tot de vele studies waarbij geblindeerde ‘centrale’ lezers worden gebruikt die 
vooraf worden getraind en gekalibreerd. Hoofdstuk 7 is een replicatiestudie waarin is gekeken 
in hoeverre discrepanties in interpretatie van het verricht beeldvormend onderzoek (MRI-SI en 
X-SI) tussen lokale lezers (radiologen) en centrale lezers van invloed waren op de classificatie 
van patiënten in het SPACE-cohort. Deze studie liet zien dat in 16% van de gevallen er 
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onenigheid was over de interpretatie van de MRI-SI, terwijl dit 11% was voor de X-SI. In 
10% van de patiënten leidde deze discrepantie in de beoordeling tot een andere classificatie 
van patiënten. Met de uitslag van centrale lezers als gouden standaard werd geconcludeerd 
dat lokale lezers de neiging hebben vaker sacroiliitis te rapporteren (fout-positieven). Deze 
bevindingen zijn in essentie in overeenstemming met de bevindingen in het DESIR-cohort 
en bevestigen dat de ASAS classificatie criteria redelijk robuust zijn tegen discrepanties die 
optreden bij beoordelingen van MRI’s en röntgenfoto’s door lokale en centrale lezers, mede 
omdat de klinische arm helpt om foute classificaties te voorkomen. 
Hoofdstuk 8 is het laatste hoofdstuk waarin het gebruik van beeldvormend onderzoek, met 
name van de SI-gewrichten, in de dagelijkse praktijk wordt behandeld. Eveneens worden de 
effecten op de diagnose en de diagnostische zekerheid onderzocht. In het SPACE-onderzoek 
worden reumatologen gevraagd een diagnose te geven vóór en ná de interpretatie van de 
bevindingen bij beeldvormend onderzoek. Ten tweede wordt gevraagd een score te geven voor 
de mate van diagnostische zekerheid (hoe hoger de score, des te zekerder is de reumatoloog van 
zijn diagnose). Beeldvormend onderzoek werd geïnterpreteerd door lokale lezers (reumatologen 
of radiologen). Voordat de bevindingen van beeldvormend onderzoek bekend waren, had ruim 
de helft van de patiënten een diagnose axSpA (62%). Zoals reeds beschreven in hoofdstuk 3 
waren de meest frequente diagnoses bij patiënten die geen axSpA bleken te hebben aspecifieke 
rugpijn, degeneratieve discopathie of mechanische rugpijn. De ruime meerderheid van de 
patiënten met axSpA had het mannelijk geslacht, was HLA-B27 positief en had meer SpA 
kenmerken dan de patiënten zonder axSpA. Bij zowel de axSpA patiënten als de patiënten 
zonder axSpA bleek de gemiddelde mate van diagnostische zekerheid (op een schaal van 0 tot 
10) onder reumatologen matig (axSpA: 6.6 (SD 1.9), geen axSpA 5.6 (2.0)). Na het bekend 
worden van de bevindingen bij beeldvormend onderzoek werd in een aantal gevallen de diagnose 
axSpA verworpen: 21% van de patiënten een andere diagnose toebedeeld na de interpretatie van 
deze bevindingen, en de mate van diagnostische zekerheid steeg. Deze resultaten bevestigen dat 
beeldvormend onderzoek zeker een belangrijke rol speelt bij de diagnostische overwegingen 
van de reumatoloog en ook leidt tot een toename van diagnostische zekerheid. Dit gegeven 
komt overeen met de bevindingen in hoofdstuk 2, waarin de correlatie tussen sacroiliitis op 
beeldvormend onderzoek en axSpA diagnose is aangetoond. 
Toekomstperspectieven
Een belangrijke uitdaging in de Reumatologie is de tijdige en juiste diagnose van axSpA in 
patiënten met chronische rugpijn. De juiste verwijzing van patiënten naar de reumatoloog is 
sterk afhankelijk van huisartsen en andere zorgverleners in de eerstelijnszorg. Alhoewel niet 
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specifiek besproken in dit proefschrift is een vroege identificatie en verwijzing cruciaal. Een 
belangrijk aspect is de bewustwording van zowel patiënt als dokter van het bestaan van axSpA 
en de daarbij horende symptomen. Dit proefschrift biedt enkele handvatten hiervoor. Een 
belangrijke beperking van onze studies is dat de getrokken conclusies niet zomaar vertaald 
kunnen worden naar de huisartsenpraktijk of naar andere eerstelijns zorgomgevingen. De 
onderzochte cohorten, SPACE en DESIR, zijn cohorten met veel hogere prevalenties van 
axSpA dan wordt gevonden in de gewone bevolking. Enkele belangrijke onderzoeksvragen 
zijn derhalve hoe de diagnose axSpA het best wordt gesteld in situaties waarbij er een lage 
voorafkans op axSpA is, of het Berlijn algoritme inderdaad een plek heeft en houdt bij het 
diagnosticeren van axSpA en of het aantal aanwezige SpA kenmerken voldoende betrouwbaar 
de diagnose axSpA dicteert. Dit proefschrift heeft laten zien dat afwijkend beeldvormend 
onderzoek en de aanwezigheid van HLA-B27 zeer vaak de drijvende factoren achter een 
diagnose van axSpA zijn. Echter, welk specifieke SpA kenmerk door reumatologen als meest 
belangrijk wordt beschouwd is niet onderzocht. Zeer waarschijnlijk zijn er verschillen tussen 
reumatologen. Inzicht in de mate van heterogeniteit tussen behandelend artsen kan ons helpen 
te begrijpen hóe de diagnose axSpA gesteld wordt. 
De zoektocht naar meer efficiëntie in de dagelijkse praktijk heeft geleid tot het opnieuw evalueren 
van de definitie van een positieve familieanamnese voor SpA. Het is belangrijk te begrijpen 
dat een positieve familieanamnese een subjectief (patient-reported) kenmerk is en onderhevig aan 
foutieve interpretaties van de klachten en symptomen van familieleden, hetgeen kan leiden tot 
een overschatting zowel als een onderschatting (geen herinnering, geen contact met familie). 
Aanvullend onderzoek is dan nodig om de diagnose axSpA te kunnen stellen. De huidige definitie 
van een positieve familieanamnese verdient naar onze mening herziening. Het uiteindelijke doel 
van de verrichte studies is om een eerdere en accuratere diagnose van axSpA te kunnen stellen. 
Een belangrijk onderwerp van toekomstig onderzoek is het identificeren van combinaties van SpA 
kenmerken die leiden tot een hogere kans op het hebben van axSpA. Al met al zou dit kunnen 
leiden tot een betere vroegdiagnostiek en behandeling. 
Het gebruik van conventioneel beeldvormend onderzoek en MRI voor de diagnose axSpA (en 
classificatie) blijft een punt van discussie. Een belangrijke vraag is wanneer welke modaliteit 
dient te worden gebruikt en of dit inderdaad verschil maakt voor vroege herkenning van 
axSpA. Recente studies beschrijven zowel het beloop als de progressie van afwijkingen op 
beeldvormend onderzoek over de tijd. Idealiter kan men over enkele jaren voorspellen welke 
patiënten structurele laesies of permanente schade zullen ontwikkelen. Deze ‘risico-stratificatie’ 
kan leiden tot een geïndividualiseerd behandelplan en follow-up voor elke patiënt. 
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Tot slot 
In dit proefschrift werd de nadruk gelegd op de (vroege) diagnose van axSpA door middel 
van het gebruik van zowel klinische kenmerken als beeldvormend onderzoek. We hebben 
meerdere aspecten van de diagnose axSpA bestudeerd met twee hoofdthema’s: (1) het belang 
van klinische SpA kenmerken; en (2) de bijdrage van beeldvormend onderzoek voor de diagnose 
en classificatie van axSpA. De resultaten van de studies geven inzicht in hoe reumatologen 
beeldvormend onderzoek gebruiken bij hun diagnostische overwegingen. We hebben 
aangetoond dat het gebruik van de MRI-wervelkolom bij de classificatie van axSpA zinvol 
noch efficiënt is. De rode draad in dit proefschrift is dat een diagnose axSpA de uitkomst is van 
het wegen van klinische argumenten en afwijkingen gevonden bij beeldvormend onderzoek. 
We hebben ook geleerd dat clinici voorzichtig moeten zijn met het zo maar optellen van 
klinische SpA kenmerken om tot een diagnose van axSpA te komen. Enkele onbeantwoorde 
onderzoeksvragen zijn welke fenotypen er bestaan binnen axSpA en hoe axSpA het beste te 
voorspellen is bij patiënten die zich presenteren met chronische rugpijn. 
Wij hopen dat de studies in dit proefschrift zullen leiden tot meer inzicht in de diagnose axSpA 
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Behorend bij het proefschrift
DIAGNOSIS AND CLASSIFICATION 
OF AXIAL SPONDYLOARTHRITIS 
IMAGING AND NON-IMAGING FEATURES
1. A clinical diagnosis of axial spondyloarthritis is more than the sum of spondyloarthritis features; it requires 
the skill of pattern recognition. (this thesis)
2. Sacroiliitis on MRI or radiographs and HLA-B27 positivity are determinants of axial spondyloarthritis 
diagnosis. (this thesis)
3. A family history of ankylosing spondylitis or acute anterior uveitis is useful in identifying chronic back 
pain patients at increased risk of suffering from axial spondyloarthritis. (this thesis)
4. Diagnostic uncertainty is inherent to rheumatology since patients may present with heterogeneous disease 
manifestations and unequivocal diagnostic tests are lacking. (this thesis)
5. Since information obtained on MRI of the spine is not of additional diagnostic value MRI-spine should 
also not be added as an imaging criterion to the ASAS classification criteria for axial spondyloarthritis. 
(this thesis)
6. Rheumatologists have stronger belief in the results of imaging than in the information obtained by history 
and physical examination. (this thesis)
7. Our curricula should recognize diagnosis as dynamic and evolving — an iterative process that accounts 
for multiple, changing perspectives. We can speak about “hypotheses” rather than “diagnoses,” thereby 
changing the expectations of both patients and physicians and facilitating a shift in culture. (Simpkin AL 
et al. N Engl J Med 2016; 375:1713-5)
8. In rheumatology ‘earlier’ (diagnosis) is not always necessarily ‘better’, ‘more’ (treatment) is not 
automatically ‘more effective’, and ‘increased sensitivity’ (of diagnostic tests) is not synonymous to ‘better 
yield’. We need to better distinguish ‘disease’ from the ‘risk of disease’. (after Landewé RBM. Ann Rheum 
Dis 2018;77:1394-6)
9. Because of the wide range of clinical phenotypes that constitute SpA the expert opinion of a rheumatologist 
will remain the crucial step in recognition of this disease. (after van Tubergen et al. Nat Rev Rheumatol 
2012;8:253-61)
10. Unmet needs for new and accessible targeted therapies, disease prevention and ultimately cure remain a 
priority in rheumatology. (after Winthrop KL et al. Ann Rheum Dis 2019;78:872-8)
11. Je kunt beter iets dan niets opschrijven. 
12. Wie groot wil zijn, blijft het beste klein.
